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1	   Summary	  	  Serous	   ovarian	   adenocarcinoma	   (SOC)	   is	   one	   of	   the	  most	   devastating	   diseases	   among	  women	   worldwide.	   Despite	   improvements	   in	   early	   diagnosis	   and	   therapy	   in	   the	   last	  decades,	   the	   five-­‐year	   survival	   rate	   remains	   at	   30%.	   Poor	   prognostic	   outcome	   can	   be	  mainly	  explained	  by	  the	  fast	  relapse	  rate	  observed	  in	  most	  patients	  after	  cytoreductive	  surgery	  and	  chemotherapeutic	  treatment.	  Of	  note	  here	  is	  that	  intrinsically	  resistant	  cell	  populations,	   the	  so-­‐called	  cancer	  stem	  cells,	  have	  been	  recently	  associated	  with	   tumor	  recurrence,	   treatment	   failure	   and	   subsequent	   disease	   relapse.	   However,	   the	   lack	   of	  models	  that	  faithfully	  recapitulate	  the	  heterogeneity	  of	  serous	  ovarian	  cancer	  hindered	  so	  far	  the	  study	  of	  these	  phenotypically	  and	  functionally	  heterogeneous	  cancer	  cells.	  Hence,	   the	   aim	   of	   this	   thesis	   was	   to	   establish	   and	   to	   evaluate	   a	   personalized	   model	  system	   that	   fully	   mimics	   SOC.	   Furthermore,	   this	   novel	   model	   system	   serves	   as	   a	  platform	   to	   study	   the	   cellular	   and	   molecular	   processes	   involved	   in	   metastasis	  development	  and	  drug	  resistance,	  as	  well	  as	  to	  identify	  tumor	  initiating	  cell	  populations.	  	  Our	  advanced	  model	  system	  combines	  serum-­‐free	  culture	  of	  primary	  cancer	  cells	  with	  xenotransplantation	   assays.	   Xenograft	   tumors	   established	   upon	   transplantation	   of	  primary	  SOC	  cells	  show	  histopathological	  features	  of	  SOC	  and	  express	  the	  two	  clinically	  used	   SOC	   specific	   markers	   CA125	   and	   WT1.	   We	   were	   able	   to	   demonstrate	   that	   this	  model	  system	  displays	  major	  hallmarks	  of	  SOC	  such	  as	  the	  development	  of	  ascites	  and	  metastatic	  colonization	  of	  the	  diaphragm.	  Additionally,	  the	  molecular	  characteristics	  of	  the	  respective	  tumor	  are	  preserved	  throughout	  our	  models	  and	  the	  recently	   identified	  four	  transcriptional	  subtypes	  of	  SOC	  are	  conserved	  within	  our	  in	  vitro	  cultured	  primary	  cell	  lines	  as	  well	  as	  the	  corresponding	  xenograft	  tumors.	  	  Using	   this	   model	   system,	   we	   were	   able	   to	   identify	   the	   heterogeneously	   expressed	  surface	  marker	  CD151,	  which	  defines	  a	  functionally	  different	  subpopulation	  within	  the	  tumor.	  Xenotransplantation	  assays	  demonstrated	   that	  exclusively	  CD151+	  cells	  possess	  tumor	   initiation	   capacity	   whereas	   CD151-­‐	   cells	   do	   not.	   Gene	   expression	   profiling	  predicted	   a	   selective	   subpopulation-­‐specific	   activation	   of	   various	   proliferation-­‐associated	  pathways	  in	  CD151+	  cells.	  Determination	  of	  the	  phosphorylation	  status	  of	  key	  
	   	   Summary	   	  	   	  pathway	  members	  of	  the	  JNK/MAPK-­‐	  and	  EGFR	  signaling	  as	  well	  as	  members	  of	  the	  Src	  kinases	  (SFKs)	  verified	  these	  findings.	  Ablation	  of	  CD151	  almost	  completely	  abrogated	  the	   activating	   phosphorylation	   suggesting	   CD151	   to	   play	   a	   central	   in	   regulation	   of	  described	  pathways.	  Analysis	   of	   a	   patient	   cohort,	   comprising	   489	   SOC	   patients,	   resulted	   in	   a	   significant	  correlation	  of	  CD151	  expression	  with	  an	  advanced	  disease	  stage	  and	  a	  shorter	  overall	  survival	  in	  low-­‐grade	  tumor	  patients.	  	  Taken	  together,	  our	  data	  indicate	  that	  CD151	  defines	  a	  tumor	  initiating	  subpopulation	  of	  cells	   in	   SOC	   and	   also	   plays	   a	   functional	   role	   in	   mediating	   the	   activation	   of	   various	  proliferative	  pathways.	  Thus,	  CD151	  should	  be	  evaluated	  as	  a	  prognostic	  marker	  as	  well	  as	  a	  target	  of	  therapeutic	  treatment	  in	  SOC.	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2	   Zusammenfassung	  	  Das	   seröse	   Ovarialkarzinom	   ist	   eines	   der	   verheerendsten	   Erkrankungen	   bei	   Frauen	  weltweit.	  Trotz	  Verbesserungen	  in	  der	  Früherkennung	  und	  der	  Therapie	  in	  den	  letzten	  Dekaden,	  beträgt	  die	  5-­‐Jahres	  Überlebenswahrscheinlichkeit	  gerade	  einmal	  30	  Prozent.	  Diese	   schlechte	  Prognose	   ist	   größtenteils	   auf	   den	   relativ	   schnell	   verlaufenden	  Rezidiv	  der	  Patientinnen	  nach	  zytoreduktiver	  Operation	  und	  Chemotherapie	  zurück	  zu	  führen.	  	  Mehrere	  Beweise	  machen	  eine	  kleine	  resistente	  Population	  von	  Zellen,	  die	  sogenannten	  Krebsstammzellen,	  für	  diesen	  Rezidiv	  verantwortlich.	  Eine	  der	  größten	  Schwierigkeiten	  bei	  der	  Untersuchung	  phänotypischer	  und	  funktioneller	  Heterogenität	  von	  Krebszellen	  des	   serösen	   Ovarialkarzinoms	   war	   bisher	   der	   Mangel	   an	   Modellen,	   welche	   die	  Erkrankung	  wirklichkeitsgetreu	  abbilden.	  	  Das	  Ziel	  dieser	  Arbeit	  war	  die	  Entwicklung	  und	  Beurteilung	  eines	  fortgeschrittenen	  und	  personalisierten	   Modells	   für	   das	   seröse	   Ovarialkarzinom,	   welches	   die	   Erkrankung	  möglichst	  wirklichkeitsgetreu	  widerspiegelt.	  Des	  Weiteren,	  sollte	  dieses	  Modell	  als	  Basis	  für	   die	   Aufklärung	   von	   Metastasierungsprozessen,	   Therapieresistenz	   und	   der	  Identifikation	  von	  Tumor	  induzierenden	  Zellen	  verwendet	  werden.	  	  Das	   von	   uns	   entwickelte	   fortgeschrittene	   Modellsystem	   kombiniert	   die	   Serum-­‐freie	  Kultivierung	   primärer	   Krebszellen	   mit	   deren	   Transplantation	   in	   immundefiziente	  Mäuse.	  Xenografttumore,	  welche	  durch	  die	  Transplantation	  primärer	  Zellen	  des	  serösen	  Ovarialkarzinoms	  erzeugt	  wurden,	  zeigen	  histopathologische	  Eigenschaften	  des	  serösen	  Ovarialkarzinoms	   und	   exprimieren	   die	   beiden	   klinischen	   Marker	   für	   das	   seröse	  Ovarialkarzinom;	  CA125	  und	  WT1.	  Wir	   konnten	   zeigen,	   dass	   dieses	   Modell	   wichtige	   Charakteristika	   des	   serösen	  Ovarialkarzinoms	   widerspiegelt,	   wie	   die	   Entwicklung	   von	   Aszites	   und	   die	  Metastasierung	   der	   Krebszellen	   in	   das	   Diaphragma.	   Darüber	   hinaus,	   werden	   die	  molekularen	  Eigenschaften	  der	  jeweiligen	  Tumore	  in	  unseren	  Modellen	  erhalten	  und	  die	  vier	  kürzlich	  beschriebenen	  Subtypen	  des	  serösen	  Ovarialkarzinoms	  widergespiegelt.	  	  Mit	   Hilfe	   dieses	   Modellsystems	   waren	   wir	   in	   der	   Lage	   den	   heterogen	   exprimierten	  Marker	  CD151	  zu	   identifizieren,	  welcher	  eine	   funktionell	  verschiedene	  Population	  von	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1	  
3	   Introduction	  	  
Ovarian	  cancer	  Ovarian	  cancer	  represents	  the	  fifth	  leading	  cause	  of	  cancer	  related	  death	  among	  women	  in	  the	  United	  States,	  accounting	  for	  6%	  of	  all	  female	  cancer	  deaths.	  In	  2013,	  an	  estimated	  22.240	  new	  ovarian	   carcinomas	  will	   be	   diagnosed,	   and	   approximately	   14.030	  ovarian	  carcinoma-­‐related	  deaths	  are	  expected	  (Figure	  1)	  1.	  Despite	  improvements	  in	  therapy,	  ovarian	   cancer	   remains	   the	   most	   deadly	   type	   of	   gynaecological	   cancers.	   Sixty-­‐nine	  percent	  of	  all	  ovarian	  cancer	  patients	  will	  succumb	  to	   their	  disease,	  as	  compared	  with	  19%	   of	   those	   suffering	   from	   breast	   cancer.	   This	   can	   be	  mainly	   explained	   due	   to	   late	  diagnosis	  as	  a	  result	  of	  the	  absence	  of	  an	  effective	  screening	  strategy	  2.	  Still,	  only	  20%	  of	  the	   ovarian	   cancer	   patients	   are	   diagnosed	   while	   the	   tumour	   is	   still	   localized	   to	   the	  ovaries.	   	   At	   this	   stage,	   more	   than	   80%	   of	   the	   patients	   can	   be	   cured	   by	   conventional	  surgery	   and	   chemotherapy	   3.	   Once	   the	   tumour	   has	   spread	   to	   the	   pelvic	   organs,	   the	  abdomen	  or	   beyond	   the	   peritoneal	   cavity,	   the	   five-­‐year	   survival	   rate	   decreases	   below	  40%	  4.	  	  	  Described	   risk	   factors	   for	   the	   development	   of	   ovarian	   carcinoma	   include	   age,	   obesity,	  family	   history	   of	   ovarian	   and	   other	   associated	   malignancies,	   like	   breast,	   uterine	   and	  colorectal	  carcinomas	  as	  well	  as	  inherited	  mutations	  in	  carcinoma	  predispositing	  genes	  5-­‐7.	  	  Various	  studies	  also	  revealed	  that	  the	  risk	  of	  ovarian	  carcinoma	  might	  be	  increased	  by	   hormonal	   and	   reproductive	   factors	   like	   prolonged	   consumption	   of	   unopposed	  estrogen	   replacement	   therapy,	   infertility	   or	   long-­‐term	   use	   of	   fertility	   drugs	   and	   low	  parity	  or	  nulliparity.	  Approximately	   10-­‐15%	   of	   invasive	   ovarian	   carcinomas	   are	   the	   result	   of	   hereditary	  susceptibility	   8,9.	   The	  most	   common	   germline	  mutations	   are	   in	   the	  BRCA1	   and	  BRCA2	  genes,	   followed	  by	  the	  MLH1	  and	  MSH2	  genes,	  which	  are	  also	   implicated	   in	  hereditary	  nonpolyposis	  colorectal	  cancer	  7.	   	  The	  risk	  of	  suffering	  from	  ovarian	  cancer,	  carrying	  a	  
BRCA1	  mutation	  lies	  between	  30%	  and	  60%;	  when	  carrying	  a	  BRCA2	  mutation	  the	  risk	  lies	  between	  10%	  and	  27%	  to	  develop	  ovarian	  cancer	  8,9. 	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Figure	  1-­‐	  Cancer	  statistics	  published	  by	  Siegel	  et	  al.	  1	  depicting	  estimated	  new	  cases	  (left	  table)	  and	  estimated	  cancer	  deaths	  (right	  table)	  in	  the	  United	  States,	  2013.	  	  
Pathophysiology	  Ovarian	  cancers	  are	  remarkably	  heterogeneous	  at	   the	  cellular	  and	  the	  molecular	   level.	  More	  than	  90%	  show	  an	  epithelial	  histology.	  Epithelial	  ovarian	  cancer	  is	  thought	  to	  arise	  from	  cells	  that	  cover	  the	  ovarian	  surface	  or	  that	  line	  subsurface	  inclusion	  cysts	  10.	  These	  cells	   are	   derived	   from	   the	   coelomic	   epithelium	   in	   fetal	   development,	   which	   is	   also	  involved	  in	  formation	  of	  the	  Müllerian	  ducts.	  The	  Fallopian	  tubes,	  uterus,	  cervix	  and	  the	  upper	  vagina	  evolve	  from	  these	  ducts.	  	  Clinically,	   epithelial	   ovarian	   tumors	  often	  present	   as	   a	   complex	   cystic	  mass	  with	   solid	  components	   in	   the	  pelvis.	   	  Ovarian	  cancer	  cells	  most	   frequently	  spread	   initially	  within	  the	  peritoneal	  cavity	  where	  they	  implant	  on	  the	  peritoneal	  surface,	  the	  diaphragm,	  the	  bladder	   and	   the	   liver.	   	   This	   is	   associated	  with	   the	   development	   of	   ascites	   –	   a	   typical	  symptom	  of	   all	   types	   of	   ovarian	   cancer.	   	  Outside	   the	  peritoneal	   cavity,	  metastasis	   can	  occur	   in	   the	   parenchyma	   of	   the	   lung	   or	   the	   lymph	   nodes	   11.	   Unlike	   other	   cancers,	   no	  anatomical	   barrier	   exists	   for	   the	   invasion	   of	   ovarian	   cancer	   cells	   throughout	   the	  peritoneal	  cavity.	  Five	  distinct	  main	  histologic	  subtypes	  have	  been	  described	  for	  epithelial	  ovarian	  cancer:	  low-­‐grade	  and	  high-­‐grade	  serous	  ovarian	  carcinoma,	  which	  both	  resemble	  cells	  that	  line	  the	   fallopian	   tube,	   the	  endometrioid-­‐	   (endometrium),	   the	  mucinous-­‐	   (endocervix),	  and	  the	  clear	  cell	  ovarian	  carcinoma	  (mesonephros)	  histotype	  (Figure	  2).	  The	  classification	  of	  ovarian	  tumors	  into	  these	  subtypes	  is	  of	  great	  importance	  as	  mucinous	  tumors	  have	  a	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significantly	   worse	   prognosis	   than	   serous	   and	   endometrial	   cancers	   and	   respond	   less	  favourably	  to	  platinum-­‐	  and	  taxane	  based	  chemotherapies	  12.	  	  
	  
Figure	  2	  -­‐	  Histopathological	  staining	  of	  the	  five	  different	  main	  subtypes	  of	  epithelial	  ovarian	  cancer.	  These	  histotypes	  bear	  strong	  resemblance	  to	  the	  normal	  cells	  lining	  different	  organs	  in	  the	  female	  genital	  tract.	  (A)	  High-­‐grade	  serous	  ovarian	  carcinoma,	  (B)	  clear	  cell	  ovarian	  carcinoma,	  (C)	  endometrioid	  ovarian	  carcinoma,	  (D)	  mucinous	  ovarian	  carcinoma,	  (E)	  low-­‐grade	  serous	  ovarian	  carcinoma	  (Figure	  adapted	  from	  Gilks	  et	  al.	  13)	  	  
Diagnosis	  and	  staging	  80%	  of	  patients	  with	  ovarian	  cancer	  have	  symptoms	  when	  the	  tumour	  is	  still	  localized,	  only	  20%	  of	  these	  patients	  are	  diagnosed	  at	  this	  stage.	  The	  main	  reason	  for	  this	   is	   the	  rather	   unspecific	   nature	   of	   these	   symptoms.	   Typical	   presented	   symptoms	   range	   from	  diffuse	  abdominal	  complaints,	  changes	  in	  bowel	  habits,	  and	  unexplained	  weight	  loss	  to	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Table	  1	  –	  Staging	  of	  ovarian	  cancer	  according	  to	  TNM	  and	  International	  Federation	  of	  Gynaecology	  and	  Obstetrics	  (FIGO)	  18	  	  




metastasis	   FIGO	  
5-­‐year	  
survival	   Characteristics	  IA	   T1a	   N0	   M0	   IA	   87%	   Tumor	  limited	  to	  1	  ovary,	  capsule	  intact,	  no	  ascites	  present	  	  IB	   T1b	   N0	   M0	   IB	   71%	   Tumor	  limited	  to	  both	  ovaries,	  capsules	  intact,	  no	  ascites	  present	  	  
IC	   T1c	   N0	   M0	   IC	   79%	   Tumor	  stage	  IA	  or	  IB,	  tumor	  on	  surface	  of	  1	  or	  both	  ovaries	  with	  capsule	  ruptured,	  ascites	  present	  	  IIA	   T2a	   N0	   M0	   IIA	   67%	   Extension	  and/or	  metastases	  to	  the	  uterus	  and/or	  tubes	  	  IIB	   T2b	   N0	   M0	   IIB	   55%	   Extension	  to	  other	  pelvic	  tissues	  	  
IIC	   T2c	   N0	   M0	   IIC	   57%	   Tumor	  stage	  IIA	  or	  IIB,	  tumor	  on	  surface	  of	  1	  or	  both	  ovaries,	  with	  capsule(s)	  ruptured,	  ascites	  present	  	  
IIIA	   T3a	   N0	   M0	   IIIA	   41%	  
Tumor	  grossly	  limited	  to	  the	  true	  pelvis,	  negative	  nodes,	  but	  with	  histologically	  confirmed	  microscopic	  seeding	  of	  peritoneal	  surfaces	  or	  small	  bowel	  mesentery	  	  
IIIB	   T3c	   N0	   M0	   IIIB	   25%	   Tumor	  of	  1	  or	  both	  ovaries,	  peritoneal	  metastasis	  ≤	  2	  cm	  in	  diameter,	  negative	  nodes	  	  
IIIC	   T3c,	  Any	  T	   N0	  N1	   M0	  	   IIIC	   23%	   Peritoneal	  metastasis	  beyond	  the	  pelvis	  >	  2	  cm	  in	  diameter	  and/or	  positive	  retroperitoneal	  or	  inguinal	  nodes	  	  
IV	   Any	  T	   Any	  N	   M1	   IV	   11%	   Tumor	  involving	  1	  or	  both	  ovaries	  with	  distant	  metastases,	  parenchymal	  liver	  metastasis	  qualifies	  as	  stage	  IV	  disease	  	  	  	  
Molecular	  genetics	  	  Several	   genetic	   and	   epigenetic	   changes	   have	   been	   found	   in	   ovarian	   cancers	   from	  different	  patients.	  As	  in	  other	  solid	  tumors,	  ovarian	  cancer	  develops	  from	  a	  progeny	  of	  single	  cells	  that	  have	  accumulated	  a	  series	  of	  five	  or	  more	  genetic	  alterations.	  Around	  30	  of	   these	   genetic	   abnormalities	   in	   oncogenes	   or	   tumor	   suppressor	   genes	   have	   been	  described	  for	  ovarian	  oncogenesis	  19.	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The	   most	   frequent	   genetic	   abnormality,	   shared	   by	   60%	   to	   80%	   of	   patients,	   is	   the	  mutation	   or	   loss	   of	   the	   tumor	   suppressor	  TP53	  20.	   The	   encoded	  protein	  p53	   acts	   as	   a	  crucial	   regulator	   of	   G1/S	   transition	   in	   cell	   cycle	   and	   induces	   apoptosis	   upon	   DNA	  damage.	  	  Loss	  or	  mutation	  of	  TP53	  enables	  neoplastic	  cells	  to	  avoid	  apoptosis	  and	  hence	  cell	   division	   will	   occur	   despite	   DNA	   damage	   resulting	   in	   the	   accumulation	   of	   further	  genomic	  rearrangements	  21.	  	  As	  mentioned	  above,	  hereditary	  defects	  in	  DNA	  repair	  genes	  themselves	  account	  for	  10-­‐15%	   of	   ovarian	   cancer	   cases	   22,23.	   For	   carriers	   of	   these	  mutations	   the	   lifetime	   risk	   to	  develop	  ovarian	  cancer	  varies	  between	  30-­‐60%	  for	  BRCA1,	  15-­‐30%	  for	  BRCA2	  and	  7%	  for	  MLH1	  and	  MLH2.	  BRCA1	  and	  BRCA2	  play	  a	  crucial	  role	  in	  the	  reliable	  repair	  of	  DNA	  double	  strand	  breaks	  by	  homologous	  recombination	  8,9.	  Like	   in	  familial	  breast	  cancers,	  all	   ovarian	   cancer	   cells	   inherit	   an	   inactivated	   allele.	   Loss	   of	  BRCA1	   or	  BRCA2	   function	  occurs	  through	  loss	  of	  the	  normal	  allele	  (loss	  of	  heterozygosity	  or	  LOH).	  Around	   15	   different	   oncogenes	   have	   been	   found	   in	   ovarian	   cancers,	   and	   11	   of	   them	  showing	  genomic	  amplification	  19,24.	  One	  of	  the	  most	  common	  amplified	  genes	  in	  ovarian	  cancers	   is	   the	   small	   G-­‐protein	   Rab25.	   Rab25	   is	   involved	   in	   the	   regulation	   of	  motility,	  aggressiveness,	  apoptosis	  and	  autophagy	  25.	  It	  also	  has	  been	  shown	  to	  mediate	  survival	  in	   response	   to	   stress,	   as	   induced	   by	   chemotherapy,	   ultraviolet	   radiation,	   serum	  depletion	  or	  glucose	  starvation	  26.	  	  Other	   common	   amplified	   oncogenes	   in	   ovarian	   cancer	   are	   Aurora	   kinases,	   which	   are	  essential	  for	  cell	  proliferation.	  They	  are	  required	  for	  the	  completion	  of	  cytokinesis	  and	  their	  dysregulation	  leads	  to	  aneuploidy,	  which	  is	  a	  trait	  of	  many	  cancers	  27.	  	  	  
	  Studies	   relating	   genetic	   alterations	   to	   clinical	   presentation	   and	   tumor	   morphological	  features	   indicate	   that	   low-­‐grade	   and	   high-­‐grade	   serous	   ovarian	   carcinomas	  may	   arise	  via	  different	  genetic	  pathways	  28-­‐30.	  Low-­‐grade	  tumors	  (neoplasms),	  develop	  in	  a	  known	  stepwise	   fashion	   from	   adenoma	   to	   low	  malignant	   state	   and	   ultimately	   to	   a	   low-­‐grade	  serous	   carcinoma.	   This	   tumors	   are	   characterized	   by	   mutations	   in	   KRAS,	   BRAF	   and	  
PIK3CA	   and	   LOH	   on	   Xq,	   suggesting	   that	   these	   tumors	   develop	   by	   a	   dysregulated	  RAF/MAPK	   pathway	   31,32	   (Figure	   3A).	   The	   mutated	   KRAS	   encodes	   for	   an	   abnormal	  protein,	   which	   is	   constitutively	   active	   and	   thereby	   aberrantly	   activating	   downstream	  effector	  pathways,	  namely	  PI3K,	  RAF/MAPK,	  and	  RAL-­‐GEFs.	  In	  contrast,	  high-­‐grade	  tumors	  develop	  de	  novo	  from	  the	  surface	  epithelium.	  They	  grow	  rapidly	  and	  show	  no	  morphologically	  recognizable	  precursor	  lesions.	  High-­‐grade	  serous	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tumors	  have	  a	  high	  frequency	  of	  mutations	  in	  TP53	  and	  potential	  aberrations	  in	  BRCA1	  and	  BRCA2	  as	  well	  as	  LOH	  on	  7q	  and	  9p	  33,34.	  Thus,	  these	  tumors	  most	  probably	  arise	  via	  
TP53	  mutations	  and	  BRCA1	  or	  BRCA2	  dysfunction	  35-­‐37	  (Figure	  3B).	  	  
	  
Figure	  3	  –	  Dualistic	  models	  for	  the	  development	  of	  Serous	  ovarian	  adenocarcinoma	  (SOC).	  (A)	  Development	  of	  low-­‐grade	  serous	  carcinoma	  is	  characterized	  by	  morphologically	  recognizable	  precursors,	  from	  inclusion	  cystadenoma	  or	  cystadenofibroma	  to	  serous	  tumor	  of	  low	  malignant	  potential	  and	  low-­‐grade	  serous	  carcinoma.	  They	  show	  a	  high	  frequency	  of	  KRAS	  and	  BRAF	  mutations.	  (B)	  High-­‐grade	  serous	  tumors	  are	  characterized	  by	  a	  high	  frequency	  of	  TP53	  mutations	  and	  the	  absence	  of	  KRAS	  and	  BRAF	  mutations.	  They	  develop	  de	  novo	  without	  a	  recognizable	  intermediate.	  (Figure	  adapted	  from	  Rosen	  et	  al.	  38)	  
	  
Signaling	  pathways	  More	  than	  50%	  of	  ovarian	  cancers	  show	  an	  activation	  of	  at	  least	  one	  out	  of	  seven	  certain	  signaling	  pathways	  26.	  The	  most	  frequent	  triggered	  pathway,	  shared	  by	  approximately	  70%	  of	  ovarian	  cancers,	  is	  the	  Phosphatidylinositide	  3-­‐kinase	  (PI3K)	  pathway.	  Activation	  of	  the	  PI3K	  pathway	  can	  be	  driven	  by	  direct	  mutation	  or	  amplification	  of	  genes	  encoding	  key	  members	  of	  the	  pathway	  like	  PIK3CA	  and	  AKT2,	  or	  by	  inactivating	  mutations	  of	  PTEN	  39-­‐41.	  In	  many	  cancers	  autocrine	  or	  paracrine	  signaling	  by	  receptor	  tyrosine	  kinases	  also	  trigger	  this	  pathway	  42,43.	  	  Signaling	   via	   the	   PI3K-­‐Akt	   promotes	   survival	   and	   cell	   growth	   by	   several	  mechanisms	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death	   promoting	   proteins	   by	   down	   regulation	   of	   forkhead	   transcription	   factors	   46.	   In	  addition,	   cell	   proliferation	   can	   be	   stimulated	   by	   Akt	   mediated	   activation	   of	   mTor	   47.	  	  mTor	   is	   crucial	   for	   the	   regulation	   of	   translation	   in	   response	   to	   nutrients	   and	   growth	  factors	  by	  phosphorylating	  members	  of	  the	  protein	  synthesis	  machinery.	  This	   includes	  the	   ribosomal	   protein	   S6	   kinases	   (p70S6K)	   and	   the	   4E-­‐binding	   protein	   (4E-­‐BP).	   The	  latter	  is	  responsible	  for	  the	  release	  of	  translation	  initiation	  factor	  eIF4E,	  which	  is	  known	  to	  have	  transforming	  and	  anti-­‐apoptotic	  activities	  in	  vitro	  47-­‐50.	  Inhibitors	  against	  PI3K	  and	  Akt	  have	  been	  shown	  to	  inhibit	  the	  growth	  of	  ovarian	  cancer	  xenografts	  and	  could	  potentiate	  the	  cytotoxic	  effects	  of	  chemotherapeutics	  used	  against	  ovarian	  cancer	  51.	  
	  
	  
Figure	  4	  –	  The	  Phosphatidylinositide	  3-­‐kinase	  (PI3K)	  signalling	  cascade.	  PI3K	  signaling	  impacts	  on	  cell	  growth,	  survival	  and	  metabolism.	  (Figure	  modified	  from	  Hennessy	  et	  al.	  52)	  	  The	   pro-­‐inflammatory	   cytokine	   IL-­‐6	   is	   overexpressed	   in	   most	   ovarian	   cancers.	   This	  leads	   to	  an	  autocrine	   stimulation	  of	   the	   IL-­‐6	   receptor,	  which	   triggers	   the	  activation	  of	  Janus	   kinas	   2	   (JAK2).	   JAK2	   activation	   facilitates	   the	   phosphorylation	   and	   nuclear	  translocation	  of	  Signal	  Transducer	  and	  Activator	  of	  Transcription	  3	  (STAT3),	  resulting	  in	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the	   upregulation	   of	   genes	   that	   stimulate	   proliferation,	   inhibit	   survival	   and	   induce	  angiogenesis	   53.	   More	   than	   70%	   of	   ovarian	   cancers	   exhibit	   nuclear	   localization	   of	  phosphorylated	  STAT3,	  an	  observation	  associated	  with	  decreased	  overall	  survival	  54.	  	  The	   transcription	   factor	  NF-­‐κB	   is	   constitutively	  activated	   in	  more	   than	  half	   of	  ovarian	  cancers	   55	   and	   has	   been	   implicated	   as	   a	   major	   regulator	   that	   controls	   cancer	   cell	  survival,	   proliferation	   and	   metastasis	   56,57.	   NF-­‐κB	   is	   composed	   primarily	   of	  heterodimeric	  complexes	  of	  Rel	  family	  proteins	  p65	  and	  p50.	  Several	  cytokines	  such	  as	  IL-­‐1	  and	  TNFα	  and	  growth	  factors	  like	  EGF	  bind	  to	  their	  receptors	  and	  trigger	  a	  cascade	  of	  signaling	  events	  that	  ultimately	  leads	  to	  the	  release	  of	  NF-­‐κB	  from	  its	  inhibitor	  IκB	  58.	  Mitogen-­‐activated	   protein	   kinase	   kinase	   kinase	   3	   (MEKK	   3),	   which	   is	   one	   of	   several	  kinases	  that	  can	  induce	  the	  release	  of	  NF-­‐κB	  59,60,	  is	  overexpressed	  in	  more	  than	  50%	  of	  ovarian	   cancers.	   As	   a	   result,	   NF-­‐κB	   translocates	   to	   the	   nucleus	   where	   it	   binds	   to	  regulatory	  DNA	  elements.	  The	  expression	  of	  many	  genes	  essential	  for	  growth	  regulation	  and	  differentiation,	  such	  as	  cytokines,	  growth	  factors	  or	  angiogenic	  factors	  60	  and	  their	  receptors,	   are	   regulated	   by	   NF-­‐κB	   56,61-­‐63.	   It	   also	   induces	   the	   upregulation	   of	   genes,	  which	  are	  important	  for	  the	  control	  of	  cell	  survival	  such	  as	  Bcl-­‐2,	  Bcl-­‐xl,	  Survivin	  and	  the	  Iap	  family	  61,63.	  Consistent	  with	  these	  data,	  NF-­‐κB	  has	  been	  correlated	  with	  resistance	  of	  cancer	  cells	  to	  radiation-­‐	  and	  chemotherapeutic	  agent-­‐induced	  apoptosis.	  Hence,	  NF-­‐κB	  has	  also	  been	  associated	  to	  the	  development	  of	  resistance	  of	  tumor	  cells	  to	  apoptosis.	  	  
Molecular	  classification	  of	  tumors	  
Cancer	  subtypes	  	  In	   the	   past,	   cancer	   was	   considered	   as	   one	   disease	   with	   varying	   histopathological	  features	   and	   response	   to	   systemic	   treatment.	   However,	   DNA	   sequencing	   and	   gene	  expression	  analysis	  have	  changed	  this	  view.	  Today,	  several	  cancer	  entities	  are	  not	  longer	  regarded	  as	  single	  diseases,	  but	  rather	  as	  a	  collection	  of	  different	  diseases,	  which	  need	  distinct	  therapeutic	  approaches.	  	  The	   first	   clinically	   relevant	   tumor	   subtyping	   started	   in	   the	   1970s	  with	   the	   division	   of	  breast	   cancer	  on	   the	  basis	  of	   estrogen	   receptor	   (ER)	  expression.	  To	  date,	   patients	   are	  classified	  into	  five	  main	  subtypes	  according	  to	  the	  expression	  of	  estrogen	  receptor	  (ER),	  progesterone	   receptor	   (PR),	   epidermal	   growth	   factor	   recptor	   2	   (HER2)	   as	  well	   as	   the	  proliferative	   index	   assessed	   by	   Ki67	   64.	   Treatment	   decisions	   are	   made	   based	   on	   this	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classification	   in	   combination	   with	   clinicopathological	   variables	   such	   as	   tumor	   size,	  lymph	  node	   involvement,	  and	  histological	  grade.	  Although,	   this	  strategy	  has	  been	  very	  successful	  as	  seen	  in	  a	  steady	  reduction	  in	  breast	  cancer	  mortality	  in	  the	  last	  decades,	  it	  is	   still	   not	   sufficient	   for	   the	   implementation	   of	   personalized	   therapy	   into	   clinical	  practise.	  	  The	  rapid	  technical	  development	  in	  DNA	  sequencing-­‐	  and	  genome	  expression	  profiling	  techniques	   allowed	   the	   identification	   of	   mutations	   that	   are	   common	   and	   shared	   by	  tumors	  of	  different	  entities.	  	  The	   aim	   of	   these	   studiesis	   to	   exploit	   the	   existence	   of	   these	   molecular	   changes	   for	  targeted	   therapy.	   The	   paradigms	   are	   patients	   with	   EGFR	   mutations	   in	   lung	   cancer,	  patients	  with	  a	  non-­‐mutated	  KRAS	  in	  colon	  and	  pancreas	  or	  a	  subset	  of	  patients	  with	  a	  BRAF	  mutation	  in	  melanoma	  65.	  Additionally,	  gene	  expression	  analyses	  could	  enable	  the	  identification	   of	   patients	   with	   a	   significantly	   worse	   prognosis	   by	   the	   use	   of	  transcriptional	   signatures	   predicting	   progression	   or	   overall	   survival.	   These	   patients	  might	  then	  be	  treated	  with	  a	  more	  aggressive	  therapy	  65.	  In	  summary,	  in	  the	  last	  years	  has	  been	  demonstrated	  that	   intrinsic	  molecular	  characteristics	  of	   the	  tumors	  are	  often	  better	  prognostic	  factors	  of	  treatment	  response	  than	  anatomical	  variables	  such	  as	  tumor	  size	  or	  nodal	  status	  64.	  In	  the	  next	  five	  years	  more	  than	  25000	  cancer	  genomes	  are	  expected	  to	  be	  sequenced	  by	  the	   Cancer	   Genome	   Atlas	   Research	   Network	   (TCGA)	   and	   the	   International	   Cancer	  Genome	   Consortium	   (ICGC)	   in	   cooperation	   with	   many	   individual	   partners	   from	  academia	  64.	  First	  studies	  describing	  novel	  subtypes	  based	  on	  gene	  expression	  patterns	  in	  several	  tumor	  entities	  have	  been	  already	  published	  in	  the	  last	  years	  66,67.	  The	  results	  obtained	   from	   these	   studies	   will	   lead	   to	   a	   new	   stratification	   of	   patients	   according	   to	  subtypes,	  pathway	  dependency	  or	  important	  mutations.	  	  	  
Ovarian	  cancer	  subtypes	  Ovarian	   cancer	   is	   clinically	   classified	   according	   to	   the	  histology	  of	   the	   tumor	   into	   five	  main	  histotypes.	  These	  histotypes	  reflect	  the	  epithelial	  lining	  they	  arise	  from:	  low-­‐grade	  and	   high-­‐grade	   serous	   ovarian	   carcinoma	   (from	   the	   fallopian	   tube),	   endometrioid	  (endometrium),	   mucinous	   (endocervix),	   and	   clear	   cell	   (mesonephros)	   (Figure	   2).	  Additionally,	   the	   histotypes	   show	   differences	   in	   gene	   expression,	   tumor	  markers	   and	  therapy	   response	   12.	   Approaches	   to	   further	   classify	   these	   histotypes	   were	   based	   on	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Treatment	  of	  ovarian	  cancer	  
Surgery	  For	   ovarian	   cancer,	   post-­‐operative	   residual	   tumor	   is	   the	   most	   crucial	   independent	  parameter	  in	  prognosis	  after	  disease	  stage	  12.	  Therefore,	  it	  is	  one	  of	  the	  few	  malignancies	  in	  which	  cytoreductive	  surgery	   is	   carried	  out	   to	  eliminate	   the	  bulk	  of	   the	   tumor,	  even	  when	   complete	   resection	   is	   impossible	   26.	   Recent	   data	   from	   the	   analysis	   of	   three	  different	  large	  studies	  showed	  that	  patients	  with	  a	  complete	  tumor	  resection	  survived	  a	  median	  of	  five	  years	  longer	  than	  patients	  with	  post-­‐operative	  residual	  tumor	  12.	  Even	  for	  patients	   with	   advanced	   ovarian	   cancer,	   a	   residual	   tumor	   of	   less	   than	   1	   cm	   can	   be	  achieved,	   if	   specialists	   in	   gynaecological	   oncology	   perform	   the	   surgery	   71.	   The	  appropriate	   surgery	  mostly	   depends	   if	   the	   tumor	   is	   still	   limited	   to	   the	   ovaries	   (FIGO	  stages	  I	  to	  IIA)	  or	  already	  metastasized	  within	  the	  pelvis	  or	  elsewhere	  in	  the	  abdomen	  (FIGO	  stages	  IIB	  to	  IV).	  To	  date,	  longitudinal	  laparotomy	  is	  the	  state	  of	  the	  art	  technique	  for	  examination	  of	  the	  abdominal	  cavity,	  as	  laprascopy	  does	  not	  provide	  the	  same	  value	  and	   oncological	   safety	   72.	   This	   approach	   involves	   a	   vertical	   midline	   incision	   to	   allow	  sufficient	   exposure	   of	   the	   upper	   abdomen	   and	   pelvis.	   Typically,	   a	   total	   abdominal	  hysterectomy	  and	  bilateral	  salpingo-­‐oophorectomy	  are	  carried	  out.	  This	  goes	  along	  with	  careful	  examination	  of	  all	  peritoneal	  surfaces,	  omentectomy,	  biopsy	  of	  paraaortic	  lymph	  nodes	   and	   peritoneal	   washings.	   The	   dissection	   of	   the	   paraaortic	   lymph	   nodes	   is	  especially	   important	   in	   patients	  with	   low	   stage	   disease,	   since	   such	   patients	  may	   have	  more	  advanced	  disease	  73.	  The	  5-­‐year	  overall	  survival	  rate	  for	  ovarian	  cancer	  patients,	  which	  underwent	  surgery,	  ranges	   from	   40%	   to	   46%.	   Independent	   poor	   prognostic	   factors	   are	   advanced	   tumor	  stage,	   age,	   general	   health,	   post-­‐operative	   residual	   tumor,	   high-­‐grade	   or	   clear-­‐cell	  histology	  and	  pre-­‐operative	  ascites	  71,74-­‐77.	  Approximately	  69%	  of	  patients	  operated	  will	  develop	  recurrent	  disease	  2.	  	  
Early	  ovarian	  cancer	  (FIGO	  stages	  I	  to	  IIA)	  For	  patients	  with	  early	  stage	  ovarian	  cancer	  an	  adequately	  surgically	  staging	  is	  essential	  because	   of	   the	   significant	   incidence	   of	   microscopic	   metastases.	   Therefore,	   a	   systemic	  examination	   of	   the	   whole	   abdomen	   with	   multiple	   peritoneal	   biopsies	   as	   well	   as	   the	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removal	   of	   macroscopic	   tumor	   manifestations	   is	   carried	   out.	   This	   procedure	   also	  includes,	   pelvic	   and	   paraaortic	   lymph	   node	   dissection	   because	   of	   the	   affection	   of	   the	  retroperitoneal	   lymph	   nodes	   in	   20-­‐25%	   of	   patients	   in	   stage	   T1	   72.	   The	   aspiration	   of	  ascetic	   fluid	   and	   peritoneal	   washings	   for	   cytology	   studies	   is	   also	   performed	   and	  integrated	  in	  the	  assessment	  of	  stage.	  	  Following	  surgery,	  patients	  with	  early	  stage	  ovarian	  cancer	  (except	  patients	  with	  stage	  IA,	  grade	  1)	  receive	  three	  to	  six	  cycles	  of	  platinum-­‐based	  chemotherapy.	  This	  adjuvant	  treatment	   leads	   to	   an	   increase	   in	   the	   5-­‐year	   overall	   survival	   from	   74%	   to	   82%	   and	  disease-­‐free	   survival	   from	   65%	   to	   76%	   78.	   For	   the	   reasons	   mentioned	   below,	  postoperative	   chemotherapy	   with	   a	   combination	   of	   carboplatin	   and	   paclitaxel	   is	  commonly	  used	  for	  early	  stage	  ovarian	  cancer	  patients.	  The	  optimum	  number	  of	  cycles	  that	  should	  be	  applied	  is	  discussed	  controversy.	  A	  randomized	  trial	  by	  the	  Gynecologic	  Oncology	   Group	   (GOG)	   showed	   no	   significant	   difference	   in	   overall	   survival	   between	  groups	   treated	   with	   three	   cycles	   versus	   six	   cycles	   of	   Carboplatin	   and	   Paclitaxel	  chemotherapy	   in	   early	   stage	   disease	   79.	   However,	   for	   patients	   receiving	   a	   three-­‐cycle	  regimen,	  a	  higher	  rate	  of	  relapse	  has	  been	  reported	  80.	  	  Even	  if	  adjuvant	  radiotherapy	  of	  the	  whole	  abdomen	  is	  used	  in	  some	  selected	  high-­‐risk	  patients	  with	  early	  stage	  ovarian	  cancer,	  platinum-­‐based	  chemotherapy	  is	  the	  state-­‐of-­‐the-­‐art	  therapy	  and	  most	  widely	  applied	  81.	  	  
Advanced	  ovarian	  cancer	  (FIGO	  stages	  IIB	  to	  IV)	  Only	  20%	  of	  patients	  with	  ovarian	  cancer	  are	  diagnosed	  while	  cancer	   is	   limited	  to	   the	  ovaries	  2.	  The	  remaining	  part	  already	  shows	  metastatic	  spread	  to	  the	  pelvic	  organs,	  the	  abdomen	  or	  beyond	  the	  peritoneal	  cavity.	  For	  these	  patients	  a	  complete	  tumor	  resection	  or	  at	  least	  a	  reduction	  of	  post-­‐operative	  residual	  tumor	  to	  less	  than	  1	  cm	  is	  the	  strongest	  factor	   in	   prognosis	   12.	   In	   approximately	   30-­‐50%	   of	   cases	   an	   intestinal	   surgery	   is	  necessary	   to	   reduce	   the	   tumor	   burden	   to	   less	   than	   1	   cm.	   This	   could	   include	   partial	  resection	  of	  the	  liver	  or	  pancreas,	  splenectomy,	  cholecystectomy	  or	  diaphragm	  stripping	  72.	   This	   applies	   even	   for	   stage	   IV	   patients,	   which	   benefit	   more	   from	   complete	   tumor	  reduction	  or	  tumor	  reduction	  to	  less	  than	  1	  cm	  than	  patients	  with	  larger	  residual	  tumor	  82-­‐85.	  	  To	   date,	   only	   one	   prospective	   study	   could	   show	   a	   therapeutic	   benefit	   of	   systematic	  pelvic	  and	  paraaortic	   lymph	  node	  removal	   in	  advanced	  ovarian	  cancer.	  The	  systematic	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lymph	   node	   removal	   significantly	   prolonged	   progression-­‐free	   survival	   but	   had	   no	  influence	   overall	   survival,	   when	   compared	   to	   patients	   who	   underwent	   removal	   of	  enlarged	  lymph	  nodes	  only	  86.	  	  The	  current	  standard	  of	  post-­‐operative	  care	  for	  patients	  with	  advanced	  ovarian	  cancer	  is	   six	   cycles	   of	   platinum-­‐	   and	   taxane-­‐based	   chemotherapy.	   Carbo-­‐	   and	   cisplatin	   have	  been	   shown	   to	   be	   the	   most	   active	   drugs	   against	   ovarian	   cancer.	   They	   mediate	   their	  effects	  by	   the	   formation	  of	  DNA	   intrastrand	  crosslinks.	  Taxanes	  such	  as	  paclitaxel	  and	  docetaxel	  act	  by	  a	  different	  mechanism.	  They	  exert	  their	  cytotoxic	  effects	  by	  binding	  and	  stabilization	  of	  tubulin	  polymers,	  thereby	  inhibiting	  the	  process	  of	  cell	  division	  87.	  Meta-­‐analysis	   of	   studies	   performed	   so	   far	   showed	   that	   the	   combination	   of	   platinum	   and	  taxane	   is	   superior	   to	   platinum	   monotherapy	   88.	   In	   total,	   the	   risk	   of	   death	   decreases	  about	   30%	   when	   paclitaxel	   is	   included	   in	   first-­‐line	   therapy	   89,90.	   The	   combination	   of	  paclitaxel	  and	  carboplatin	  is	  as	  effective	  as	  Paclitaxel	  and	  Cisplatin	  in	  first-­‐line	  therapy,	  but	  was	  reported	  to	  have	  less	  side	  effects	  like	  emesis,	  leukopenia	  and	  nephropathy	  91,92.	  Even	   for	   patients	  with	   advanced	   ovarian	   cancer	  who	  had	  undergone	   optimal	   surgery,	  this	   treatment	   regimen	   resulted	   in	   a	   median	   overall	   survival	   of	   nearly	   five	   years	   91.	  Despite	   improved	  treatment	  strategies,	   the	  majority	  of	  patients	  with	  advanced	  disease	  still	  undergo	  relapse	  and	  only	  10-­‐30%	  of	  such	  patients	  have	  long-­‐term	  survival.	  Factors	  that	   predict	   poor	   survival	   include	   an	   advanced	   tumor	   stage,	   an	   age	   of	   more	   than	   65	  years,	   post-­‐operative	   residual	   tumor,	   high	   grade	   or	   clear-­‐cell	   histology,	   pre-­‐operative	  ascites,	  a	  increased	  CA-­‐125	  level	  even	  after	  three	  cycles	  of	  chemotherapy,	  and	  a	  CA-­‐125	  level	  of	  more	  than	  20	  U/ml	  at	  end	  of	  first	  line	  therapy	  12,71,74-­‐77.	  	  
	  
Treatment	  of	  advanced	  disease	  Recurrent	  disease	  after	  platinum-­‐based	  first-­‐line	  chemotherapy	  is	  a	  major	  problem	  for	  patients	   with	   advanced	   ovarian	   cancer.	   In	   these	   cases	   a	   hormonal	   therapy	   with	  Tamoxifen	  or	  an	  aromatase	   inhibitor	   is	  often	  considered	  93,94.	  Even	  if	   less	  than	  20%	  of	  patients	  respond	  to	  hormonal	  therapy,	  some	  patients	  have	  a	  prolonged	  period	  of	  stable	  disease	  and	  less	  side	  effects	  as	  for	  cytotoxic	  treatment.	  Generally,	  the	  choice	  of	  second-­‐line	  chemotherapy	  depends	  on	  the	  duration	  of	  the	  prior	  remission.	  A	   relapse	   after	  more	   than	   six	  months	   after	   completion	  of	   first-­‐line	   therapy	  points	  to	  a	  platinum-­‐sensitive	  disease	  95,96.	  For	  these	  patients	  single	  agent	  chemotherapy	  with	   carboplatin	   is	   often	   considered.	   A	   platinum-­‐
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reasonable	  for	  selected	  patients	  with	  more	  severe	  symptoms	  and	  a	  rapidly	  progressive	  disease	  97.	  Patients,	  who	  have	  a	  relatively	  short	  remission,	  lasting	  less	  than	  six	  months	  after	  first-­‐line	  therapy,	  usually	  have	  a	  platinum-­‐resistant	  disease	  98.	  They	  are	  normally	  treated	  with	  a	  regimen	  that	  does	  not	  contain	  platinum.	  Possible	  agents	  for	  treatment	  include	  liposomal	  Doxorubicin,	  Topotecan,	  Gemcitabine,	  Paclitaxel,	  oral	  Etoposide	  and	  Vinorelbine	  95,99-­‐102.	  The	  overall	  response	  rate	  for	  each	  of	  these	  drugs	  ranges	  between	  10	  to	  20	  %	  in	  patients	  with	  platinum-­‐resistant	  ovarian	  cancer.	  The	  decision,	  which	  drug	  should	  be	  administered,	  is	  often	  made	  according	  to	  the	  side	  effect	  profile	  and	  the	  convenience	  of	  administration.	  
	  
Targeted	  therapy	  The	   significance	   of	   targeted	   therapies	   is	   increasing	   in	   several	   tumor	   types.	   Based	   on	  specific	   molecular	   and	   biochemical	   pathways	   that	   cause	   the	   malignant	   phenotype,	   a	  number	  of	  compounds	  are	  under	  clinical	  investigation.	  These	  drugs	  target	  proliferation,	  angiogenesis,	   invasion,	  metastasis	  and	  decreased	  apoptosis	  and	  rely	  on	  the	  differential	  expression	   of	   specific	   targets	   in	   ovarian	   cancer	   compared	   to	   normal	   epithelial	   cells.	  They	  are	  under	  evaluation	  as	  single	  agents	  and	  in	  combination	  with	  chemotherapy	  103.	  However,	  until	  now	  no	  targeted	  therapy	  has	  been	  approved	  for	  the	  treatment	  of	  ovarian	  cancer.	  The	  expression	  of	  epidermal	  growth	  factor	  receptor	  (EGFR)	  in	  ovarian	  cancer	  has	  been	  shown	   to	   be	   associated	   with	   poor	   prognosis.	   EGFR	   is	   known	   to	   activate	   cellular	  processes	  that	  drivee	  a	  malignant	  phenotype	  are	  initiated	  by	  EGFR	  activation	  104.	  Signal	  transduction	   by	   EGFR	   can	   be	   disturbed	   by	  monoclonal	   antibodies	   such	   as	   Cetuximab	  that	   block	   ligand	   binding	   or	   by	   inhibition	   of	   the	   enzymatic	   activity	   of	   EGFR	   tyrosine	  kinase	  by	  small	  molecule	  inhibitors	  as	  Gefintinib,	  Lapatinib	  or	  Erlotinib	  105,106.	  A	  recent	  phase	   II	   study	   of	   Erlotinib	   treatment	   in	   combination	   with	   Carboplatin	   treatment	  resulted	   in	  a	  response	  rate	  of	  57%	  in	  platinum	  sensitive	  recurrent	  ovarian	  cancer	  and	  7%	   in	   platinum-­‐resistant	   patients	   107.	   In	   contrast,	   a	   phase	   II	   study	   with	   Erlotinib,	  Carboplatin	   and	   Paclitaxel	   as	   first-­‐line	   therapy	   showed	   no	   significant	   better	   response	  rates	  compared	  to	  historical	  controls	  108.	  The	  monoclonal	  antibody	  Cetuximab	  failed	  to	  demonstrate	  a	  benefit	   in	  progression-­‐free	  survival	   in	  a	  phase	  II	  study,	  when	  combined	  with	  Carboplatin	  and	  Paclitaxel	  105.	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Also	  inhibitors	  that	  affect	  other	  members	  of	  the	  epidermal	  growth	  factor	  receptor	  family	  such	  as	  HER2	  have	  entered	  clinical	  evaluation.	  Clinical	   trials	  with	   the	   two	  monoclonal	  antibodies	   Trastuzumab	   and	   Pertuzumab	   showed	   modest	   activity	   in	   ovarian	   cancer	  109,110.	   Nevertheless,	   HER2	   expression	   in	   ovarian	   cancer	   has	   not	   been	   studied,	   as	  extensively	  as	   in	  breast	  cancer	  and	  data	  on	   the	   impact	  of	  HER2	  on	  survival	  of	  ovarian	  cancer	  patients	  are	  still	  inconsistent.	  Angiogenesis	  plays	  a	  crucial	  role	  in	  ovarian	  cancer	  metastasis	  and	  ascites	  development	  111.	   In	   this	   context,	   vascular	   endothelial	   growth	   factor	   (VEGF)	   has	   been	   shown	   to	   be	  important	   regulator	   of	   angiogenesis	   and	   is	   involved	   in	   various	   aspects	   of	   ovarian	  carcinogenesis	   112.	   Bevacizumab,	   a	  monoclonal	   antibody	   targeting	   VEGF-­‐A,	   showed	   in	  two	   phase	   II	   clinical	   trials	   a	   response	   of	   16	   to	   21%	  when	   used	   as	   single	   agent	   113,114.	  Phase	   III	   studies	   of	   Bevacizumab	   in	   combination	   with	   chemotherapy	   resulted	   in	   a	  modest	  improvement	  of	  progression-­‐free	  survival,	  but	  showed	  a	  greater	  survival	  benefit	  for	  patients	  with	  a	  high	  risk	  for	  progression	  115.	  Further	   compounds	  which	   are	   currently	   under	   clinical	   evaluation	   in	   phase	   I/II	   target	  different	   specific	   pathways,	   which	   have	   been	   implicated	   in	   ovarian	   cancer	  tumorigenesis,	  metastasis	  development	  and	  relapse	  103,116.	  These	  studies	   include	  PARP	  inhibitors	   such	   as	   ABT	   888	   and	   Olaparib,	   mTOR	   pathway	   inhibitors	   such	   as	  Temsirolimus	  and	  Everolimus,	  or	  MAPK	  pathway	  inhibitors	  such	  as	  Cabozantinib.	  	  Even	   though	   many	   of	   such	   compounds	   are	   currently	   investigated	   in	   clinical	   trials,	  targeted	   therapy	   in	   ovarian	   cancer	   is	   for	   almost	   all	   cases	   still	   experimental	   and	   no	  targeted	  drug	  has	  been	  approved	  as	  clinical	  standard	  so	  far.	  Further	  studies	  are	  needed	  to	  identify	  subgroups	  of	  patients	  that	  would	  benefit	  of	  a	  specific	  targeted	  therapy.	  	  
	  
Therapy	  resistance	  Resistance	  of	  tumors	  against	  certain	  drugs	  causes	  treatment	  failure	  and	  death	  in	  more	  than	   90%	   of	   patients	   with	   advanced	   disease.	   Already	   small-­‐fold	   changes	   in	   the	  sensitivity	   of	   the	   tumor	   cells	   can	   lead	   to	   clinical	   resistance.	   A	   main	   reason	   for	   this	  phenomenon	   is	   the	   low	   therapeutic	   index	   of	   most	   chemotherapeutic	   agents.	   Drug	  resistance	   result	   mainly	   from	   three	   different	   factors:	   pharmacokinetics,	   properties	   of	  the	  tumor	  microenvironment	  and	  specific	  molecular	  alterations	   inherent	   to	   the	  cancer	  cells	  (Figure	  5)	  117.	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According	   to	   experimental	   data,	   some	   cases	   of	   drug	   resistance	  might	   be	   explained	   by	  interpatient	   differences	   in	   pharmacokinetic	   variables.	   As	   a	   consequence	   of	   these	  differences	   between	   patients	   only	   an	   insufficient	   intratumor	   drug	   concentration	   is	  reached,	   which	   leads	   to	   the	   development	   of	   drug	   resistance.	   Pharmacokinetic	  parameters	   that	   influence	   drug	   concentration	   in	   the	   tumor	   include	   first-­‐pass	  metabolism,	   conversion	   of	   prodrugs	   into	   active	   metabolites,	   renal	   clearance,	   hepatic	  drug	  metabolism	  and	  tumor	  vascularity	  118.	  	  As	  stated	  above,	  also	  the	  tumor	  environment	  modulates	  the	  response	  to	  certain	  drugs.	  For	  the	  resistance	  against	  radiotherapy	  it	  has	  been	  known	  for	  a	  long	  time	  that	  hypoxia	  plays	   an	   important	   role.	   This	   could	   now	   also	   been	   translated	   to	   chemotherapy	   119.	  Consequences	   of	   a	   hypoxic	   environment	   that	   influence	   resistance	  might	   be	   related	   to	  lower	  amount	  of	  proliferating	  cells	  and	  therefore	  a	  decreased	  generation	  of	  free	  radicals,	  an	  increased	  drug	  degradation,	  increased	  genomic	  instability	  as	  well	  as	  a	  HIF1-­‐mediated	  transcriptional	  activation	  of	  survival	  genes	  and	  inhibition	  of	  apoptosis	  120.	  Additionally,	  it	  has	  been	  shown	  that	  stromal	  cells	  can	  also	  activate	  anti-­‐apoptotic	  signalling	  pathways	  121.	  The	   genetic	   background	   of	   cancer	   cells	   present	   in	   a	   tumor	   can	   be	   very	   different	   in	  distinct	  patients.	  It	  is	  a	  well-­‐accepted	  model	  that	  tumors	  consist	  of	  quite	  heterogeneous	  populations	  of	  cells.	  Even	  if	  they	  are	  clonally	  derived,	  several	  clones	  can	  co-­‐exist	  within	  one	   tumor.	   The	   acquisition	   of	   somatic	   mutations	   or	   epigenetic	   changes	   induces	   the	  expression	  of	  a	  huge	  variety	  of	  drug	  tolerance	  genes,	  which	  are	  the	  basis	  of	  resistance	  development	  122.	  During	  treatment	  the	  high	  genetic	  instability	  of	  cancer	  cells	  promotes	  the	  selection	  of	  drug	  resistant	  clones,	  which	  results	  in	  the	  outgrowth	  of	  these	  clones.	  It	  is	  important	  to	  keep	  in	  mind	  that	  cytotoxic	  agents	  target	  primarily	  proliferating	  cells,	  however,	   tumors	  consist	  also	  of	  a	   significant	  proportion	  of	  quiescent	   cells.	  These	  cells	  therefore	  show	  a	  higher	  degree	  of	  drug	  resistance	  compared	  to	  proliferating	  cells.	  This	  subpopulation	   of	   cells	   within	   the	   tumor	   bulk	   often	   exhibits	   a	   higher	   expression	   of	  multidrug	  efflux	  transporters	  or	  pro	  survival	  pathways	  being	  able	  to	  regrow	  the	  tumor	  after	   the	   treatment.	   These	   cells	   are	   called	   cancer	   stem	   cells.	   In	   haematological	  malignancies	  such	  as	  CML	  this	  model	  has	  already	  been	  substantiated	  123.	  	  In	  summary,	  resistance	  to	  a	  certain	  therapy	   is	   influenced	  by	  multiple	  mechanisms	  and	  probably	   different	   between	   patients.	   Large	   scale	   sequencing	   as	   well	   as	   expression	  profiling	  of	  individual	  tumors	  might	  improve	  the	  identification	  of	  molecular	  targets	  and	  lead	  to	  a	  more	  individualized	  treatment	  of	  each	  patient	  in	  the	  future.	  
	  	  





Figure	  5	  –	  Overview	  of	  the	  three	  categories	  of	  drug	  resistance:	  pharmacokinetics,	  the	  tumor	  micro-­‐environment	  or	  cancer-­‐cell-­‐specific	  properties.	  Yellow	  –	  pathway	  of	  drug	  action;	  blue	  –	  pathways	  promoting	  cell	  death;	  green	  –	  pathways	  mediating	  drug	  resistance;	  brown	  –	  pathways	  with	  potentially	  pro-­‐	  and	  anti-­‐cytotoxic	  effects;	  TS	  –	  tumor	  suppressor;	  EC	  –	  extracellular	  (Figure	  adapted	  from	  Agarwal	  et	  al.	  117) 
	  
Cancer	  Stem	  Cells	  
Heterogeneity	  within	  cancer	  Nowadays,	   it	   is	   well	   accepted	   that	   many	   tumors	   consist	   of	   cancer	   cells,	   which	   are	  phenotypically	   and	   functionally	   heterogeneous.	   This	   so	   called	   intratumoral	  heterogeneity	   can	   arise	   in	  multiple	   ways.	   The	   best-­‐established	  model	   uses	   stochastic	  genetic	  or	  epigenetic	  changes	   (clonal	  evolution)	   to	  explain	   intrinsic	  differences	  among	  cancer	  cells	  (Figure	  6A)	  124.	  Alternatively,	  extrinsic	  factors	  such	  as	  interactions	  between	  tumor	   cells	   and	  different	  microenvironments	  might	   also	  play	   a	   substantial	   role	   in	   the	  determination	   of	   tumor	   heterogeneity.	   For	   example,	   cancer	   cells	   adjacent	   to	   blood	  vessels	  have	  a	  different	  supply	  with	  nutrients	  compared	  to	  cancer	  cells	  in	  distance	  from	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blood	   vessels.	   (Figure	   6B)	   125,126.	   The	   third	   possible	   explanation	   for	   heterogeneity	  within	  a	  tumor	  is	  that	  some	  cancers	  follow	  the	  so-­‐called	  stem	  cell	  model.	  According	  to	  this	   model	   tumorigenic	   cancer	   stem	   cells	   “differentiate”	   into	   nontumorigenic	   cancer	  cells	   in	   a	   hierarchical	   organization	   (Figure	   6C)	   127,128.	   This	   model	   would	   allow	   the	  explanation	  of	  phenotypic	  and	  functional	  differences	  that	  cannot	  be	  attributed	  to	  clonal	  evolution	   or	   environmental	   differences.	   In	   addition,	   the	   different	   models	   are	   not	  mutually	  exclusive	  and	  may	  influence	  the	  tumor	  each	  at	  different	  extents	  depending	  on	  the	   tumor	  (Figure	   6D).	  However,	   the	  perception	   that	  heterogeneity	  can	  arise	   through	  multiple	  mechanisms	  alone	  does	  not	  automatically	  prove	  the	  existence	  of	  a	  cancer	  stem	  cell	  hierarchy.	  	  
 
Figure	  6	  –	  Overview	  of	  different	  	  possible	  sources	  of	  heterogeneity	  within	  cancer.	  (A)	  Heterogeneity	  in	  tumors	  can	  arise	  via	  stochastic	  genetic	  changes	  (clonal	  evolution).	  (B)	  Extrinsic	  environmental	  differences	  can	  be	  a	  source	  of	  heterogeneity	  within	  tumors.	  (C)	  According	  to	  the	  stem	  cell	  model,	  cancers	  contain	  intrinsically	  different	  subpopulations	  of	  tumorigenic	  and	  nontumorigenic	  cells	  organized	  in	  hierarchical	  fashion.	  (D)	  The	  different	  sources	  of	  heterogeneity	  are	  not	  mutually	  exclusive	  and	  may	  influence	  the	  tumor	  each	  at	  variable	  extents	  depending	  on	  the	  cancer.	  (Figure	  modified	  from	  Magee	  et	  al.	  124) 	  
The	  Cancer	  Stem	  Cell	  Model	  For	   several	   cancers	   it	   has	   been	   shown	   decades	   ago	   that	   they	   can	   differentiate	   into	  progeny,	   which	   have	   limited	   proliferative	   potential	   compared	   to	   their	   malignant	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progenitors	  129,130.	  For	  some	  germ	  lineage	  cancers	  it	  could	  be	  shown	  that	  the	  presence	  of	  only	  differentiated	  cells	  after	  chemotherapy	   is	  a	   favourable	  prognostic	   factor,	  whereas	  the	  presence	  of	  undifferentiated	  cells	  predicts	  disease	  recurrence	  131.	  According	  to	  this	  data	  undifferentiated	  cells	  would	  be	  mainly	  responsible	   for	   tumor	  growth	  and	  disease	  progression.	  Similar	  results	  were	  obtained	  for	  neuroblastomas,	  which	  also	  exhibit	  variable	  degrees	  of	  differentiation	  124.	  Patients	  with	  broad	  differentiated	  neuroblastomas	  in	  general	  have	  a	  better	   prognosis	   than	   patients	   with	   low	   degree	   of	   differentiation	   132.	   Additionally,	  patients	   with	   neuroblastomas	   showed	   an	   improved	   survival	   when	   treated	   with	  therapies	  that	  promote	  differentiation	  133.	  	  Taken	  together	  these	  clinical	  observations	  support	  the	  cancer	  stem	  model	  showing	  that	  undifferentiated	  tumor	  cells	  are	  the	  ones	  most	  likely	  driving	  cancer	  progression.	  However,	  the	  cancer	  stem	  cell	  model	  became	  ever	  more	  important	  when	  first	  evidence	  emerged	   suggesting	   that	   this	   model	   could	   be	   also	   relevant	   for	   more	   common	   adult	  cancer	  types.	  By	  the	  comparison	  of	  the	  tumorigenic	  potential	  of	  phenotypically	  distinct	  subpopulations	   separated	   according	   to	   specific	   markers	   by	   flow	   cytometry,	   Dick	   and	  colleagues	   could	   show	   that	   some	  acute	  myeloid	   leukemias	   follow	   the	   cancer	   stem	  cell	  model	  134.	  Later	  on,	  the	  presence	  of	  a	  subpopulation	  with	  the	  exclusive	  ability	  to	  initiate	  new	   tumors	   was	   also	   verified	   for	   breast	   cancers	   135	   opening	   the	   possibility	   that	   the	  cancer	  stem	  cell	  model	  might	  be	  applicable	  to	  a	  broader	  spectrum	  of	  cancers.	  	  Indeed,	   further	   studies	   using	   similar	   approaches	   have	   been	   now	   used	   to	   study	   the	  cancer	  stem	  cell	  model	  in	  colon	  cancer	  136,137,	  pancreatic	  cancer	  138,	  brain	  tumors	  139	  and	  ovarian	  cancer	  140-­‐143.	  	  In	  every	  case,	  the	  ability	  to	  form	  tumors	  was	  restricted	  to	  a	  small	  subpopulation	   of	   cells,	   what	   indicates	   that	   tumorigenic	   cells	   are	   rare.	   These	   studies	  suggest	  that	  therapies	  that	  only	  shrink	  the	  tumor	  mass	  might	  not	  be	  curative	  if	  they	  fail	  to	  eliminate	  the	  cancer	  stem	  cells.	  
	  
Cancer	  stem	  cells	  in	  ovarian	  cancer	  As	   stated	   above,	   several	   studies	   focused	   on	   the	   identification	   of	   tumor	   initiating	  subpopulations	  in	  ovarian	  cancer.	  Anyhow,	  the	  distinct	  phenotype	  of	  the	  ovarian	  cancer	  stem	   cell	   population	   has	   not	   been	   defined	   sufficiently.	   Ovarian	   cancer	   initiating	   cells	  have	  been	  described	  to	  be	  enriched	  in	  CD24+	  144,	  CD44+	  140,	  CD44+CD117+	  143,	  CD133+	  141	  subpopulations.	  However,	  the	  study	  describing	  CD24	  as	  a	  putative	  stem	  cell	  marker	  was	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based	  only	  on	  one	  patient	   tumor	  and	  hence	  has	  been	  considered	  carefully.	  The	   tumor	  initiating	  properties	  of	  the	  CD44+CD117+	  subpopulation	  could	  not	  been	  confirmed	  when	  evaluated	   in	   large	   cohort	   of	   ovarian	   cancers.	   Most	   of	   the	   ovarian	   cancers	   showed	   no	  expression	  of	  the	  CD44+CD117+	  subpopulation.	  For	  the	  tumors	  expressing	  both	  markers,	  an	   increased	   tumorigenic	   potential	   in	   the	   described	   subpopulation	   could	   not	   be	  observed	  142.	  Another	  marker	  defining	  a	  putative	  cancer	  stem	  cell	  population	  in	  ovarian	  cancer	  is	  CD133.	  Curley	  et	  al.	  reported	  tumorigenic	  ovarian	  cancer	  cells	  to	  be	  enriched	  in	  the	  CD133+	  subpopulation.	  Also	  these	  data	  could	  not	  been	  confirmed	  in	  larger	  cohort	  of	  ovarian	  cancers.	  In	  some	  cases	  CD133	  enriched	  for	  tumorigenic	  ovarian	  cancer	  cells	  and	   in	   others	   not.	   Furthermore	   the	   expression	   levels	   of	   CD133	   changed	   on	   some	  tumorigenic	   cells	   during	   passaging	   142.	   A	   possible	   explanation	   could	   be	   that	   CD133	  marks	  ovarian	  cancer	  initiating	  cells	  only	  under	  distinct	  conditions	  in	  some	  patients.	  	  It	   appears	   to	   be	   difficult	   to	   confirm	   cancer	   stem	   cell	   markers	   in	   a	   number	   of	   solid	  cancers.	  As	  stated	  above,	  not	  every	  patient	  even	  expressed	  certain	  markers,	  raising	  the	  possibility	  that	  there	  is	  a	  particular	  diversity	  among	  patients	  in	  terms	  of	  the	  expression	  of	  these	  markers	  124.	  	  	  
Experimental	  models	  for	  ovarian	  cancer	  
Genetically	  Engineered	  mouse	  models	  targeting	  the	  ovarian	  surface	  
epithelium	  Genetically	   engineered	  mouse	  models	   are	   indispensable	   for	   the	   understanding	   of	   the	  etiology	   and	   early	   stages	  of	   epithelial	   ovarian	   cancer,	   as	  well	   as	   the	  development	   and	  assessment	   of	   novel	   therapeutics.	   Advancement	   in	   knowledge	   about	   initiation	   and	  progression	   of	   ovarian	   cancer	   was	   hampered	   mainly	   due	   to	   the	   lack	   of	   appropriate	  experimental	  models,	  which	  adequately	  recapitulate	  the	  human	  disease.	  Until	  now,	  the	  lack	   of	   specific	   promoters	   that	   could	   drive	   transgene	   expression	   exclusively	   in	   the	  ovarian	   surface	   epithelium	   made	   the	   development	   of	   traditional	   transgenic	   mouse	  models	  for	  ovarian	  cancer	  very	  difficult.	  For	  the	  generation	  of	  epithelial	  ovarian	  cancer	  models	   only	   two	   candidate	   promotors	   have	   been	   reported:	   the	   Ovarian	   Specific	  Promotor	   1	   (OSP-­‐1)	   145	   and	   the	   Mullerian	   Inhibiting	   Substance	   Type	   II	   Receptor	  promotor	  (MISIIR)	  146	  (Table	  2).	  However,	  expression	  of	  the	  early	  region	  of	  simian	  virus	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40	  T	   antigen	   (SV40	  TAg)	  under	   the	   control	   of	   the	  OSP-­‐1	  promotor	   in	   transgenic	  mice	  revealed	  a	  leaky	  expression	  leading	  to	  the	  appearance	  of	  tumors	  in	  multiple	  tissues.	  In	  addition,	   ovarian	   tumors	   that	   developed,	   originated	   from	   the	   granulosa	   cell	  compartment	  and	  not	  from	  ovarian	  surface	  epithelium	  147.	  Connolly	  et	  al.	  reported	  the	  first	  successful	  transgenic	  mouse	  model	  for	  ovarian	  cancer	  146.	  Therefore	  they	  generated	  transgenic	  mice	  expressing	  the	  early	  region	  of	  SV40	  under	  the	   control	   of	   the	   MISIIR	   promotor,	   which	   has	   been	   shown	   to	   be	   specific	   for	   female	  reproductive	   organs,	   including	   the	   fallopian	   tubes,	   uterus,	   and	   upper	   vagina.	   The	  transgenic	  mice	  developed	  bilateral	  ovarian	  tumors	  in	  about	  50%	  of	  cases	  within	  1.5-­‐3	  months	  of	  age.	  The	  appearance	  of	  tumors	  was	  associated	  with	  peritoneal	  dissemination	  as	  well	  as	   the	  development	  of	  ascites.	  However,	  SV40	  Tag	  has	  not	  been	  shown	  to	  be	  a	  genetic	   contributor	  of	   ovarian	   carcinogenesis	   148-­‐150	   and	   this	  model	  did	  not	   accurately	  represent	  human	  epithelial	  ovarian	  cancer.	  	  
Table	  2	  –	  Summary	  of	  promoters	  and	  targeted	  genes	  for	  ovarian	  epithelial	  tumorigenesis.	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  Pten	  -­‐/-­‐	   2-­‐6.5	   100	   Dinulescu	  et	  al.	  (2005)	  	  Endometroid	  ovarian	  cancer	  	   AdCre	   Apc-­‐/-­‐	  &	  Pten	  -­‐/-­‐	   1.5-­‐5	   100	   Wu	  et	  al.	  (2007)	  	  Adenoma	   FSHR	   Cre,	  Brca1	  -­‐/-­‐	   -­‐	   -­‐	   Chondankar	  et	  al.	  (2005)	  	  Hyperplasia	   AdCre	   Brca1	  Δ5-­‐13	   2-­‐8.5	   -­‐	   Clark-­‐Knowles	  et	  al.	  (2007)	  	  No	  tumorigenesis	   MISIIR	   Pttg	   -­‐	   -­‐	   El-­‐Naggar	  et	  al.	  (2007)	  	  Hyperplasia	   MISIIR	   PI3KCA	   -­‐	   -­‐	   Liang	  et	  al.	  (2009)	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Improved	  mouse	  models	  for	  the	  development	  of	  epithelial	  ovarian	  cancer	  are	  based	  on	  the	  Cre-­‐loxP	  recombination	  system	  (Figure	  7).	  A	  significant	  advantage	  of	  this	  system	  is	  the	   independence	   from	   an	   ovarian	   surface	   epithelium	   specific	   promotor.	   The	   Cre-­‐recombinase	  is	  used	  for	  the	  excision	  of	  parts	  of	  the	  DNA	  flanked	  by	  loxP	  sites.	  This	  can	  lead	   to	   activation	   of	   “lox-­‐stop”	   oncogenes	   or	   the	   inactivation	   of	   floxed	   tumor	  suppressors.	  For	  the	  induction	  of	  ovarian	  cancer	  in	  transgenic	  mice	  an	  adenoviral	  vector	  expressing	   Cre-­‐recombinase	   (AdCre)	   has	   been	   injected	   under	   the	   ovarian	   bursal	  membrane.	  In	  the	  first	  study	  applying	  this	  system	  for	  the	  generation	  of	  ovarian	  cancer,	  mice	   with	   LoxP	   sites	   containing	   TP53	   and	   Rb	   alleles	   were	   used	   to	   assess	   gene	  inactivation	   of	   two	  major	   tumor	   sppressors	   genes	   151,152.	   Upon	   intrabursal	   delivery	   of	  AdCre,	   mice	   in	   which	   both	   the	   p53	   and	   Rb	   genes	   had	   been	   inactivated	   developed	  epithelial	  ovarian	  tumors	  at	  a	  mean	  time	  of	  7.5	  months	  after	  virus	  application.	  Tumours	  were	   histopathological	   classified	   as	   either	   well-­‐differentiated	   serous	   neoplasms	   or	  poorly	   differentiated	   epithelial	   tumors.	   This	   model	   faithfully	   recapitulates	   the	  development	  of	  epithelial	  ovarian	  cancer	  in	  terms	  of	  the	  pathology	  of	  the	  tumor	  as	  well	  as	  the	  appearance	  of	  ascites	  and	  metastatic	  disease	  in	  liver	  and	  lungs	  of	  mice.	  
	  
Figure	  7	  –	  Conditional	  genetically	  engineered	  mouse	  models.	  Activation	  of	  Cre	  in	  a	  tissue-­‐specific	  manner	  is	  achieved	  by	  either	  adenoviral	  delivery	  (AdCre)	  or	  Cre-­‐estrogen	  response	  element	  (ERE)-­‐mediated	  tamoxifen	  administration.	  Examples	  are	  shown	  for	  lung	  cancer	  153	  and	  ovarian	  cancer	  154,	  and	  melanoma	  155	  (Figure	  adapted	  from	  Heyer	  et	  al.	  156).	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Primary	  xenograft	  models	  The	   transplantation	   of	   primary	   patient	   tumor	   specimen	   at	   heterotopic	   or	   orthotopic	  sites	  of	  immunodeficient	  mice	  represents	  another	  strategy	  for	  the	  generation	  of	  suitable	  tumor	  models.	  In	  this	  context,	  great	  efforts	  have	  been	  made	  to	  establish	  proper	  mouse	  models	  for	  xenotransplantation,	  especially	  for	  human	  cells.	  First	  studies	  were	  based	  on	  nude	  mice,	  which	  are	  defective	  in	  the	  thymus	  and	  thus	  have	  a	  T-­‐cell	  deficiency	  157.	  Since	  this	   time	   many	   attempts	   have	   been	   made	   to	   develop	   modified	   severe	   combined	  immunodeficiency	  (SCID)	  mice	  by	  genetic	  crossings	  with	  inbred	  or	  other	  mutant	  strains	  of	   mice	   to	   obtain	   an	   even	   more	   efficient	   model	   158-­‐161.	   Finally,	   the	   establishment	   of	  nonobese	   diabetic	   mice	   with	   severe	   combined	   immunodeficiency	   (NOD/SCID)	   by	  Greiner	  et	  al.	  could	  improve	  the	  model	  and	  show	  that	  these	  mice	  are	  superior	  recipients	  for	  human	  cells	  162.	  These	  mice	  are	  characterized	  by	  an	  immunological	  multidysfunction,	  including	   reductions	   in	   macrophage	   function,	   complement-­‐dependent	   hemolytic	  activity,	  and	  NK	  cell	  activity	  163.	  The	  NOD/SCID	  mouse	  model	  also	  has	  been	  considered	  as	   an	   appropriate	  model	   of	   human	   stem	   cell	   development	   and	   function	   164.	   However,	  residual	  NK	  cell	   activity	   in	   these	  mice	  still	  might	   interfere	  with	  engraftment	  efficiency	  165,166.	  A	  genetic	  variant	  of	  NOD/SCID	  mice,	  lacking	  functional	  NK	  cells	  (NOD/SCID	  Il	  2rg	  -­‐/-­‐),	   allowed	   a	   further	   increase	   of	   the	   transplantation	   efficiency	   up	   to	   the	   successful	  engraftment	  of	  single	  tumor	  cells	  164.	  Advantages	  of	  human	  primary	  xenograft	  models	  are	  the	  preservation	  of	  heterogeneity	  of	  the	   original	   tumor	   in	   the	   xenograft,	   recapitulation	   of	   interactions	   between	   tumor	   and	  microenvironment	  and	  most	  important	  the	  faithful	  recapitulation	  of	  disease	  progression	  141.	   Primary	   xenografts	   mimic	   the	   patient	   situation	   better	   than	   conventional	   cell	   line	  derived	   tumors,	   as	   they	   still	   contain	   stromal	   compartments	   and	   genetically	   represent	  the	  original	  patient	  carcinoma.	  However,	   large	   scale	  drug-­‐screening	  experiments	  are	  not	   feasible	  and	  would	  be	   far	   to	  expensive	   by	   using	   only	   xenograft	   models.	   Furthermore	   the	   site	   of	   tumor	   cell	  implantation	   is	   crucial	   as	   it	   also	   influences	   the	   growth	   of	   the	   tumor.	   Tumors	  transplanted	  at	  subcutaneous	  sites	  in	  general	  are	  barely	  vascularized	  and	  contain	  larger	  necrotic	  areas	  as	  orthotopic	  transplanted	  tumors.	  The	  preparation	  of	  the	  patient	  sample	  also	   plays	   an	   important	   role	   and	   has	   a	   huge	   influence	   on	   engraftment	   of	   the	   primary	  patient	  tumor.	  Primary	   tumors	   are	   heterogeneous,	   have	   a	   distinct	  morphology	   and	   express	   a	   certain	  
	  	  
	   Introduction	   	  	   	  
25	  
panel	   of	   histopathological	  markers.	   Therefore	   studies	   using	   xeongraft	  models	   have	   to	  ensure	   that	   each	   established	   tumor	   still	   faithfully	   recapitulates	   the	   original	   patient	  tumor.	   In	   summary	   primary	   xenograft	   models	   accurately	   mimic	   the	   human	   disease,	  however	   the	   site	   of	   implantation	   as	  well	   as	   the	   site	   origin	   from	   the	   patient	   influence	  features	   of	   the	   xenograft.	   In	   addition,	   as	   highly	   immunodeficient	   mice	   are	   used	   for	  xenograft	   studies,	   the	   influence	   of	   the	   immune	   system	   on	   tumor	   progression	   is	   not	  considered	  in	  primary	  xenograft	  models.	  	  
In	  vitro	  cultivation	  of	  ovarian	  cancer	  cells	  Conventional	  cancer	  cell	  lines	  cultured	  in	  fetal	  calf	  serum	  (FCS)	  have	  been	  the	  standard	  both	  for	  studies	  on	  human	  tumor	  biology	  and	  as	  a	  preclinical	  platform	  for	  screening	  of	  potential	  therapeutic	  agents	  for	  decades	  167.	  The	  advantages	  of	  these	  cell	  lines	  are	  their	  easy	  maintenance	  in	  culture	  by	  simple	  media	  formulations,	  the	  possibility	  to	  manipulate	  them	   and	   their	   good	   engraftment	   efficiency	   in	   initial	   as	  well	   as	   serial	   transplantation	  experiments.	  However,	  it	  has	  become	  increasingly	  clear	  that	  many	  of	  these	  repeatedly	  in	  
vitro	   passaged	   cancer	   cell	   lines	   not	   accurately	   mirror	   the	   human	   disease.	   Long-­‐term	  FCS-­‐based	  in	  vitro	  cultivation	  leads	  to	  a	  multitude	  of	  genetic	  aberrations	  and	  changes	  in	  phenotypic	   characteristics,	   which	   often	   bear	   little	   resemblance	   to	   those	   of	   the	  corresponding	  primary	  human	  tumor	  (Figure	  8)	  167,168.	  Selective	  pressure	  within	  these	  cultures	   may	   also	   lead	   to	   selection	   and	   outgrowth	   of	   sub-­‐clones,	   decreasing	   the	  significance	  of	   results	  obtained	   from	  such	  cell	   lines.	  Moreover,	  morphological	   features	  and	   the	  expression	  of	  histopathological	  markers	  often	  change	  or	  get	   lost	   in	  xenografts	  generated	   from	  these	  cell	   lines	  compared	  to	   the	  original	  patient	   tumor.	  The	  result	   is	  a	  rather	  undifferentiated	  mass	  of	  tumor	  cells.	  Taken	   together,	   studies	   based	   on	   conventional	   FCS-­‐cultured	   cell	   lines	   contributed	  several	  major	   points	   to	   our	   knowledge	   about	   the	   biology	   of	   cancer	   such	   as	   pathways	  involved	   in	   tumor	   maintenance,	   tumor	   progression	   and	   metastasis	   development.	  However,	   data	   generated	  by	  use	   of	   these	  models	   has	   been	   interpret	   carefully	   and	   the	  predictive	  value	  of	  clinical	  performance	  for	  novel	  therapeutic	  agents	  determined	  in	  such	  a	  preclinical	  setting	  is	  limited	  169.	  	  These	   facts	   gave	   rise	   to	   the	   development	   of	   more	   biologically	   relevant	   cell	   culture	  systems	  for	  the	  exploration	  of	   tumor	  biology	  and	  for	  the	  screening	  of	  new	  therapeutic	  agents.	   Initial	  primary	   cell	   cultures	  omitting	  FCS	   in	   the	  media	  were	  established	   in	   the	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field	   of	   neuronal	   stem	   cells	   research.	   There	   it	   was	   clearly	   shown	   that	   serum-­‐based	  cultivation	   of	   neuronal	   stem	   cells	   leads	   to	   an	   irreversible	   differentiation	   and	   an	  accumulation	  of	  de	  novo	  alterations	  (Figure	  8).	  A	  major	  step	  was	  thus	  the	  development	  of	  in	  vitro	  cultivation	  models	  based	  on	  FCS-­‐free	  media	  formulations,	  which	  allowed	  the	  growth	   of	   an	   undifferentiated	   multipotent	   population	   of	   NSCs	   170,171.	   This	   cultivation	  method	  was	  then	  applied	  to	  several	  experimental	  systems	  such	  as	  stem	  cell	  enrichment	  assays	   172,	   comparative	   gene	   expression	   profiling	   173,	   and	   in	   vitro	   models	   for	   the	  development	  of	  the	  nervous	  system.	  Also	  normal	  stem	  cells	  from	  different	  organs	  such	  as	   mammary	   progenitor/stem	   174	   cells	   as	   well	   as	   malignant	   stem	   like	   cells	   from	  glioblastoma	  175	  and	  colon	  137	  could	  be	  cultured	  using	  this	  methodology.	  However,	  these	  studies	  were	  based	  on	  growth	  of	  cells	  as	  spheroids,	  which	  has	  several	  limitations	  as	  also	  progenitor	   cells	   proliferate	   in	   suspension	   culture,	   true	   clonal	   analysis	   is	   impeded	   by	  sphere	  aggregation,	   and	   treatment	   for	   the	   identification	  of	  novel	   therapeutic	   agents	   is	  almost	   impossible.	   Very	   problematic	   in	   the	   sphere	   environment	   is	   the	   spontaneous	  differentiation	  and	  cell	  death	  of	  cultured	  cells	  176.	  An	  argument	  against	  the	  cultivation	  of	  cells	  as	  spheres	  is	  also	  the	  fact	  that	  epithelial	  cells	  in	  vivo	  need	  adhesion	  to	  avoid	  anoikis.	  More	  recent	  studies	  introduced	  an	  improved	  cultivation	  in	  a	  more	  physiological	  setting	  on	  adherent	  substrates	  176,177	  and	  showed	  an	  enrichment	  of	  tumor	  initiating	  cells	  in	  vivo	  178.	   Adherent	   cultures	   of	   primary	   cells	   maintain	   the	   stability	   of	   the	   genotype	   and	  features	   of	   the	   original	   tumor	   in	  vivo	   to	   the	   same	   extent	   like	   spheroid	   cultures	   176.	   In	  addition,	   adherent	   cultures	   provide	   a	   uniform	   access	   to	   growth	   factors	   for	   all	   cells,	  thereby	   limiting	   spontaneous	   differentiation	   and	   cell	   death	   and	   allow	   an	   easy	  manipulation	  or	   treatment	  of	   cells.	   In	   summary,	   the	  cultivation	  of	  primary	  cells	   in	   the	  absence	  of	  FCS	  represents	  advancement	   in	   the	  development	  of	   in	  vitro	  model	   systems	  and	   provides	   a	   closer	   match	   to	   the	   clinical	   situation.	   Therefore	   it	   is	   expected	   that	  findings	  made	  by	  the	  use	  of	  these	  improved	  systems	  can	  be	  more	  easily	  translated	  to	  the	  clinical	  situation.	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Figure	  8	  –	  A	  hypothetical	  model	  depicting	  the	  relationship	  between	  primary	  patient	  tumors,	  primary	  CSC	  culture	  and	  conventional	  FSC-­‐based	  culture.	  The	  heterogeneous	  nature	  of	  the	  original	  primary	  tumor	  is	  quickly	  lost	  through	  differentiation	  in	  media	  with	  serum.	  Continuous	  culturing	  of	  cells	  in	  serum	  conditions	  result	  in	  outgrowth	  of	  subpopulations	  of	  cells	  exhibiting	  additional	  genetic	  and/or	  epigenetic	  changes	  (Figure	  modified	  from	  Lee	  et	  al.	  167).	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4	   Materials	  and	  Methods	  
	  
Materials	  	  
Mouse	  strains	  	  NOD.Cg-­‐Prkdcscid	   Il2rgtm1Wjl	   	   (NSG)	   mice	   were	   obtained	   from	   Jackson	   Laboratory	   (Bar	  Harbor,	  USA)	  and	  bred	  in	  the	  DKFZ	  animal	  facility.	  All	  mice	  were	  housed	  under	  specific	  pathogen-­‐free	   conditions	   and	   used	   for	   experiments	   at	   10-­‐15	  weeks	   of	   age.	   All	   animal	  care	  and	  procedures	  followed	  German	  legal	  regulations	  and	  were	  previously	  approved	  by	  the	  governmental	  review	  board	  of	  the	  state	  of	  Baden-­‐Wuerttemberg,	  Germany.	  	  	  
Cell	  lines	  	  
Name	   Origin	   Media	  SKOV-­‐3	   ATCC	  (HTB-­‐77)	   McCoy´s	  5a	  +	  10%	  FCS	  OVCAR-­‐3	   ATCC	  (HTB-­‐161)	   RPMI-­‐1640	  +	  20%	  FCS	  	  
Cell	  culture	  products	  	  
Product	   Company	   Catalog	  No.	  15	  ml	  canonical	  falcon	  tubes	   TPP	   Z707724	  40	  µM	  cell	  strainer	   BD	   352340	  5	  ml	  round-­‐bottom	  polypropylene	  tubes	   BD	   352008	  5	  ml	  round-­‐bottom	  polypropylene	  tubes	   Sarstedt	   55.526	  50	  ml	  canonical	  falcon	  tubes	   Greiner	   T2318	  50ml	  reagent	  reservoir,	  sterile	   Corning	   4870	  70	  µM	  cell	  strainer	   BD	   352350	  ART	  XLP	  1000,	  200,	  10	  µl	  Reach	  filter	  tips	   VWR	   732-­‐2215,	  732-­‐
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2233,	  732-­‐2221	  Cryotube,	  1.8	  ml	  sterile	   Nunc	   375418	  Nalgene	  Freezing	  Container	  Mr.Frosty	   Bunc	   5100-­‐0001	  Primaria	  Cell	  Culture	  Flask,	  25	  cm²	   BD	   353808	  Primaria	  Cell	  Culture	  Flask,	  75	  cm²	   BD	   353810	  Primaria	  Cell	  Culture	  Plate,	  24-­‐well	   BD	   353847	  Primaria	  Cell	  Culture	  Plate,	  6-­‐well	   BD	   353846	  Primaria	  Cell	  Culture	  Plate,	  96-­‐well	   BD	   353872	  Safe	  lock	  tubes:	  0.5,	  1.5,	  2.0	  ml	   Eppendorf	   13625,	  12682,	  12776	  Serological	  Pipettes:	  2,	  5,	  10,	  25	  and	  50	  ml	  sterile	   BD	   3565-­‐07/-­‐29/-­‐30/-­‐35/-­‐50	  
	  
Cell	  culture	  media	  
	  
Product	   Company	   Catalog	  No.	  Advanced	  DMEM	  medium	   Life	  Technologies	   12491015	  Basic-­‐FGF	   Peprotech	   100-­‐18B	  ß-­‐Estradiol	   Sigma	   E2758	  Bovine	  Serum	  Albumine	   PAA	   K35-­‐011	  Chorionic	  Gonadotropin	   Sigma	   C1063	  CO2-­‐independent	  medium	   Life	  Technologies	   18045088	  Collagen	   Life	  Technologies	   A1048301	  Cryostor	  CS10	   Sigma	   C2874	  D-­‐PBS	   Sigma	   P5368	  EGF	   Peprotech	   100-­‐15	  FCS	  Gold	   PAA	   A11-­‐151	  Fetal	  Calf	  Serum,	  Origin:	  EU	  approved	   Life	  Technologies	   10270	  Fungizone	  (Amphotericin	  B)	   Life	  Technologies	   15290-­‐018	  Gentamycine	  (50mg/ml)	   Life	  Technologies	   15750-­‐060	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Antigen	   Clone	   Company	   Catalog	  No.	  CD133	  –	  PE	   AC133	   Miltenyi	   130-­‐080-­‐801	  CD44	  –	  PB	   IM7	   Biolegend	   103020	  CD24	  –	  APC	   ML5	   Biolegend	   311118	  CD151	  -­‐	  PE	   14A2.H1	   BD	   556056	  CD117-­‐APC	   YB5.B8	   BD	   550412	  EpCAM	  –	  FITC	   EBA-­‐1	   BD	   347197	  H2-­‐kD	  –	  AlexaFluor647	   SF1-­‐1.1	   Biolegend	   116612	  	  	  
Isotype	  controls	   Clone	   Company	   Catalog	  No.	  AlexaFluor647	  Mouse	  IgG2a	   MOPC-­‐173	   Biolegend	   400234	  APC	  Mouse	  IgG1	   MOPC-­‐21	   BD	   550854	  APC	  Mouse	  IgG2a	   MOPC-­‐173	   Biolegend	   400246	  FITC	  Mouse	  IgG1	   MOPC-­‐21	   Biolegend	   400108	  PB	  Mouse	  IgG2a	   MOPC-­‐173	   Biolegend	   400260	  PE	  Mouse	  IgG1	   MOPC-­‐21	   Biolegend	   400114	  PE	  Mouse	  IgG1	   MOPC-­‐21	   BD	   556650	  	  
Western	  Blot	  	  
Antigen	   Company	   Catalog	  No.	  ATF-­‐2	  Thr71	   Cell	  Signaling	   9912	  c-­‐Jun	  Ser63	   	   	  c-­‐Src	   Millipore	   14-­‐117	  Donkey	  Anti-­‐Rabbit	  IgG-­‐HRP	   Southern	  Biotech	   6445-­‐02	  ERK	   Cell	  Signaling	   4695	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Antigen	   Company	   Catalog	  No.	  
CA125	   Dako	   M3520	  
WT1	   Dako	   M3561	  
Ki67	   Dako	   M7240	  
CD151	   Sigma	   HPA011960	  
Venus	   Abcam	  	   Ab290	  
	  
Chemical	  and	  biological	  reagents	  
	  
Product	   Company	   Catalog	  No.	  
Accutase	   Life	  Technologies	   A11105	  
ACK	  Lysis	  Buffer	   Lonza	   10-­‐548E	  
CellTiterBlue	   Promega	   G8081	  
Ethylenediaminetetraacetic	  acid	  (EDTA)	   Sigma	   E9884	  
FiColl	  Paque	  Plus	   GE	   17-­‐1440-­‐02	  
Halt™	  Protease/Phosphatase	  Inhibitor	  
Cocktail	   Pierce	   78440	  
Isofluran	  B	   Braun	   6724123.00.00	  
Matrigel	   BD	   356234	  
NuPAGE®	  Antioxidant	   Life	  Technologies	   NP0005	  
NuPAGE®	  LDS	  Sample	  Buffer	   Life	  Technologies	   NP0007	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NuPAGE®	  MOPS	  SDS	  Running	  Buffer	  	   Life	  Technologies	   NP0001	  
NuPAGE®	  Sample	  Reducing	  Agent	   Life	  Technologies	   NP0004	  
Phenylmethanesulfonyl	  fluoride	  (PMSF)	   Sigma	   P7626	  
Propidium	  Iodide	   Biolegend	   421301	  
Western	  Blot	  Stripping	  Buffer	   Pierce	   21059	  
DNase	   Sigma	   D4263	  
Collagenase	  IV	   Sigma	   C5138	  
RIPA	  Buffer	  (10x)	   Cell	  Signaling	   9806	  
MagicMark™	  XP	  Western	  Protein	  Standard	  	   Life	  Technologies	  	   LC5602	  
Novex®	  Sharp	  Pre-­‐stained	  Protein	  Standard	   Life	  Technologies	  	   LC5800	  
Tween	  20	   Sigma	   P5927	  
Ponceau	  S	  solution	   Sigma	   P7170	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Solutions	  and	  media	  formulation	  
Cancer	  Stem	  Cell	  Medium	  
500	  ml	  Advanced	  DMEM/F12	  	  	  5	  ml	  N2	  Supplement	  2	  mM	  Glutamine	  	  1.7	  ml	  Glucose	  (45%)	  500	  µg	  GSH	  (250	  ul	  Stock)	  	  500	  µl	  each	  Trace	  Elements	  B,	  C	  	  250	  µl	  Trace	  Elements	  A	  	  25	  ml	  Sterile	  H2O	  Cell	  Culture	  Grade	  	  5mM	  HEPES	  for	  cell	  culture	  	  2	  µg/ml,	  Heparine	  	  1ml	  Sigma	  Lipid	  Mixture-­‐1	  	  50	  ng/ml	  hBasic-­‐FGF	  	  20	  ng/ml	  hEGF	  	  10	  ng/ml	  IGFR3	  100	  µM	  β-­‐Mercaptoethanol	  5	  µg/ml	  Insuline	  36	  ng/ml	  Hydrocortisone	  0,5	  ng/ml	  ß-­‐Estradiol	  
PEB	  Buffer	  1x	  PBS	  1%	  BSA	  2	  mM	  EDTA	  	  
CBP	  Buffer	  500	  ml	  CO2-­‐independent	  medium	  1%	  BSA	  2	  mM	  Glutamine	  	  	  
10x	  TBS	  Buffer	  (1L)	  24.2	  g	  Tris	  base	  80	  g	  NaCl	  adjust	  pH	  to	  7.6	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Human	  Tissue	  Specimen	  All	   human	   tissue	   samples	  were	   obtained	   from	   the	  Gynaecological	  Hospital,	   University	  Clinic	   Mannheim,	   with	   written	   informed	   consent	   under	   protocols	   approved	   by	   the	  review	   board	   of	   the	   Medical	   Faculty	   of	   the	   University	   of	   Heidelberg.	   Serous	   ovarian	  cancer	   tissue	  was	   collected	   from	  patients	  undergoing	   routine	   therapeutic	   surgery	  and	  was	  confirmed	  as	  serous	  ovarian	  carcinoma.	  
Xenografts	  of	  Primary	  Tumor	  Specimens	  and	  SOC	  Cell	  Lines	  To	  establish	  primary	  xenografts,	  tumors	  enzymatically	  disaggregated	  to	  obtain	  a	  single	  cell	   suspension	   and	   depleted	   for	   contaminating	   CD45+	  using	   anti-­‐CD45	   paramagnetic	  microbeads.	   At	   least	   1x105	   –	   1x106	   ovarian	   tumor	   cells	  were	   injected	   intraperitoneal	  into	  NOD.Cg-­‐Prkdcscid	   Il2rgtm1Wjl	   	   (NSG)	  mice,	  bred	   in	   the	  animal	   facility	  of	   the	  German	  Cancer	  Center.	  For	  the	  generation	  of	  xenografts	  from	  the	  SOC-­‐cell	  lines,	  a	  suspension	  of	  102-­‐104	  cultured	  cells	  diluted	   in	  media	  was	  prepared	  and	   injected	   intraperitoneal	   into	  NSG	  mice.	  	  Successful	   engraftment	   of	   tumors	   and	   subsequent	   growth	   was	   monitored	   by	   regular	  palpation	  of	  the	  implantation	  site.	  All	  animal	  care	  and	  procedures	  followed	  German	  legal	  regulations	   and	   were	   previously	   approved	   by	   the	   governmental	   review	   board	   of	   the	  state	  of	  Baden-­‐Wuerttemberg,	  Germany.	  	  
Dissociation	  of	  tumor	  material	  Primary	  patient	  specimen	  and	  first	  passage	  xenografts	  were	  first	  finely	  cut	  using	  sterile	  scalpels	  into	  small	  pieces	  <0.1	  mm3	  and	  dissociated	  into	  single	  cells	  by	  incubation	  with	  1	  µg/ml	   Collagenase	   IV	   for	   2h	   at	   37°C	   fixed	   on	   the	   MACSMix	   rotator	   with	   occasional	  periods	   of	   vortexing.	   The	   resulting	   suspension	   was	   filtered	   through	   a	   40	   µm	   mesh	  following	   which	   cell	   debris	   and	   dead	   cells	   were	   removed	   by	   density	   centrifugation.	  Remaining	   erythrocytes	   were	   removed	   using	   ACK	   Buffer.	   Contaminating	   CD45+	  leukocytes	  could	  be	  depleted	  using	  anti-­‐CD45	  paramagnetic	  microbeads.	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Cryopreservation	  of	  single	  cells	  derived	  from	  xenograft	  tumors	  Single	   cell	   suspensions	   derived	   from	   xenografted	   tumors	   were	   cryopreserved	   as	  described	  for	  the	  SOC	  cultures.	  
Serial	  transplantation	  assay	  Xenografts	   derived	   from	   SOC	   cells	   were	   processed	   into	   single	   cell	   suspensions	   as	  described.	  For	  analysis	  of	   serial	   transplantation	  efficacy,	  1x105	  xenograft-­‐derived	  cells	  were	  injected	  intraperitoneal	  into	  secondary	  respectively	  tertiary	  recipient	  NSG	  mice.	  
Determination	  of	  in	  vivo	  repopulation	  frequency	  SOC	  cells	  were	  processed	  into	  a	  single	  cell	  suspension	  and	  cell	  number	  was	  determined	  as	   described	   below.	   A	   group	   of	   three	   female	   NSG	  mice	   were	   injected	   intraperitoneal	  with	   104,	   103	   or	   102	   SOC	   cells,	   respectively.	   After	   100	   days	   follow-­‐up,	   mice	   were	  euthanized	  by	  cervical	  dislocation	  and	  evaluated	  for	  tumor	  growth	  at	  the	  injection	  site.	  Tumors	   were	   fixed	   in	   10%	   PFA/PBS	   for	   subsequent	   histological	   analyses.	   Resulting	  repopulation	   frequencies	   were	   determined	   using	   the	   ELDA	   webtool	  (http://bioinf.wehi.edu.au/software/elda).	  
In	  vivo	  bioluminescence	  imaging	  using	  the	  Xenogen	  system	  (IVIS-­‐200	  Caliper)	  Mice	  were	  injected	  intraperitoneally	  with	  D-­‐Luciferine	  Firefly	  Potassium	  salt	  (15	  mg/ml	  in	  PBS)	  at	  a	  dose	  of	  10	  μl	  per	  gram	  body	  weight	  (Biosynth)	  10	  minutes	  before	  imaging.	  The	  animals	  were	  anesthetized	  using	  4.5%	  isoflurane	  in	  oxygen	  (0.9	  l/min),	  maintained	  at	  1.5	  %	   isoflurane	   in	  oxygen	  and	  analyzed	   in	   the	  heated	  camera	  chamber.	  The	  Living	  Image	   software	   was	   used	   according	   to	   the	   manufacturer’s	   instructions	   (IVIS	   200,	  Caliper).	  	  
Cell	  culture	  methods	  
Coating	  of	  tissue	  culture	  flasks	  For	  coating	  of	  tissue	  culture	  flasks,	  Collagen	  at	  50µg/ml,	  Matrigel	  at	  50	  µg/ml	  and	  FCS	  at	  3%	  were	  added	  for	  to	  tissue-­‐culture	  treated	  flasks	  for	  4h	  at	  37°C.	  After	  a	  wash	  with	  PBS,	  flasks	  were	  either	  directly	  used	  or	  store	  until	  further	  use	  at	  4°C.	  
Generation	  of	  SOC	  cultures	  For	  establishing	  SOC	  culture,	  single	  cells	  (0,5	  -­‐	  1	  x	  105)	  derived	  from	  xenograft	  explants	  were	   seeded	   in	   T25	   Primaria	   flasks	   in	   CSC	   medium	   supplemented	   with	   50	   µg/ml	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Gentamycin,	   0.5	   µg/ml	   Fungizone	   and	   10	   µM	   Y-­‐27632.	   Adherent	   monolayer	   cultures	  were	  maintained	   and	   incubated	   at	   37°C	   and	   5%	   CO2.	   After	   outgrowth	   of	   tumor	   cells,	  contaminating	  fibroblasts	  were	  removed	  by	  trypsinization	  with	  Accutase	  and	  cells	  were	  subsequently	  propagated	  in	  antibiotic/ROCK-­‐inhibitor-­‐free	  CSC	  medium.	  	  	  
Splitting	  of	  SOC	  cultures	  Medium	  was	  removed	  from	  culture	  flasks	  and	  3	  ml	  Accutase	  per	  T75	  flask	  was	  added	  to	  remove	   the	   cells	   from	   the	   substrate.	   After	   10-­‐15	   minutes,	   cells	   dislodged	   from	   the	  surface	  and	  the	  single	  cell	  suspension	  was	  transferred	  into	  a	  falcon	  tube	  as	  a	  2:1	  dilution	  in	   CBP	   medium.	   After	   centrifugation	   (1200	   rpm,	   5	   min,	   4°C),	   the	   supernatant	   was	  removed	   and	   the	   pellet	   re-­‐suspended	   in	   1-­‐5	   ml	   of	   CBP	   buffer	   depending	   on	   the	  application.	  	  
Freezing	  of	  SOC	  cultures	  For	   cryopreservation	   of	   SOC	   cells,	   single	   cell	   suspensions	   were	   pelleted	   as	   described	  above	  and	  the	  resulting	  pellet	  was	  dissolved	  in	  Crystor	  CS10	  and	  subsequently	  aliqouted	  into	   cryovials.	   The	   vials	   were	   placed	   on	   ice	   for	   10	   minutes	   after	   which	   they	   were	  transferred,	   placed	   in	   a	   pre-­‐cooled	   Mr.Frosty,	   to	   the	   -­‐80°C	   freezer.	   Approximately	   5	  hours	  later,	  the	  cells	  were	  placed	  in	  the	  liquid	  nitrogen	  tank	  for	  long-­‐term	  storage.	  
Determination	  of	  cell	  number	  An	   aliquot	   of	   cell	   suspension	   was	   diluted	   1:10	   –	   1:50,	   depending	   on	   the	   expected	  number	  of	  cells,	  with	  trypan	  blue	  solution	  (0.05%	  w/v)	  to	  quantify	  the	  amount	  of	  viable	  cells.	  Cells	  were	  counted	  with	  a	  Neubauer	  chamber,	  whereas	  the	  number	  of	  viable	  cells	  was	  calculated	  according	  the	  formula:	  
Average	  cell	  number/chamber	  square	  x	  dilution	  factor	  x	  104	  
Proliferation	  assay	  SOC	  cells	  were	  seeded	  into	  96-­‐well	  plates	  at	  1000	  cells/well	  on	  Day	  0.	  Cell	  number	  was	  determined	  as	  a	  measure	  of	  cell	  viability	  using	   the	  CellTiterBlue	  assay	  as	  described	   in	  the	  manual.	   In	   order	   to	   establish	   a	   baseline,	   the	   first	   row	  was	   evaluated	   4h	   post	   cell	  plating,	  setting	  the	  derived	  emission	  values	  in	  relation	  to	  the	  plated	  cell	  number.	   	  Each	  day,	   subsequent	   rows	   were	   evaluated	   accordingly,	   thereby	   normalizing	   the	   derived	  emission	   values	   to	   the	   baseline	   derived	   from	   Day	   0.	   Therefore,	   cell	   growth	   was	  expressed	  as	  a	  function	  with	  respect	  to	  the	  initial	  number	  of	  cells.	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Determination	  of	  in	  vitro	  repopulation	  frequency	  SOC	  cells	  were	  plated	   in	  96-­‐well	  plates	   in	  a	   limiting	  dilution	  assay,	  starting	   from	  5000	  cells	  per	  well	   in	  Row	  1,	  diluted	  2-­‐fold	  in	  the	  subsequent	  rows.	  Plates	  were	  wrapped	  in	  saran	  wrap	   and	   incubated	   for	   72h	   in	   a	   humidified	   environment.	   After	   this	   incubation	  period,	   each	  well	  was	   evaluated	   for	   clonal	   outgrowth.	  A	  well	  was	   scored	  positive	   if	   it	  contained	  a	  substantial	  cell	  clone,	  mostly	  comprised	  of	  more	  than	  10	  cells.	  If	  no	  or	  only	  small	   clusters	   of	   cells	   (<10	   cells/clone)	   were	   present,	   the	   well	   was	   scored	   negative.	  Resulting	   repopulation	   frequencies	   were	   determined	   using	   the	   ELDA	   webtool	  (http://bioinf.wehi.edu.au/software/elda).	  
Flow	  cytometric	  analysis	  of	  SOC	  cells	  and	  xenograft-­‐derived	  cells	  For	  staining	  of	  cell	  surface	  antigens,	  1x106	  single	  cells	  were	  placed	  in	  PEB	  Buffer.	  In	  case	  of	  primary	  tumor	  cells	  and	  xenograft-­‐derived	  tumor	  cells,	  Fc	  receptors	  were	  blocked	  by	  incubation	  at	  4°C	  for	  15	  min	  with	  50	  µg/ml	  Intratect	  human	  IgG	  fraction.	  For	   surface	   staining,	   antibodies	  were	   added	   in	   appropriate	  dilutions	   and	   incubated	   in	  the	  fridge	  for	  at	  least	  20	  minutes.	  Following	  this	  incubation,	  cells	  were	  washed	  with	  PEB	  buffer	  and	  filtered	  through	  a	  mesh	  prior	  to	  FACS	  analysis.	  Staining	  of	  equal	  amounts	  of	  cells	   were	   prepared	   with	   corresponding	   isotypes	   for	   each	   antibody.	   Just	   prior	   to	  analysis,	  1	  µg/ml	  Propidium	  Iodide	  was	  added	  for	  death	  cell	  exclusion.	  	  Samples	  were	  acquired	  on	  a	  FACS	  LSR	  Fortessa	  cytometer	  and	  data	  was	  analysed	  with	  FlowJo	  analysis	  software.	  
Transduction	  of	  primary	  serous	  ovarian	  cancer	  cell	  lines	  	  SOC	  cells	  were	  dissociated	  using	  Accutase	  and	  single	  cell	   suspensions	  were	  seeded	   in	  T24	   Primaria	   flasks.	   Polyprene	   (10μg/ml)	   was	   added	   to	   the	   medium	   prior	   to	  transduction.	  After	  successful	   transduction	  of	   the	  serous	  ovarian	  cancer	  cells,	   the	  cells	  were	  sorted	  for	  the	  respective	  reporter	  such	  as	  Venus	  or	  GFP.	  	  
Gene	  expression	  analyses	  
RNA	  isolation	  Total	  RNA	  was	   isolated	   from	  different	   SOC	   lines	   (80%	  confluent)	   or	   tumor	   tissue	   (30	  mg)	   using	   the	   miRNeasy	   kit	   according	   the	   provided	   manual.	   SOC	   cells	   were	   directly	  lysed	   in	   the	   supplemented	   QIAZol	   Buffer,	   tumor	   tissue	   was	   submerged	   in	   the	   same	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buffer,	  using	  the	  GentleMACS	  Dissociator	  according	  the	  manufacturer’s	  instruction.	  RNA	  quantity	  was	  determined	  using	  the	  NanoDrop,	  quality	  and	  integrity	  of	  the	  RNA	  samples	  were	  assessed	  on	  the	  Agilent	  Bioanalyzer,	  using	  a	  NanoChip.	  Only	  samples	  with	  a	  RNA	  Intergrity	  Number	  (RIN)	  greater	  than	  8	  were	  subjected	  to	  expression	  analysis.	  
Microarray	  analysis	  and	  data	  processing	  
Hybridization	  and	  data	  normalization	  was	  performed	  by	  the	  Genomics	  core	  facility	  of	  the	  
German	  Cancer	  Research	  Center	  	  Gene	   expression	   analysis	   was	   performed	   using	   the	   Illumina	   BeadChip	   Technology	  (HumanHT-­‐12v4).	   cDNA	   and	   cRNA	   synthesis	   ,	   hybridization	   and	   scanning	   was	  performed	   according	   to	   the	  manufacturer’s	   instruction.	   Signal-­‐to-­‐noise	   ratio	  was	   very	  high	  across	  all	  chips	  analyzed	  with	  minimal	  background	  interference	  in	  all	  experiments.	  Raw	   data	   from	   the	   microarray	   analysis	   was	   background	   subtracted	   and	   median-­‐normalized	  using	  the	  Illumina	  BeadStudio	  software	  workbench.	  	  
Data	  and	  gene-­‐set-­‐enrichment	  analysis	  For	   analysis	   of	   differential	   gene	   expression	   and	   clustering	   we	   employed	   the	   TM4	  Microarray	  Software	  Suite.	  Significant	  Analysis	  of	  Microarray	  (SAM)	  was	  used	  to	  identify	  differentially	  regulated	  genes	  between	  subtypes	  selected	  at	  a	  FDR	  <	  0.05	  and	  with	  a	  fold	  change	   of	   >	   2.	   Correlation	   plots	   and	   respective	   Pearson	   coefficients	   (R2)	   between	  samples	  were	  generated	  using	  ‘R’.	  Gene	  set	  enrichment	  analysis	  on	  normalized	  data	  was	  conducted	  as	  described	  previously	   179	  using	   the	  complete	  MSig	  database	  on	   the	  Broad	  Institute	  server.	  Gene	  sets	  were	  considered	  significantly	  enriched	  with	  an	  FDR	  <	  0.2.	  	  
Immunohistology	  methods	  	  
	  
Immunohistology	  and	  initial	  evaluation	  of	  staining	  and	  tissue	  morphology	  were	  performed	  
by	  the	  department	  of	  Pathology,	  University	  Clinic	  Heidelberg	  
Immunohistology	  Tumor	   specimens	   were	   fixed	   in	   10%	   PFA	   overnight	   and	   embedded	   in	   paraffin.	   For	  immunohistochemistry,	   slides	   were	   de-­‐paraffinized	   and	   rehydrated.	   Antigens	   were	  retrieved	   by	   boiling	   in	   in	   a	   steam	   pot	   at	   pH	   6	   (Dako	   target	   retrieval	   solution,	   Dako,	  Glostrup)	   for	   15	   min,	   allowed	   to	   cool	   for	   30	   min	   and	   washed	   in	   distilled	   water.	  Nonspecific	   binding	  was	   blocked	   using	   the	   Linaris	   Avidin/Biotin	   blocking	   Kit	   (Vector	  Labs,	  Burlingame)	   according	   to	   the	  manufacturers	   instructions.	   Slides	  were	   incubated	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with	   primary	   antibodies	   for	   30	   min,	   rinsed	   in	   PBS-­‐T	   (PBS	   with	   0.5%	   Tween-­‐20),	  incubated	   for	   20	  min	  with	   the	   appropriate	   secondary	   antibody	   using	   the	   Dako	   REAL	  Detection	   System	   and	   rinsed	   in	   PBS-­‐T.	   After	   blocking	   of	   endogenous	   peroxidase	   and	  incubation	  with	  Streptavidin	  HRP	  (20	  min	  at	  RT),	  slides	  were	  developed	  with	  AEC	  and	  counterstained	  with	  Hematoxylin.	  	  
Primary	  antibodies	  were	  used	  at	  the	  following	  dilutions	  CA125	  1:25,	  WT1	  1:100,	  Ki67	  1:200,	  
CD151	  1:50	  and	  Venus	  1:500.	  All	  antibodies	  were	  diluted	  in	  Dako	  antibody	  diluent	  and	  two	  
pathologists	  scored	  all	  sections	  independently.	  	  
Western	  Blot	  methods	  
Cell	  lysis	  SOC	   cells	  were	   seeded	   into	   T75	   flasks	   and	   grown	   till	   80-­‐90%	   confluence.	   After	   three	  washing	   steps	   with	   ice-­‐cold	   PBS,	   remaining	   PBS	   was	   drained	   and	   400	   µl	   of	   1x	   RIPA	  Buffer	   supplemented	  with	  1x	  HALT	  Proteinase/Phosphatase	  Cocktail,	   1mM	  EDTA	  and	  1mM	  PMSF	  was	  evenly	  dispersed	  onto	  the	  cells.	  Flasks	  were	  incubated	  for	  5	  minutes	  on	  ice	  with	  occasional	  rocking	  of	  the	  flask.	  After	  the	  incubation,	  the	  cells	  were	  scraped	  with	  sterile	   spatulas	   and	   the	   resulting	   homogenate	   was	   transferred	   into	   a	   pre-­‐cooled	  Eppendorf	   tube.	  The	   lysate	  was	  vortexed	  at	   full	   speed	   for	  one	  minute	  and	   transferred	  into	   a	   pre-­‐cooled	   centrifuge	   (15	   min,	   20.000	   rpm).	   The	   resulting	   supernatant	   was	  transferred	  into	  a	  new	  Eppendorf	  tube	  and	  separated	  in	  20	  µl	  aliquots.	  Protein	  content	  was	  determined	  with	  a	  BCA	  Protein	  Assay	  as	  described	  in	  the	  manufacturer’s	  protocol.	  	  
Immunoblotting	  Samples	  were	  prepared	  for	  western	  blotting	  prior	  to	  loading	  the	  gel.	  20	  µg	  per	  sample	  were	   mixed	   with	   1x	   SDS	   Buffer	   and	   1x	   reducing	   agent	   and	   heated	   to	   70°C	   for	   10	  minutes.	  After	  that,	  the	  sample	  was	  loaded	  onto	  a	  NuPage	  4-­‐12%	  Bis/Tris	  Gel.	  A	  mixture	  of	  2	  µl	  MagicMarkXP	  and	  10	  µl	  Per-­‐Stained	  Marker	  was	  loaded	  in	  the	  first	  well	  of	  each	  gel	   and	   served	   as	  marker	   for	   determining	  molecular	  weight	   of	   the	   detected	   proteins.	  Gels	  were	  run	  in	  1x	  MOPS	  Buffer	  as	  described	  by	  the	  manufacturer	  for	  1	  h	  at	  120	  V/250	  mA.	  Blotting	  of	  proteins	  to	  nitrocellulose	  membranes	  was	  performed	  as	  depicted	  in	  the	  NuPage	   manual	   as	   a	   wet-­‐blot	   setup	   for	   2	   h	   at	   25V/300mA	   using	   transfer	   buffer	   as	  described	  above.	  A	  brief	  Ponceau	  S	  staining	  prior	  to	  blocking	  of	  the	  membrane	  verified	  successful	  transfer	  of	  proteins	  to	  the	  membrane.	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Membranes	   were	   blocked	   by	   incubating	   for	   2h	   at	   room	   temperature	   on	   an	   orbital	  shaker	  with	  TBS	  +	  0.1%	  Tween	  (TBS/T)	  +	  5%	  milk.	  After	   that	   the	  blot	  was	  washed	  5-­‐times	   5	   minutes	   with	   TBS/T.	   Primary	   antibodies	   were	   diluted	   as	   indicated	   in	   the	  datasheet	  in	  TBS/T	  +	  5%	  milk,	  in	  case	  of	  phospho-­‐antibodies,	  5%	  BSA	  was	  used	  instead,	  and	   incubated	  at	  4°C	  over	  night.	  After	   another	  wash	   (5-­‐times	  5	  minutes	  with	  TBS/T),	  isotype-­‐matched	  secondary	  antibodies	  were	   incubated	  at	  1:10000	  dilution	   in	  TBS/T	  +	  5%	  milk	  for	  1h	  at	  room	  temperature.	  After	  a	  final	  wash	  	  (5-­‐times	  5	  minutes	  with	  TBS/T),	  blots	   were	   developed	   using	   ECL	   development	   reagent.	   An	   initial	   10-­‐second	   exposure	  was	  used	  to	  determine	  the	  proper	  exposure	  time.	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5	   Results	  
	  
An	  improved	  model	  system	  for	  human	  Serous	  ovarian	  
carcinoma	  
Establishment	  of	  a	  primary	  xenograft	  model	  for	  Serous	  ovarian	  
carcinoma	  Long-­‐term	   serum	   cultured	   cell	   lines	   often	   fail	   to	   recapitulate	   the	   heterogeneity	   and	  characteristics	   of	   the	   original	   patient	   disease	   137,167,180.	   Therefore,	   we	   wanted	   to	  establish	  an	  improved	  in	  vitro	  culture	  model,	  able	  to	  faithfully	  reflect	  the	  unique	  features	  of	   each	   patient´s	   tumor.	   For	   this	   purpose,	   we	   evaluated	   the	   direct	   culture	   of	   cells	  isolated	   from	   primary	   tumor	   tissue	   specimens	   as	   well	   as	   serous	   effusions	   from	   the	  peritoneal-­‐	  or	  pleural	  cavity.	  However,	  only	  the	  cultivation	  of	  cells	  from	  serous	  effusions	  resulted	  in	  the	  efficient	  outgrowth	  of	  tumor	  cells	  in	  culture	  (data	  not	  shown).	  	  In	  order	  to	   expand	   the	   tumor	   material	   for	   further	   studies,	   we	   decided	   to	   establish	   a	   murine	  xenograft	  model	  in	  parallel	  (Figure	  9A).	  To	  achieve	  a	  preferably	  high	  engraftment	  rate,	  we	  chose	  the	  NOD.Cg-­‐Prkdcscid	  Il2rgtm1Wjl	  (NSG)	  mouse	  model,	  which	  has	  been	  described	  to	  be	  more	  permissive	  to	  xenotransplants	  compared	  to	  NOD/SCID	  mice	  181,182.	  For	  every	  clinical	  specimen,	  we	  injected	  at	  least	  three	  of	  these	  immunodeficient	  mice	  with	  1x105	  –	  1x106	  ovarian	  tumor	  cells	  into	  the	  peritoneal	  cavity,	  respectively.	  Contaminating	  human	  CD45+	   cells	   could	   be	   depleted	   using	   anti-­‐CD45	   paramagnetic	   microbeads	   before	  injection.	  	  In	   cooperation	  with	  Gynaecological	  Hospital,	  University	  Clinic	  Mannheim,	  we	   received	  from	  March	  2011	  to	  May	  2013	  in	  total	  15	  primary	  ovarian	  tumor	  samples	  and	  9	  serous	  effusions	   in	   total.	  Out	  of	   these	  23	  (96%)	  were	  histologically	  verified	  as	  serous	  ovarian	  adenocarcinoma,	  one	  was	  classified	  as	  a	  mucinous	  ovarian	  carcinoma	  (Appendix,	  Table	  
1).	  From	  a	  total	  number	  of	  23	  transplanted	  primary	  tumors	  we	  were	  able	  to	  establish	  15	  (65%)	   xenograft	   models.	   The	   established	   primary	   serous	   ovarian	   carcinoma	   (SOC)	  xenografts	   recapitulated	   many	   characteristics	   of	   the	   human	   disease	   such	   as	   the	  development	  of	  ascites	  and	  tumor	  growth	  at	  the	  ovaries	  and	  the	  abdomen	  (Figure	  9B).	  All	   xenografted	   tumors	   were	   stained	   for	   the	   expression	   of	   serous	   ovarian	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adenocarcinoma	   specific	   markers	   and	   histologically	   classified	   as	   serous	   ovarian	  adenocarcinoma	  (Appendix,	  Table	  1).	  	  	  
	  
Figure	  9	  –	  (A)	  Schematic	  overview	  of	  the	  experimental	  workflow	  for	  the	  generation	  of	  xenograft	  and	  primary	  ovarian	  cancer	  cell	  lines.	  (B)	  Primary	  xenograft	  models	  established	  by	  injection	  of	  primary	  human	  specimen	  into	  the	  peritoneal	  cavity	  faithfully	  mimic	  the	  human	  disease	  with	  development	  of	  ascites	  (left),	  tumor	  growth	  at	  ovary	  and	  abdomen	  as	  well	  as	  distant	  sites	  (right,	  white	  arrows).	  	  
	  As	   soon	  as	   any	  palpable	   tumor	  or	   any	  ascites	  development	   could	  be	  detected,	   tumors	  were	   surgically	   removed	   and	   further	   processed.	   In	   general,	   the	   volume	   of	   excised	  tumors	  ranged	  between	  1	  –	  1,5	  cm3	  and	  the	  median	  latency	  of	  xenograft	  tumor	  growth	  was	  114	  (+/-­‐49)	  days.	  We	  detected	  tumor	  growth	  at	  the	  ovaries	  and	  into	  the	  abdomen	  of	  xenograft	  mice.	  Metastatic	  deposits	  could	  be	  detected	  at	  the	  abdominal	  wall,	  the	  liver	  and	  the	  diaphragm	  (Figure	  9B).	  All	  xenografts	  were	  serially	  transplantable	  in	  mice.	  The	   comparison	   of	   xenografted	   tumors	   with	   the	   appropriate	   primary	   patient	   tumor	  revealed	   that	   morphological	   features	   and	   the	   expression	   of	   specific	   histopathological	  markers	  for	  SOC	  were	  well	  conserved.	  Importantly,	  all	  the	  xenografted	  tumors	  obtained	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from	  patient	  samples	  showed	  strong	  positive	  stainings	  for	  both	  of	  the	  two	  clinically	  used	  markers	   for	   the	  diagnosis	  of	  SOC,	  CA125	  and	  WT1	  (Figure	   10).	  We	  also	  observed	  the	  appearance	   of	   stromal	   compartments	   especially	   in	   the	   first	   in	   vivo	   passage	   of	   the	  xenografts.	   However,	   compared	   to	   the	   original	   patient	   tumor	   we	   found	   relative	   an	  enrichment	  in	  tumor	  cell	  content	  versus	  stroma	  content	  in	  our	  xenografted	  models.	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Establishment	  of	  a	  primary	  in	  vitro	  culture	  system	  for	  Serous	  ovarian	  
carcinoma	  Despite	  many	  advantages	  of	  primary	  xenograft	  models,	  an	   in	  vitro	  model	   is	  crucial	   for	  the	  manipulation	  of	  cells	  and	  a	  more	  detailed	  study	  of	  cellular	  mechanisms.	  Therefore,	  we	   tried	   to	   set	  up	   low	  passage	  primary	   cell	   cultures	  out	  of	   our	   successful	   established	  primary	   xenografts.	   Freshly	   excised	   xenograft	   tumors	   as	   well	   as	   ascites	   were	  enzymatically	   disaggregated	   to	   obtain	   a	   single	   cell	   suspension.	   Single	   cells	   were	  subsequently	  plated	  at	  a	  density	  of	  0,5	  -­‐	  1	  x	  105	  cells	  per	  25	  cm2	  flask	  and	  cultured	  in	  a	  serum-­‐free	  media	   formulation	   180	   (Figure	   9A).	   In	   order	   to	   define	   culture	   conditions,	  able	   to	   lead	   to	   a	   maximum	   outgrowth	   of	   epithelial	   ovarian	   cancer	   cells,	   we	   tested	  different	  combinations	  of	  various	  growth	  factors	  and	  substrates	  additionally	  to	  the	  basic	  stem	  cell	  media	  (SCM)	  (Figure	  11).	  Already	   between	   7	   to	   14	   days,	   we	   observed	   growth	   of	   a	   mixed	   culture	   consisting	   of	  epithelial	   cell	   clusters	   as	  well	   as	   fibroblast-­‐like	   cells.	  These	  mixed	  populations	  of	   cells	  showed	   adherent	   growth	   on	   every	   substrate	   verified.	   However,	   the	   amount	   of	  proliferating	  cells	  varied	  between	  different	  settings.	  We	  observed	  that	  most	  of	  the	  cells	  attached	   to	   Primaria	   and	   FCS-­‐coated	   flasks,	   whereas	   cells	   seeded	   on	   Collagen-­‐coated	  flasks	   displayed	   less	   attachment	   (Figure	   11A).	   Taken	   together,	   these	   experiments	  revealed	  that	  a	  larger	  fraction	  of	  cells,	  including	  fibroblast-­‐like	  cells,	  was	  able	  to	  grow	  on	  FCS-­‐coated	   flasks,	   indicating	   that	   this	   substrate	   supports	   adhesion	   in	   general.	  Furthermore,	   we	   analysed	   the	   cultivation	   of	   primary	   human	   ovarian	   cancer	   cells	   in	  spheroids	   as	   this	   approach	   has	   been	   described	   in	   several	   studies	   for	   the	   successful	  establishment	  of	  primary	  cultures	  for	  ovarian	  cancer	  182,183.	  	  A	  comparison	  of	  the	  two	  above	  mentioned	  procedures,	  cultivation	  as	  spheroids	  on	  ultra-­‐low	   attachment	   flasks	  with	   the	   adherent	   culture	   on	   Primaria	   flasks,	   revealed	   that	   the	  adherent	   culture	   setting	   promoted	   a	   significantly	   faster	   growth	   of	   cells	   and	   a	   lower	  amount	  of	  dead	  cells	  (Figure	  11A,	  data	  not	  shown).	  This	  might	  be	  due	  to	  the	  fact	  that	  in	  adherent	   cultures	   every	   cell	   has	   an	   optimal	   supply	   of	   nutrients	   and	   growth	   factors,	  whereas	  in	  sphere	  cultures	  only	  the	  cells	  on	  the	  sphere	  surface	  do	  so	  as	  well.	  In	  FCS-­‐	  and	  Collagen-­‐	  coated	  flasks	  we	  noted	  a	  higher	  proportion	  of	  fibroblast-­‐like	  cells	  attached	  to	  the	   substrate.	   Especially	   coating	   with	   FCS	   promoted	   outgrowth	   of	   these	   type	   of	   cells	  
(Figure	   11A).	   While	   in	   Primaria	   flasks,	   fibroblast-­‐like	   cells	   could	   be	   removed	   by	  sequential	  treatment	  with	  accutase,	  these	  cells	  were	  able	  to	  endure	  in	  FCS-­‐coated	  flasks.	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Figure	  11	  –	  (A)	  Exemplary	  images	  of	  cells	  derived	  from	  a	  primary	  SOC	  xenograft	  (OT12)	  cultured	  on	  different	  substrates.	  (B)	  Exemplary	  images	  of	  cells	  derived	  from	  a	  primary	  SOC	  xenograft	  (OT13)	  cultured	  with	  several	  combinations	  of	  hormones	  and	  growth	  factors	  in	  addition	  to	  the	  basic	  stem	  cell	  media	  (scale	  bar	  100	  μm)	  	  	  To	  determine	  the	  optimal	  conditions	  for	  the	  growth	  and	  expansion	  of	  primary	  ovarian	  cancer	  cells,	  we	  tested	  several	  hormones	  and	  growth	  factors	  additionally	  to	  the	  factors	  bFGF,	   EGF	   and	   IGFR3,	   which	   are	   included	   in	   the	   basic	   stem	   cell	   media.	   According	   to	  previous	  reports	  about	  the	  cultivation	  of	  primary	  ovarian	  cells	  and	  their	  dependency	  on	  hormones	  184	  and	  growth	  factors	  185,	  we	  focused	  on	  female	  sex	  hormones	  such	  as	  human	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menopausal	   gonadotropin,	   human	   chorionic	   gonadotropin	   and	   estradiol.	   They	   were	  described	   to	   stimulate	   proliferation	   of	   human	   primary	   ovarian	   tumor	   cells.	   We	   also	  included	  the	  growth	  factor	  heregulin,	  which	  was	  reported	  to	  be	  effective	  in	  stimulating	  the	  outgrowth	  of	  ovarian	  tumor	  cells	  183.	  However,	  we	  observed	  only	   in	  combination	  with	  estradiol	  a	  significant	   increase	   in	   the	  number	  of	  outgrowing	  cells.	   In	  parallel,	  we	  noted	   in	   the	  plates	   treated	  with	  hMG,	  hCG	  and	  hMG/hCG	   a	   higher	  number	   of	   differentiated	   cells,	   indicating	   that	   these	  hormones	  drive	   differentiation	   of	   primary	   ovarian	   cancer	   cells	   (Figure	   11B).	   The	   results	   of	  experiments	   for	   the	   definition	   of	   the	   optimal	   growth	   conditions	   for	   primary	   ovarian	  cancer	  cells	  are	  summarized	  in	  Table	  3.	  	  
 
Table	  3	  –	  Summary	  and	  results	  of	  the	  different	  combinations	  of	  substrates	  and	  growth	  factors	  tested	  to	  establish	  a	  primary	  culture	  of	  ovarian	  cancer	  cells	  Substrate	  	   Basic	  SCM	   +Estradiol	   +menopausal	  Gonadotropin	  (hMG)	   +chorionic	  Gonadotropin	  (hCG)	   +hMG/hCG	   +He-­‐regulin	  Primaria	   ++	   +++	   ++	   ++	   ++	   ++	  Ultra-­‐low	  attachment	   +	   ++	   +	   +	   +	   +	  3%	  FCS	   ++F	   ++F	   ++F	   ++F	   ++F	   ++F	  10μg/ml	  Collagen	   +F	   +F	   +F	   +F	   +F	   +F	  	  +++	   High	  amount	  of	  growing	  epithelial	  tumor	  cells	  	  	  ++	   Medium	  amount	  of	  growing	  epithelial	  tumor	  cells	  +	   Low	  amount	  of	  growing	  epithelial	  tumor	  cells	  F	   Significant	  outgrowth	  of	  fibroblast-­‐like	  cells	  	  According	   to	   these	   results,	   we	   supplemented	   the	   basic	   SCM	   with	   estradiol	   and	   used	  Primaria	  flasks	  for	  the	  establishment	  of	  primary	  human	  SOC	  cultures	  in	  all	  subsequent	  studies.	  By	  utilizing	  these	  conditions,	  we	  were	  able	  to	  establish	  8	  stable	  cell	  lines	  out	  of	  15	  primary	  SOC	  xenografts.	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Interestingly,	   when	   we	   compared	   the	   different	   SOC	   cell	   lines,	   we	   observed	   a	   broad	  heterogeneity	   in	   morphological	   features.	   Moreover,	   the	   individual	   SOC	   cell	   lines	   also	  showed	  discrepancies	  in	  growth	  behaviour.	  The	  cell	   lines	  OC18,	  OC19,	  OC20	  and	  OC21	  grew	  in	  clusters	  of	  cells	  and	  showed	  an	  epithelial	  cell	  like	  growth	  (Figure	  12).	  These	  cell	  lines	   displayed	   a	   quite	   differentiated	   morphology.	   The	   remaining	   group	   of	   cell	   lines	  (OC12,	  OC14	  and	  OC15)	  reflected	  the	  rather	  undifferentiated	  histology	  of	  their	  primary	  tumors.	   In	   these	   lines	   we	   observed	   a	   loss	   of	   epithelial	   characteristics	   and	   a	   spindle-­‐shaped	  morphology	  (Figure	  12).	  	  	  
	  
Figure	  12	  –	  Representative	  images	  of	  different	  primary	  SOC	  cell	  lines	  established	  in	  this	  study	  (scale	  bar	  100	  μm).	  	  A	  more	  precise	   analysis	   of	   the	   growth	  behaviour	   confirmed	  our	   previous	   observation	  and	   revealed	   significant	   differences	   in	   the	   in	  vitro	  growth	   between	   the	   individual	   cell	  lines.	  While	  the	  majority	  of	  cell	  lines	  with	  a	  rather	  undifferentiated	  morphology	  (OC12,	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OC14,	  OC15)	  were	  highly	  proliferative,	  the	  remaining	  SOC	  cell	  lines	  (OC18,	  OC19,	  OC20,	  OC21)	  displayed	  a	   lower	  growth	  rate	  (Figure	   13A).	  To	   further	   investigate	   the	  growth	  pattern	  of	   the	  different	   cell	   lines,	  we	  performed	  additional	   cell	   cycle	   and	  proliferation	  analysis	   by	   nucleotide	   analogue	   uptake	   assay.	   However,	   we	   did	   not	   observe	   any	  significant	  differences	  between	   the	   individual	   cell	   lines	   in	   cell	   cycle	   stage	  distribution.	  We	  only	  realized	  a	  tendency	  pointing	  towards	  two	  groups	  of	  different	  cycling	  cell	  lines.	  SOC	  cell	   lines,	  which	   showed	  significantly	   slower	  growth	   rates	   (OC18	  and	  OC20),	   also	  contained	  less	  active	  cycling	  cells	  (cells	  in	  S	  and	  G2/M	  phase)	  compared	  to	  faster	  cycling	  cell	  lines	  (OC12	  and	  OC14)	  (Figure	  13B/C).	  	  
	  
Figure	  13	  –	  (A)	  Analysis	  of	  the	  growth	  behaviour	  of	  different	  SOC	  lines	  revealed	  that	  they	  differ	  in	  their	  proliferation	  index	  in	  vitro.	  (B-­‐C)	  Cell	  cycle	  analysis	  of	  different	  SOC	  cell	  lines	  confirmed	  the	  differences	  in	  growth	  behaviour.	  	  	  To	   investigate	   if	   the	   differential	   growth	   patterns	   are	   also	   linked	   to	   differences	   in	   the	  capacity	  of	  clonal	  outgrowth,	  we	  analysed	  the	  in	  vitro	  clonogenicity	  of	  the	  individual	  SOC	  cell	   lines	   (Figure	   14).	   Interestingly,	   we	   found	   that	   SOC	   cells	   that	   showed	   a	   higher	  proliferation	   index	   also	   exhibited	   an	   increased	   clonogenic	   potential.	   Cell	   lines	   with	   a	  more	  differentiated	  morphology	  consistently	  had	  the	  lowest	  repopulation	  frequency.	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Figure	  15	  –	  (A)	  Representative	  FACS	  analysis	  of	  different	  primary	  SOC	  cell	  lines	  (OC12,	  OC14,	  OC15,	  OC18	  and	  OC20)	  revealed	  a	  strong	  heterogeneity	  in	  the	  expression	  of	  CD24/CD44	  compared	  to	  conventional	  cell	  lines	  (SKOV-­‐3	  and	  OVCAR3).	  (B)	  Frequency	  of	  CD24	  and	  CD44	  for	  individual	  SOC	  cell	  lines.	  	  
Table	  4	  –	  Frequencies	  of	  described	  TIC	  markers	  for	  individual	  SOC	  cell	  lines	  as	  determined	  by	  FACS	  
Cell	  line	  
	   CD24
+	   CD44+	   CD133+	   CD44
+/	  
CD117+	  
OC12	   83%	   100%	   0%	   2%	  
OC14	   73%	   98%	   0%	   0%	  
OC15	   34%	   39%	   0%	   5%	  
OC18	   13%	   48%	   0%	   0%	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Primary	  SOC	  cell	  lines	  are	  tumorigenic	  in	  vivo	  and	  preserve	  the	  
original	  tumor	  heterogeneity	  upon	  xenotransplantation	  In	   order	   to	   further	   investigate	   the	   previous	   established	   primary	   SOC	   cell	   lines	  concerning	  tumorigenicity	  and	  stability	  in	  vivo,	  we	  set	  up	  transplantation	  experiments	  in	  secondary	  recipient	  mice.	  We	  were	  especially	  interested	  in	  the	  repopulation	  frequency	  of	   the	   different	   cell	   lines	   and	   possible	   correlations	  with	   the	   expression	   of	   certain	   TIC	  markers.	   In	   addition,	   we	   wanted	   verify	   whether	   the	   histopathology	   of	   the	   original	  primary	  xenograft	  was	  conserved	  (Figure	  9A).	  	  In	   order	   to	   investigate	   if	   the	   significant	   differences	   in	   the	   clonogenicity	   between	   the	  different	   SOC	   lines	   were	   also	   reflected	   in	   vivo,	   we	   set	   up	   a	   limiting	   dilution	   assay.	  Therefore	   we	   injected	   different	   concentrations	   of	   cells,	   ranging	   from	   1x102	   to	   1x104,	  intraperitoneal	   into	  NSG	  mice.	   For	   non-­‐invasive	  monitoring	   of	   tumor	   growth	   in	  mice,	  tumor	   cells	   were	   transduced	   with	   a	   lentiviral	   reporter	   expressing	   luciferase	   and	   the	  fluorescent	   protein	   Venus.	   After	   successful	   transduction,	   Venus-­‐positive	   cells	   were	  sorted	   by	   FACS	   in	   order	   to	   obtain	   cells	   which	   are	   completely	   positive	   for	   the	   two	  reporters.	   In	   vivo	   growth	   of	   the	   tumors	   was	   monitored	   every	   two	   weeks	   via	  bioluminescence	  imaging	  using	  the	  Xenogen	  system	  (IVIS®	  200	  series,	  Caliper)	  (Figure	  
16A).	   As	   for	   the	   in	   vitro	   cultures,	   we	   observed	   significant	   differences	   in	   growth	  behaviour	  and	  clonogenicity	  between	  the	  SOC	  xenografts.	  In	  general,	  a	  first	  appearance	  of	   signal	   was	   detected	   between	   4	   and	   7	   weeks	   post	   injection,	   and	   the	   timeframe	   of	  tumor	  growth	  ranged	  between	  68	  and	  189	  days.	  We	  detected	  no	  significant	  differences	  in	  growth	  between	  tumors	  originating	  from	  serous	  effusions	  or	  directly	  from	  the	  tumor.	  Within	  the	  groups	  injected	  with	  the	  highest	  number	  of	  cells	  (1x104)	  all	  mice	  of	  each	  cell	  line	   developed	   tumors.	   First	   differences	   in	   in	   vivo	   clonogenicity	   became	   apparent	  between	  different	  SOC	  lines	  in	  groups	  injected	  with	  1x103	  tumor	  cells.	  In	  these	  groups,	  only	  mice	   injected	  with	   the	   cell	   lines	  OC12	  and	  OC14	   showed	   tumor	  appearance	  with	  100%	   frequency.	  We	   observed	   an	   overall	   agreement	   between	   the	   in	  vitro	   determined	  clonogenicity	  and	  the	  tumor	  initiating	  potential	  in	  vivo	  for	  the	  tested	  SOC	  cell	  lines.	  Mice	  injected	  with	   the	   lowest	   cell	   number	   (1x102)	   developed	   no	   tumors	   in	   the	   same	   time	  frame	   (Table	   5).	  Noteworthy,	   tumor	  growth	   for	  mice	   injected	  with	  1x102	   tumor	   cells	  could	   be	   observed	   beyond	   the	   time	   frame	   shown	   in	   Figure	   15A,	   e.g.	   after	   77	   days	  (OC12).	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Figure	  15	  –	  Representative	  tumor	  growth	  curves	  of	  the	  OC12	  cell	  line.	  (A)	  In	  vivo	  bioluminescence	  measurement	  of	  2	  groups	  of	  mice	  injected	  with	  different	  cell	  numbers	  using	  the	  Xenogen	  system.	  (B)	  Growth	  curve	  according	  to	  bioluminescence	  signal	  of	  intraperitoneal	  injected	  mice	  (n=3	  per	  group).	  
	  All	  SOC	  cell	   lines	  we	  generated	  retained	  the	  capacity	   to	   form	  xenograft	   tumors	   in	  NSG	  mice.	  In	  addition,	  in	  every	  cell-­‐line	  derived	  tumors	  (DT)	  we	  observed	  a	  strikingly	  robust	  development	  of	  the	  stromal	  compartments.	  These	  morphological	  properties	  were	  barely	  seen	  in	  xenografts	  derived	  from	  conventional	  cell	  lines	  (Figure	  17B).	  Intriguingly,	  each	  SOC	   cell	   line	   DT	   could	   also	   reveal	   a	   characteristic	   metastatic	   potential.	   Spontaneous	  metastasis	   formation	  could	  be	  observed	  for	  3	  out	  of	  7	  different	  primary	  SOC	  cell	   lines.	  Intraperitoneal	   injection	  of	  both	  OC14	  and	  OC20	   led	   to	   the	   remarkable	   appearance	  of	  distant	  metastases	   in	   the	   lungs	  while	  OC18	  developed	  both	   liver	   and	   lung	  metastases	  
(Table	   5)	   (Figure	   17C).	   Furthermore,	   all	   the	   mice	   injected	   with	   SOC	   cell	   lines	  developed	   ascites	   and	   showed	   typical	   collateral	   hallmarks	   of	   SOC,	   such	   as	  metastatic	  deposits	   at	   the	   abdominal	  wall,	   the	   liver	   and	   the	   diaphragm.	  We	   observed	   significant	  correlations	  between	   the	  metastatic	   capacity	   of	   the	  derived	   xenograft	   tumors	   and	   the	  origin	  of	  the	  primary	  tumor	  material.	  	  Primary	  cell	  lines	  that	  were	  derived	  from	  serous	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effusions	   such	   as	   ascites	   or	   pleural	   effusions	   exhibited	   an	   increased	   capability	   for	   the	  metastatic	  colonization	  of	  lungs	  or	  liver	  (Table	  5)	  (Appendix,Table	  1).	  	  	  






incidence	   Metastases	   Latency	  (days)	  
Repopulation	  
frequency)	  OC12	   1x104	   3/3	   -­‐	   70	   1/417	  	   1x103	   3/3	   -­‐	   	   	  	   1x102	   0/3	   -­‐	   	   	  OC14	   1x104	   3/3	   Lung	   91	   1/417	  	   1x103	   3/3	   -­‐	   	   	  	   1x102	   0/3	   -­‐	   	   	  OC15	   1x104	   3/3	   -­‐	   112	   1/2340	  	   1x103	   1/3	   -­‐	   	   	  	   1x102	   0/3	   -­‐	   	   	  OC18	   1x104	   3/3	   Lung,	  Liver	   68	   1/1072	  	   1x103	   2/3	   Lung/Liver	   	   	  	   1x102	   0/3	   -­‐	   	   	  OC19	   1x104	   3/3	   -­‐	   135	   1/2340	  	   1x103	   1/3	   -­‐	   	   	  OC20	   1x104	   3/3	   Lung	   75	   1/1072	  	   1x103	   2/3	   Lung	   	   	  	   1x102	   0/3	   -­‐	   	   	  OC21	   1x104	   3/3	   -­‐	   189	   ND	  	  Finally,	  we	  found	  similarities	  in	  the	  morphological	  heterogeneity	  and	  the	  expression	  of	  the	   SOC	   specific	   markers	   CA125	   and	  WT1	   in	   the	   SOC	   cell	   lines	   derived	   tumors	   (DT)	  
(Figure	   17	   A).	   	   The	   comparison	   of	   the	   histopathological	   characteristics	   between	   the	  original	   patient´s	   tumor,	   the	   corresponding	   primary	   xenograft	   and	   cell	   line	   derived	  tumors,	   revealed	   that	   the	   overall	   features	  were	  well	   conserved	   along	  with	   the	  model	  system	  (Figure	   17A).	  Taken	   together,	  our	  primary	  SOC	  cell	   line	  derived	   tumors	  show	  several	  hallmarks	  of	  human	  SOC,	  which	  are	  often	   lost	   in	  xenografts	   from	  conventional	  cell	  lines.	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Figures	  17	  –	  (A)	  Morphological	  characteristics	  as	  well	  as	  the	  expression	  of	  SOC	  specific	  markers	  CA125	  and	  WT1	  observed	  in	  of	  the	  original	  ovarian	  cancer	  patient	  tumor	  (top)	  and	  the	  corresponding	  primary	  xenograft	  (middle)	  are	  well	  conserved	  in	  the	  SOC	  cell	  line	  derived	  tumors	  (DT).	  (B)	  Xenograft	  tumors	  established	  from	  conventional	  cell	  lines	  do	  not	  display	  morphological	  features	  of	  SOC.	  (C)	  Spontaneous	  metastases	  to	  liver	  (top)	  and	  lung	  (bottom)	  detected	  in	  derived	  tumors	  (scale	  bar	  100	  μm)	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We	  next	  wanted	  to	  investigate	  if	  the	  SOC	  cell	  line	  derived	  tumors	  retain	  their	  ability	  to	  form	  tumors	  in	  secondary	  and	  tertiary	  recipient	  mice.	  Therefore	  we	  injected	  single	  cell	  suspensions	  derived	  from	  the	  respective	  tumors	  into	  further	  mice.	  We	  found	  that	  all	  SOC	  cell	   line	  derived	   tumors	  were	  able	   to	   form	  tumors	   for	  at	   least	   three	  serial	  passages	   in	  
vivo.	   Once	   again,	   these	   tumors	  maintained	   their	   histopathology	   and	   the	   expression	   of	  serous	  ovarian	  carcinoma	  specific	  markers	  (Figure	  18).	  
	  
	  
Figure	  18	  –	  (A)	  SOC	  cell	  line	  derived	  tumors	  maintain	  their	  ability	  to	  form	  tumors	  for	  at	  least	  three	  passages	  in	  vivo.	  Shown	  are	  representative	  images	  from	  a	  primary	  SOC	  line.	  Importantly,	  the	  expression	  of	  CA125	  and	  WT1	  is	  retained	  throughout	  all	  serial	  passages	  (2nd	  to	  4th	  row)(scale	  bar	  100	  μm).	  	  
	  	  
	   Results	   	  	   	  
60	  
According	  to	  the	  results,	  we	  obtained	  from	  the	  determination	  of	  the	  clongenicity	  in	  vivo,	  we	   wondered	   if	   the	   differences	   between	   the	   cell	   lines	   might	   be	   explained	   by	   the	  frequency	  of	  TIC	  markers,	  which	  are	  described	  for	  ovarian	  cancer.	  As	  we	  observed	  for	  the	  in	  vitro	  cultures,	  also	  the	  corresponding	  DTs	  showed	  significant	  differences	  in	  their	  TIC	  marker	  profile	  as	  assessed	  by	  FACS	  analysis	  (Figure	  19).	   	  Importantly,	  the	  specific	  marker	  profile	  of	   every	  SOC	   line	  was	   relatively	   stable	  between	  primary	  xenograft	   and	  SOC	  cell	  line	  derived	  tumor	  (Table	  6)	  and	  consistently	  with	  the	  in	  vitro	  data,	  we	  found	  no	  significant	  correlation	  between	  the	  TIC	  frequency	  in	  vivo	  and	  the	  clonogenic	  capacity	  of	  the	  SOC	  line	  derived	  tumors.	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differences	   (Figure	   19).	   Similar	   results	   also	  were	   gained	   for	   the	  markers	   CD133	   and	  CD117	  (Table	  6).	  In	  conclusion,	  we	  could	  show	  that	  our	  approach	  leads	  to	  the	  generation	  of	  cell	  lines	  that	  remarkably	   recall	   the	   patient’s	   disease	   upon	   experimental	   transplantation	   in	  vivo.	  We	  could	   observe	   a	   huge	   heterogeneity	   in	   morphology	   and	   marker	   expression	   between	  different	  patient	  tumors	  and	  that	  these	  features	  were	  maintained	  by	  our	  culture	  model.	  	  




CD24+	   CD44+	   CD44+/	  CD117+	  Primary	  xenograft	   Derived	  tumor	   Primary	  xenograft	   Derived	  tumor	   Primary	  xenograft	   Derived	  tumor	  
OC12	   3.49%	   8.2%	   57.3	  %	   91%	   5.3%	   7.8%	  
OC14	   13.7%	   27.1%	   87.8%	   98.3%	   3%	   6%	  
OC15	   11.9%	   26.4%	   23.7%	   32.5%	   0%	   0%	  
OC18	   13.4%	   19.4%	   21.9%	   39.4%	   0%	   0%	  
OC20	   11.4%	   21.3%	   20.8%	   32.2%	   0%	   0%	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Gene	  expression	  profiling	  on	  the	  SOC	  model	  
Altered	  pathways	  in	  primary	  SOC	  lines	  In	  order	  to	  identify	  molecular	  alterations	  that	  influence	  pathophysiology,	  histology	  and	  constitute	  possible	  therapeutic	  targets,	  we	  performed	  gene	  expression	  analyses	  on	  the	  SOC	   lines.	   For	   the	   generation	   of	   mRNA	   expression	   profiles	   we	   applied	   the	   Illumina	  Human	  HT12	  v4	  bead	  chip	  technology	  at	  the	  Genomics	  Proteomics	  Core	  Facility	  of	  the	  German	   Cancer	   Research	   Center.	   We	   integrated	   the	   gene	   expression	   profiles	   of	   our	  primary	   SOC	   cell	   lines,	   the	   corresponding	   derived	   xenograft	   tumors	   and	   a	   described	  human	  ovarian	  surface	  epithelial	  cell	  line	  (Hosepic)	  186	  in	  our	  analyses.	  A	  comparison	  of	  our	  primary	  culture	  models	  and	   their	  derived	   tumors	  with	  ovarian	  surface	  epithelium	  might	  allow	  the	  identification	  of	  pathways	  that	  specifically	  altered	  in	  ovarian	  cancer.	  Hence,	   our	   first	   focus	  was	   the	   analysis	   of	   differentially	   expressed	   genes	   between	   our	  SOC	   models	   and	   the	   human	   ovarian	   surface	   epithelium.	   Gene	   expression	   datasets	   of	  seven	   SOC	   cell	   lines	   and	   their	   corresponding	   xenografts	   were	   compared	   with	   gene	  expression	   data	   of	   human	   ovarian	   surface	   epithelial	   cells	   using	   Gene	   Set	   Enrichment	  Analysis	   (GSEA).	   The	   obtained	   results	   delivered	   insights	   into	   the	   expression	   of	   genes	  involved	  in	  the	  maintenance	  of	  serous	  ovarian	  carcinoma.	  We	  found	  that	  the	  majority	  of	  the	   genes	   most	   strongly	   upregulated	   in	   the	   SOC	   model	   compared	   to	   normal	   human	  ovarian	  surface	  epithelium	  were	  associated	  with	  the	  regulation	  of	  mitosis,	  cell	  division,	  cell	   cycle	  processes	  and	  proliferation	  (Figure	   20A).	  Furthermore,	   several	  members	  of	  the	   FOXM1	   transcription	   network	   such	   as	   AURA,	   CCNB1,	   BIRC5	   and	   CDC25	   were	  overexpressed	  in	  the	  SOC	  cell	  lines.	  With	  the	  help	  of	  further	  gene	  network	  analysis	  using	  GeneMANIA,	  we	  were	  able	  to	  link	  single	  identified	  genes	  to	  global	  networks	  and	  existing	  functional	  contexts.	  GeneMANIA,	  an	  interactive	  database	  analysis	  system,	  integrated	  the	  individual	  strongest	  upregulated	  genes	   into	  several	  hundreds	  of	  genomic	  and	  proteomic	  datasets,	  assembled	   from	  GEO,	  BioGRID,	   Pathway	   Commons	   and	   I2D	   databases	   187.	   The	   analysis	   combined,	   with	   the	  help	  of	  described	  datasets,	  functional	  interactions	  of	  single	  genes	  and	  expanded	  the	  gene	  lists	   with	   known	   interaction	   partners.	   Our	   network	   analysis	   of	   the	   most	   strongly	  upregulated	  genes	  in	  the	  SOC	  models	  postulated	  a	  significant	  functional	  involvement	  of	  genes	   implicated	   in	   cell	   division,	   the	   regulation	   of	   cell	   cycle	   and	   spindle	   apparatus,	  mitosis	  and	  cell	  cycle	  (Figure	  20B).	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Figure	  20	  –	  (A)	  Heatmap	  generated	  by	  GSEA	  depicting	  the	  strongest	  upregulated	  expressed	  genes	  in	  the	  SOC	  models	  compared	  to	  human	  ovarian	  epithelial	  cells.	  (B)	  Global	  gene-­‐network	  analysis	  of	  the	  strongest	  upregelated	  genes	  expressed	  in	  the	  SOC	  models	  compared	  to	  human	  ovarian	  epithelial	  cells	  (www.genemania.org).	  
	  To	  gain	  further	  insights	  into	  pathways	  driving	  SOC,	  we	  performed	  gene	  set	  enrichment	  analysis	  using	  the	  MSig	  database	  of	   the	  Broad	  Institute	  (3.82,	  10/2011)	  with	  our	  gene	  expression	   datasets.	   This	   database	   allowed	   us	   the	   correlation	   of	   our	   gene	   expression	  profiles	  with	  more	  than	  6770	  published	  gene	  expression	  datasets	  179	  (Figure	  21A).	  We	  identified	  308	  gene	  sets	  to	  be	  positively	  correlated	  with	  a	  nominal	  p-­‐value	  <	  0.01	  with	  the	   gene	   expression	   profiles	   of	   the	   SOC	   model	   (primary	   SOC	   cell	   lines	   and	   derived	  xenografts).	   A	   more	   precise	   analysis	   revealed	   a	   strong	   enrichment	   of	   multiple	   gene	  signatures	   associated	   with	   alterations	   in	   DNA	   repair	   pathways	   and	   an	   increased	  proliferation.	   Interestingly,	   also	   signatures	   that	   point	   to	   an	   activation	  of	   the	   IL-­‐6-­‐	   and	  the	   Notch	   pathway	   were	   highly	   enriched	   in	   the	   gene	   expression	   profiles	   of	   the	   SOC	  model	   (Figure	   21B,C).	   These	   results	   are	   in	   line	   with	   recent	   publications	   describing	  pathways	  driving	  high-­‐grade	  serous	  ovarian	  carcinoma	  on	  the	  basis	  of	  gene	  expression	  data	  66,188.	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Figure	  21	  –	  (A)	  Schematic	  overview	  of	  Gene	  Set	  Enrichment	  Analysis	  using	  the	  MSig	  database	  (Broad	  Institute).	  (B,C)	  Overview	  of	  differentially	  enriched	  pathway	  signatures	  as	  predicted	  by	  GSEA	  for	  expression	  data	  from	  SOC	  cell	  lines	  and	  derived	  xenografts	  compared	  to	  ovarian	  surface	  epithelium	  (statistics	  calculated	  by	  GSEA).	  	  
The	  SOC	  model	  reflects	  four	  distinct	  molecular	  subtypes	  of	  SOC	  The	   researchers	   of	   The	   Cancer	   Genome	   Atlas	   (TCGA)	   recently	   identified	   four	   distinct	  molecular	   subtypes	   of	   SOC	   by	   combined	   gene	   expression	   analysis	   and	   non-­‐negative	  matrix	  factorization	  consensus	  clustering	  of	  a	  set	  of	  489	  human	  serous	  ovarian	  tumors.	  They	   defined	   gene	   panel’s	   specific	   for	   every	   subtype	   that	   allow	   the	   allocation	   of	  individual	   tumor	   samples	   into	   one	   of	   the	   four	   subtypes.	   The	   subtypes	   were	   termed:	  ‘differentiated’,	  ‘immunoreactive’,	  ‘mesenchymal’	  and	  ‘proliferative’	  on	  the	  basis	  of	  gene	  content	  in	  the	  clusters	  66.	  As	  no	  xenograft	   or	   in	  vitro	  models	  were	   included	   in	   this	   study,	  we	  were	   interested	   to	  verify	  whether	  these	  four	  subtypes	  are	  also	  present	  in	  our	  SOC	  model.	  The	  presence	  of	  different	   subtypes	   within	   our	   model	   system	   might	   serve	   as	   an	   explanation	   for	   the	  observed	  heterogeneity	  in	  growth	  behaviour	  and	  clonogenicity.	  The	  described	  subtype-­‐
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specific	  gene	  panels	  were	  used	  together	  with	  the	  expression	  data	  of	  SOC	  cell	  line	  derived	  xenografts	   for	  Gene	  Set	  Enrichment	  Analysis	  (GSEA)	  to	  evaluate	  the	  subtype	  affiliation	  of	  each	  SOC	  line.	  We	  were	  able	  to	  clearly	  match	  every	  SOC	  derived	  xenograft	  to	  a	  specific	  subtype	   with	   a	   significant	   enrichment	   score	   (FDR	   q<	   0.2).	   According	   to	   the	   subtype	  specific	   gene	   panels	   defined	   by	   The	   Cancer	   Genome	   Atlas	   (TCGA)	   we	   were	   able	   to	  determine	   individual	   gene	   expression	   profiles	   for	   every	   subtype.	   Out	   of	   the	   gene	  expression	  data	  of	  seven	  different	  derived	  SOC	  xenograft	  tumors	  we	  could	  classify	  two	  tumors	  as	  differentiated	  (OC18DT,	  OC21DT),	  two	  as	  mesenchymal	  (OC12DT,	  OC14	  DT),	  two	  as	  proliferative	  (OC19DT,	  OC20DT)	  and	  one	  as	  immunoreactive	  subtype	  (OC15DT).	  After	  the	  classification	  of	  the	  xenograft	  models	  we	  wondered	  if	  also	  our	  cell	  lines	  would	  match	  to	  the	  individual	  subtypes.	  Therefore,	  we	  applied	  the	  same	  analysis	  sequence	  to	  the	   gene	   expression	   data	   of	   the	   in	   vitro	   cultured	   cell	   lines	   and	   could	   confirm	   the	  previous	  subtype	  affiliation	  (Figure	  22A-­‐D)	  (Table	  7).	  	  	  
	  
Figure	  22	  –	  (A-­‐D)	  Enrichment	  plots	  and	  corresponding	  statistics	  generated	  by	  GSEA	  using	  subtype	  specific	  signatures	  66	  on	  expression	  datasets	  of	  SOC	  cell	  lines	  and	  derived	  tumors.	  Shown	  are	  Enrichment	  score	  (ES),	  Normalized	  Enrichment	  Score	  (NES)	  and	  False	  Discovery	  Rate	  (FDR).	  (A)	  –	  differentiated	  subtype,	  (B)	  –	  immunoreactive	  subtype,	  (C)	  –	  mesenchymal	  subtype,	  (D)	  –	  proliferative	  subtype.	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Importantly,	  as	  shown	  in	  Table	  7,	  the	  four	  subtypes	  were	  stably	  maintained	  in	  vitro	  and	  
in	  vivo.	  Our	  previous	  results	  revealed	  significant	  differences	  in	  morphology,	  growth	  and	  clonogenicity	  between	  the	  individual	  primary	  SOC	  cell	  lines.	  We	  suggested	  the	  existence	  of	  at	  least	  two	  groups	  of	  cell	  lines	  showing	  different	  growth	  behaviour	  and	  clonogenicity	  present	  in	  our	  model	  system.	  This	  observation	  raised	  the	  question	  if	  they	  might	  belong	  to	  distinct	  molecular	  subtypes.	  Indeed,	  we	  found	  that	  the	  rather	  undifferentiated	  tumors	  (OC12DT	   and	   OC14DT)	   were	   classified	   as	   mesenchymal	   subtypes,	   whereas	   the	  morphological	   group	   of	   well-­‐differentiated	   tumors	   consisted	   exclusively	   of	   the	   other	  three	  subtypes.	  We	  were	  not	  able	  to	  further	  subclassify	  this	  group	  of	  tumors	  according	  to	  molecular	  properties	  such	  as	  growth	  behaviour	  or	  clonogenicity.	  Furthermore,	   as	   we	   were	   able	   to	   establish	   in	   vitro	   cultures	   for	   all	   four	   subtypes,	   we	  concluded	  that	  there	  is	  no	  tendency	  for	  one	  subtype	  to	  prevail	  nor	  being	  excluded	  under	  conditions	  provided	  by	  our	  model	  system.	  	  
Table	  7–	  Subtype	  classification	  of	  SOC	  cell	  lines	  and	  corresponding	  derived	  xenografts	  (NES	  –	  Normalized	  enrichment	  score,	  FDR	  –	  False	  discovery	  rate;	  statistics	  calculated	  by	  GSEA)	  
Cell	  line	  
	   Subtype	   NES	   p-­‐value	   FDR	  
OC18	   Differentiated	   1.60	   0.011	   0.018	  
OC18	  DT	   Differentiated	   2.13	   <0.001	   <0.001	  
OC15	   Immunoreactive	   1.66	   <0.001	   0.004	  
OC15	  DT	   Immunoreactive	   2.44	   <0.001	   <0.001	  
OC12	   Mesenchymal	   1.14	   0.149	   0.2	  
OC12	  DT	   Mesenchymal	   2.47	   <0.001	   <0.001	  
OC14	   Mesenchymal	   2.17	   <0.001	   <0.001	  
OC14	  DT	   Mesenchymal	   2.43	   <0.001	   <0.001	  
OC19	   Proliferative	   1.46	   0.002	   0.028	  
OC19	  DT	   Proliferative	   1.62	   0.004	   0.002	  
OC20	   Proliferative	   1.44	   0.049	   0.017	  
OC20	  DT	   Proliferative	   1.65	   0.016	   0.017	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Identification	  of	  tumor	  initiating	  cells	  in	  Serous	  ovarian	  
carcinoma	  
Large	  scale	  surface	  marker	  profiling	  identifies	  differentially	  
expressed	  cell	  populations	  After	   the	   investigation	  of	   the	   intertumoral	  heterogeneity	  between	  our	  SOC	  models,	  we	  next	   wanted	   to	   analyse	   the	   expression	   of	   different	   cell	   populations	   on	   the	   SOC	   lines.	  Therefore,	  we	  performed	  a	  large	  scale	  surface	  marker	  screen	  using	  the	  BD	  Lyoplate	  Cell	  Surface	   Screening	   Panel,	   consisting	   of	   monoclonal	   antibodies	   against	   242	   different	  known	   cell	   surface	   proteins.	   The	   analysis	   of	   the	   screen	   confirmed	   several	   previous	  gained	  results	   like	  for	  the	  expression	  of	  CD24	  and	  CD44,	  but	  even	  more	  important,	  we	  identified	   multiple	   differentially	   expressed	   markers	   (Figure	   23).	   These	  heterogeneously	   expressed	  markers	   are	   of	   particular	   interest	   as	   they	  may	   lead	   to	   the	  identification	   of	   functional	   subpopulations	   such	   as	   drug	   resistant	   cells	   or	   even	   a	   CSC	  subpopulation.	   In	   addition,	   we	   could	   show	   that	   our	   in	   vitro	   model	   preserves	   the	  heterogeneity	  of	  cell	  populations	  within	  the	  SOC	  cell	  lines.	  	  As	   stated	   above,	  we	   identified	   several	   already	  described	  markers	   for	   cancer	   initiating	  cells	   in	   ovarian	   cancer	   such	   as	  CD24	  or	  CD44.	  However,	   our	   aim	  was	   to	  discover	   and	  characterize	  novel	  surface	  markers	  for	  subpopulations,	  which	  show	  properties	  of	  cancer	  initiating	   cells.	   Therefore,	   we	   focused	   on	   markers	   that	   have	   not	   been	   implicated	   in	  tumor	   initiation	   in	   ovarian	   cancer	   before.	   One	   of	   these	   molecules,	   which	   were	   also	  highly	  differential	  expressed,	  was	  CD151	  (Tetraspanin	  24,	  PETA-­‐3)	  (Figure	  23,	  Plate2).	  CD151	  is	  a	  member	  of	  the	  transmembrane	  4	  superfamily,	  also	  known	  as	  the	  tetraspanin	  family.	   Tetraspanins	   are	   characterized	   by	   four	   transmembrane	   domains	   and	   play	   an	  important	   role	   in	   a	   variety	   of	   cellular	   functions,	   including	   cell	   proliferation,	  differentiation,	   and	  cancer	   cell	   invasion	  and	  metastasis	   189,190.	  CD151	   in	  particular	  has	  been	  shown	  to	  interact	  directly	  with	  the	  α	  subunit	  of	  several	  integrins	  191	  and	  mediates	  their	  function	  by	  the	  regulation	  of	  cytoplasmic	  signaling.	  Specifically,	  CD151	  is	  involved	  in	   the	   adhesion	   dependent	   activation	   of	   Ras,	   RAC1,	   and	   integrin-­‐associated	   Cdc42	  signaling	   192.	   In	   addition,	   the	   expression	   of	   CD151	   correlates	   with	   a	   poor	   prognosis,	  advanced	  disease	  stage	  and	  enhanced	  metastatic	  spread	  in	  several	  cancer	  entities	  193-­‐196.	  CD151	  has	  also	  been	  described	  as	  a	  marker	  for	  tumor	  initiating	  cells	  in	  prostate	  cancer	  197.	   As	  we	  wanted	   to	   investigate	   if	   CD151	   plays	   a	   likewise	   role	   in	   ovarian	   cancer,	  we	  went	  on	  with	  further	  analysis	  on	  this	  transmembrane	  protein.	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Remarkably,	   when	   we	   analysed	   the	   results	   obtained	   from	   the	   Lyoplate	   Cell	   Surface	  Screen,	  we	  also	  found	  several	  markers	  implicated	  in	  stemness	  and	  pluripotency	  such	  as	  SSEA-­‐1,	   SSEA-­‐3,	   SSEA-­‐4	   and	   TRA	   -­‐1-­‐81	   to	   be	   differentially	   expressed	   on	   our	   primary	  ovarian	  cancer	  cell	  lines	  (Figure	  23	  Plate3).	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Figure 1. Array layout of the BD Lyoplate Human Cell Surface 
Marker Screening Panel.
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total	  expression	  level	  was	  very	  variable	  between	  the	  cell	  lines,	  ranging	  between	  17.8%	  (OC12)	  and	  86.2%	  (OC15).	  Interestingly,	  the	  expression	  level	  of	  CD151	  correlated	  with	  an	  advanced	  disease	  stage.	  SOC	  cell	  lines	  that	  were	  derived	  from	  serous	  effusions	  such	  as	  ascites	  or	  pleural	  effusion	  showed	  a	  significant	  higher	  expression	  of	  CD151	  compared	  to	  cell	  lines	  derived	  directly	  from	  tumor	  material.	  	  	  	  	  
Figure	  24	  –	  (A)	  CD151	  is	  heterogeneously	  expressed	  on	  all	  tested	  SOC	  lines.	  (B)	  The	  expression	  levels	  of	  CD151	  show	  a	  high	  variability	  throughout	  the	  SOC	  lines	  ranging	  from	  17.8%	  to	  86.2%.	  	  	  Having	  proved	  that	  CD151	  is	  heterogeneously	  expressed	  on	  all	  established	  cell	  lines,	  we	  wanted	  to	  evaluate	  the	  expression	  pattern	  on	  the	  corresponding	  cell	  line	  derived	  tumors	  by	  immunohistochemistry.	  The	  analysis	  of	  the	  immunohistochemical	  stainings	  revealed	  a	  specific	  membrane	  associated	  expression	  pattern	  of	  CD151.	  Additionally,	  we	  observed	  that	  expression	  levels	  of	  the	  SOC	  cell	  lines	  are	  reflected	  by	  their	  corresponding	  derived	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tumors.	  Cell	   lines	   showing	  a	   low	  expression	  of	  CD151	  also	  gave	   rise	   to	   tumors	  with	  a	  low	  expression	   level	   and	  vice	  versa	  (Figure	   25).	  This	  observation	  also	   confirmed	  our	  previous	  findings	  that	  the	  phenotype	  of	  the	  tumor	  cells	  is	  conserved	  in	  derived	  tumors.	  	  
	  
Figure	  25	  –	  Immunhistochemical	  stainings	  for	  CD151	  on	  SOC	  cell	  line	  derived	  tumors	  reveals	  that	  expression	  levels	  are	  conserved	  in	  the	  tumors	  (scale	  bar	  100	  μm).	  	  In	   summary,	   we	   could	   show	   that	   our	   SOC	   models	   can	   be	   utilized	   for	   large	   scale	  screening	   approaches,	   which	   might	   lead	   to	   the	   identification	   of	   functional	  subpopulations	  that	  play	  a	  role	  in	  drug	  resistance	  or	  tumor	  initiation.	  Here,	  we	  applied	  a	  surface	  marker	  screen	  to	  get	  an	  overview	  of	  the	  main	  surface	  markers	  expressed	  on	  our	  SOC	  models.	  We	  successfully	  identified	  several	  interesting	  targets	  that	  were	  described	  to	  be	  involved	  in	  metastatic	  processes,	  tumor	  initiating	  as	  well	  as	  stemness.	  These	  surface	  markers	   could	  be	   confirmed	  by	  additional	  FACS	  analysis.	  Furthermore,	  we	   focused	  on	  the	   transmembrane	  protein	  CD151,	  which	  has	  been	   implicated	   in	   cancer	   cell	   invasion	  and	  metastasis	  and	  correlates	  with	  a	  poor	  prognosis	  in	  several	  cancer	  entities.	  CD151	  is	  heterogeneously	   expressed	   on	   all	   our	   SOC	   cell	   lines	   and	   the	   expression	   level	   is	  conserved	  between	  SOC	  cell	  lines	  and	  corresponding	  xenograft	  tumor.	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Growth	  characteristics	  of	  CD151+	  and	  CD151-­‐	  subpopulations	  in	  vitro	  CD151	  showed	  a	  heterogeneous	  expression	  throughout	  all	  tested	  SOC	  cell	  lines	  in	  vitro	  as	  well	  as	   for	   the	  corresponding	  xenograft	   tumors	  resulting	   in	  a	  CD151	  positive	  and	  a	  CD151	  negative	  subpopulation.	  In	  order	  to	  investigate	  the	  capacity	  for	  self-­‐renewal	  and	  differentiation	   in	   the	   observed	   phenotypes,	   we	   sorted	   Venus+/CD151+	   and	   Venus-­‐/CD151-­‐	  cells	  from	  the	  primary	  SOC	  cell	  line	  OC12	  (transduced	  with	  a	  lentiviral	  reporter	  containing	   the	  Venus	   fluorochrome),	  mixed	   them	   in	   the	  same	  ratio	  and	  cultured	   them	  under	  regular	  conditions.	  The	  additional	   labelling	  of	   the	  CD151+	  subpopulation	  with	  a	  reporter	  construct	  allowed	   the	  discrimination	  between	   the	   two	  originally	  populations.	  Expression	  of	  Venus	  and	  CD151	  was	  monitored	  for	  17	  days	  by	  flow	  cytometry	  (Figure	  
26A).	  We	  found	  that	  the	  proportion	  of	  CD151+	  cells	  dramatically	  declined	  over	  time	  in	  the	  purified	  Venus+/CD151+	  population,	  and	  reached	  almost	  the	  original	  distribution	  of	  CD151	  expression.	  As	  expected,	  the	  expression	  of	  the	  Venus	  fluorchrome	  did	  not	  change	  in	   the	   monitored	   time	   frame	   (Figure	   26B).	   In	   contrast,	   the	   purified	   Venus-­‐/CD151-­‐	  population	  retained	  their	  phenotype	  and	  we	  observed	  no	  Venus-­‐	  cells	  expressing	  CD151	  
(Figure	  26C).	  	  We	  concluded	  from	  this	  experiment	  that	  CD151+	  tumor	  cells	  arose	  only	  from	  the	  CD151+	  population,	   which	   is	   also	   able	   to	   give	   rise	   to	   CD151-­‐	   cells.	   CD151-­‐	   cells	   gave	   rise	  exclusively	   to	   CD151-­‐	   progeny.	   In	   parallel,	   we	   analysed	   the	   ratio	   of	   the	   two	   purified	  populations	  by	  measuring	  the	  expression	  of	  the	  Venus	  fluorchrome.	  At	  the	  beginning	  of	  the	   experiment	   equal	   proportions	   of	   Venus+/CD151+	  and	   Venus-­‐/CD151-­‐	  were	   seeded	  
(Figure	   26D).	   The	   determination	   of	   Venus	   positive	   cells	   over	   time	   allowed	   us	   the	  evaluation	  of	  the	  growth	  of	  both	  populations	  under	  exactly	  the	  conditions.	  An	  increase	  of	  Venus+	  cells	  in	  the	  culture	  indicated	  that	  the	  originally	  Venus+/CD151+	  subpopulation	  had	  a	  stronger	  ability	   to	  grow	  compared	   to	   the	  Venus-­‐/CD151-­‐	   subpopulation	  (Figure	  
26E).	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Figure	  26	  –	  Differentiation	  of	  purified	  CD151+	  and	  CD151-­‐	  cells	  in	  vitro	  (A)	  FACS	  analysis	  of	  Venus	  and	  CD151	  expression	  before	  sorting,	  right	  after	  sorting	  and	  splitting,	  and	  after	  17	  days	  in	  culture.	  Directly	  after	  sorting	  Venus+/CD151+	  and	  Venus-­‐/CD151-­‐	  cells	  were	  mixed	  in	  equal	  amounts.	  (B)	  Bar	  diagrams	  summarizing	  obtained	  expression	  values.	  The	  purified	  Venus+/CD151+	  population	  generated	  both	  Venus+/CD151+	  and	  Venus+/CD151-­‐	  cells,	  (C)	  whereas	  Venus-­‐/CD151-­‐	  remained	  unchanged.	  (D)	  Venus+/CD151+	  and	  Venus-­‐/CD151-­‐	  cells	  were	  seeded	  in	  a	  50:50	  ratio	  and	  Venus	  expression	  was	  monitored	  over	  17	  days.	  (E)	  Summary	  of	  the	  change	  in	  Venus	  expression.	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Given	   the	   observed	   discrepancies	   in	   the	   growth	   of	   the	   purified	   CD151	   positive	  subpopulation	   in	   comparison	  with	   the	   purified	   CD151	   negative	   population,	   we	   asked	  whether	   this	  could	  be	  explained	  by	  differences	   in	   the	  proliferative	  capacity	  of	   the	   two	  subpopulations.	  Therefore	  we	  performed	  an	  EdU	  proliferation	  assay	  and	  compared	  the	  cell	  cycle	  status	  of	  the	  different	  subpopulations.	  The	  proliferation	  of	  cells	  was	  measured	  by	   the	   incorporation	   of	   the	  modified	   nucleoside	   EdU	   (5-­‐ethynyl-­‐2	  -́­‐deoxyuridine)	   into	  newly	  synthesized	  DNA	  (Figure	  27A).	  We	  tested	  three	  representative	  SOC	  cell	  lines	  that	  showed	   various	   levels	   in	   the	   expression	   of	   CD151.	   In	   the	   cell	   line	   OC12,	  we	   detected	  differences	   in	   the	  amount	  of	  active	  cycling	  cells	  of	  48.9%	  in	  the	  CD151+	  subpopulation	  compared	  to	  38.5%	  in	  the	  CD151	  negative	  cells.	  OC15	  showed	  only	  a	  minor	  variation	  in	  cells	  in	  S-­‐phase	  between	  the	  two	  populations.	  The	  biggest	  difference	  in	  cell	  cycle	  status	  between	  CD151+	  and	  CD151-­‐	  cells	  was	  observed	  in	  the	  cell	  line	  OC18.	  Whereas	  only	  57%	  of	  cells	  expressing	  CD151	  could	  be	  assigned	  to	   the	  G0/1	  phase,	  86%	  of	   the	  CD151-­‐	  cells	  were	   found	   to	   be	   in	   this	   phase.	   In	   parallel,	   the	   amount	   of	   active	   cycling	   cells	   was	  significantly	  higher	  in	  the	  CD151	  positive	  subpopulation	  (Figure	  27B).	  In	  summary,	  we	  were	  able	  to	  show	  that	  purified	  CD151+	  cells	  were	  gave	  rise	  to	  CD151+	  and	   CD151-­‐	   cells,	   whereas	   purified	   CD151-­‐	   cells	   did	   not.	   In	   a	   competition	   assay,	   the	  amount	   of	   the	   originally	   CD151+	   cells	   increased	   from	   54%	   at	   the	   beginnining	   of	   the	  experiment	   to	   84%	   at	   the	   end,	   meaning	   that	   the	   originally	   CD151-­‐	   cells	   were	  outcompeted.	   In	   all	   tested	   cell	   lines,	   the	   CD151+	  cells	   exhibited	   a	   higher	   proliferative	  capacity	  compared	  to	  the	  CD151-­‐	  cells.	  This	  difference	  between	  the	  two	  subpopulations	  was	  displayed	  to	  variable	  extents	  in	  the	  cell	  lines.	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Figure	  27	  –	  Cell	  cycle	  analysis	  of	  CD151+	  and	  CD151-­‐	  subpopulations	  of	  SOC	  cell	  lines	  in	  vitro.	  (A)	  Gating	  scheme	  of	  the	  analysis,	  (B)	  Comparison	  of	  cell	  cycle	  phases	  between	  CD151	  subpopulations	  confirms	  observed	  differences	  in	  growth	  behaviour.	  	  
CD151	  defines	  a	  tumor	  initiating	  subpopulation	  in	  serous	  ovarian	  
carcinoma	  In	  order	  to	  further	  explore	  the	  functional	  differences	  between	  CD151+	  and	  CD151-­‐	  cells,	  we	   set	   up	   a	   xenotransplantation	   assay	   comparing	   the	   two	   purified	   CD151	  subpopulations.	   Therefore,	   Venus+	  /CD151+	  and	   Venus+	  /CD151-­‐	   cells	   were	   sorted	   by	  flow	   cytometry.	   Purity	   of	   these	   sorted	   populations	   as	   assessed	   by	   post	   sort	   flow	  cytometry	  was	  >90%	  for	  the	  CD151+	  fraction	  and	  >75%	  for	  the	  CD151-­‐	  fraction	  (Figure	  
28A).	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Figure	  28	  –	  (A)	  Gating	  scheme	  used	  for	  FACS	  purification	  of	  Venus+	  /CD151+	  and	  Venus+	  /CD151-­‐	  cells	  (doublet-­‐	  and	  dead	  cell	  exclusion	  were	  performed	  before).	  Note	  the	  high	  purity	  of	  both	  fractions.	  (B)	  Representative	  bioluminescence	  images	  of	  mice	  injected	  with	  purified	  CD151+	  cells	  (red	  boxes)	  and	  mice	  injected	  with	  CD151-­‐	  cells.	  (C)	  Growth	  curve	  according	  to	  bioluminescence	  signal	  (left)	  and	  Kaplan-­‐Meier	  plots	  (right)	  of	  mice	  injected	  with	  the	  respective	  subpopulation.	  	  We	   injected	   1x104	   cells	   of	   each	   purified	   subpopulation	   from	   the	   OC12	   cell	   line	  intraperitoneal	   into	   immunocompromised	  mice.	   In	   this	   experimental	   setting,	  we	   used	  seven	   mice	   for	   the	   CD151-­‐	   cohort,	   six	   mice	   for	   CD151+	   cohort	   and	   one	   mouse	   as	   a	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control	   for	   Luciferase	   background.	   Hence,	   13	   mice	   were	   injected	   in	   total.	   Constant	  monitoring	  of	  tumor	  growth	  in	  vivo	  was	  performed	  by	  weekly	  bioluminescence	  imaging	  using	   the	  Xenogen	   system	  as	  described	  before.	  The	   first	  measurement	  was	   conducted	  one	  week	  after	  injection	  of	  tumor	  cells.	  Tumor	  growth	  was	  monitored	  until	  termination	  conditions	   for	  animals	  were	   reached.	  We	  observed	   tumor	  growth	  and	  development	  of	  ascites	  in	  six	  out	  of	  six	  mice	  in	  the	  group	  injected	  with	  purified	  CD151+	  cells.	  The	  tumor	  latency	  ranged	  between	  98	  and	  119	  days	  (Figure	  28C).	  In	  contrast,	  in	  the	  group	  of	  mice	  injected	  with	  CD151-­‐	  cells,	  only	  one	  mouse	  showed	  an	  increase	  in	  bioluminescent	  signal.	  A	  comparison	  of	  the	  tumor	  growth	  curves,	  which	  were	  determined	  by	  bioluminescence	  measurement,	   of	   the	   two	   groups	   resulted	   in	   a	   significant	   difference	   between	   mice	  injected	  with	  purified	  CD151+	  cells	  compared	  to	  mice	  injected	  with	  purified	  CD151-­‐	  cells	  
(Figure	  28B).	  FACS	  analysis	  of	  tumor	  material	  dissected	  from	  the	  single	  mouse	  with	  an	  increased	  bioluminescence	  signal	  revealed	  a	  contamination	  with	  CD151+	  cells.	  140	  days	  post	   injection	   remaining	  mice	   from	   this	   group	  were	   analysed	   for	   tumor	  development.	  We	  were	   not	   able	   to	   detect	   any	   tumor	   growth	   in	   the	  mice	   injected	  with	   CD151-­‐	  cells.	  Therefore,	  we	   assumed	   that	   tumor	   initiating	   cells	   are	   enriched	   in	   the	   CD151	   positive	  subpopulation	  of	   the	  OC12	  cell	   line.	  Subsequent	  analyses	  of	  generated	   tumors	  by	   flow	  cytometry	   revealed	   a	   heterogeneous	   expression	   pattern	   of	   CD151	   suggesting	   that	   the	  diverse	   tumor	   phenotype	   was	   recapitulated	   following	   injection	   of	   a	   highly	   purified	  fraction	  of	  CD151	  expressing	  cells	  (data	  not	  shown).	  Importantly,	  immunhistochemical	  analysis	  of	  dissected	  tumors	  from	  mice	  injected	  with	  purified	  CD151+	  cells	  confirmed	  that	  they	  originated	  from	  injected	  cells	  by	  expression	  of	  Venus	  fluorochrome.	  Additionally,	  we	  analysed	  the	  expression	  of	  CD151	  in	  these	  tumors	  and	   found	   an	   enrichment	   for	   CD151+	   cells	   compared	   to	   the	   original	   OC12	   cell	   line	  derived	   tumor.	   However,	   the	   tested	   tumors	   displayed	   a	   heterogeneous	   expression	   of	  CD151	   containing	   CD151+	   and	   CD151-­‐	   cells.	   Investigation	   of	   the	   organs	   that	   were	  dissected	   from	  mice	  of	   this	  experiment	   revealed	  metastatic	   spread	  of	  purified	  CD151+	  cells	   to	   the	   lungs.	   Tumor	   cells	   in	   the	   lungs	   of	   the	  mice	   expressed	   CD151	   and	   stained	  positive	   for	   the	   proliferation	   marker	   Ki67,	   pointing	   to	   the	   fact	   that	   these	   cells	   did	  proliferate	  in	  the	  lungs	  of	  the	  mice.	  In	  contrast,	  we	  observed	  no	  tumor	  cells	  in	  the	  lungs	  of	  mice	  injected	  with	  CD151-­‐	  cells	  (Figure	  29).	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Figure	  29	  –	  Immunohistochemical	  stainings	  of	  tumors	  and	  lungs	  dissected	  from	  mice	  injected	  with	  the	  parental	  OC12	  cell	  line	  (left	  column)	  or	  purified	  CD151+	  cells	  (middle	  and	  right	  column).	  CD151	  enriched	  tumors	  show	  an	  increased	  expression	  of	  membraneous	  CD151	  compared	  to	  the	  parental	  tumor	  (top	  row).	  Verification	  of	  the	  used	  reporter	  construct	  by	  detection	  of	  cytoplasmatic	  Venus	  fluorochrome	  (middle	  row).	  Metastasis	  in	  the	  lung	  of	  mice	  injected	  with	  CD151+	  cells	  express	  CD151	  and	  Ki67	  (bottom	  row).	  (scale	  bar	  100	  μm).	  	  In	   order	   to	   validate	   these	   results,	   the	   same	   experiment	   was	   carried	   out	   using	   two	  further	   primary	   SOC	   cell	   lines.	   CD151+	   and	   CD151-­‐	  cells	   from	   the	   cell	   lines	   OC14	   and	  OC15	   were	   purified	   by	   flow	   cytometry.	   Every	   group	   consisted	   of	   six	   mice	   that	   were	  injected	   intraperitoneal	   with	   a	   concentration	   of	   1x104	   cells	   of	   the	   respective	  subpopulation.	  For	  non-­‐invasive	  monitoring	  also	  these	  cells	  had	  been	  transduced	  with	  a	  lentiviral	   reporter	   containing	   luciferase	  and	   the	  Venus	   fluorochrome.	  Again,	   similar	   to	  the	  results	  gained	  from	  the	  experiment	  using	  the	  OC12	  cell	   line,	  we	  observed	  a	  higher	  tumorigenic	   potential	   in	   the	   purified	   CD151+	   cells	   compared	   to	   the	   CD151-­‐	  cells.	  Mice	  injected	  with	  purified	  CD151+	  cells	  from	  the	  cell	  line	  OC14	  showed	  a	  significant	  increase	  in	  the	  bioluminescence	  signal	  compared	  to	  mice	  injected	  with	  purified	  CD151-­‐	  cells	  from	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the	   same	  cell	   line	  over	   time	  (Figure	   30A,	   left).	   Injection	  of	  CD151+	  cells	   led	   to	   tumor	  and	  ascites	  development	  in	  six	  out	  of	  six	  mice	  with	  tumor	  latency	  between	  119	  and	  147	  days.	  Immunhistochemistry	  was	  used	  to	  additionally	  investigate	  the	  expression	  pattern	  of	  CD151	  in	  the	  individual	  tumors	  and	  to	  detect	  possible	  metastatic	  spread	  to	  the	  lungs	  of	  the	  mice	  (Figure	  31).	  	  Conversely,	   in	   the	   group	   injected	   with	   CD151-­‐	  cells,	   none	   of	   the	   mice	   showed	   tumor	  development.	   Analysis	   of	   luminescence	   signals	   from	   this	   group	   revealed	   only	   a	   slight	  increase	  in	  signal	  intensity	  compared	  to	  the	  group	  injected	  with	  CD151+	  cells.	  Remaining	  mice	  injected	  with	  CD151-­‐	  cells	  were	  monitored	  for	  161	  days	  until	  endpoint	  analysis,	  but	  we	  were	  not	  able	  to	  detect	  tumor	  growth	  in	  these	  mice	  (Figure	  30A,	  right).	  	  	  
	  
Figure	  30	  –	  Growth	  curves	  calculated	  based	  on	  bioluminescence	  signals	  (left)	  as	  well	  as	  Kaplan-­‐Meier	  plots	  (right)	  for	  mice	  mice	  which	  were	  injected	  with	  purified	  CD151+	  as	  well	  as	  CD151-­‐	  cells	  from	  the	  cell	  line	  OC14	  (A)	  and	  OC15	  (B).	  	  For	   purified	   subpopulations	   originating	   from	   the	   cell	   line	   OC15,	   we	   observed	   similar	  results	  as	  seen	  for	  the	  cell	  lines	  OC12	  and	  OC14.	  Also	  for	  this	  cell	  line,	  purified	  CD151+	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showed	   a	   significant	   increased	   tumorigenic	   capacity	   compared	   to	   the	   CD151-­‐	   cell	  fraction.	  Remarkably,	  we	  detected	  growth	  of	   tumors	   in	  two	  mice	  of	   the	  group	   injected	  with	   purified	   CD151-­‐	   cells	   (Figure	   30B,	   left).	   Subsequent	   end	   point	   analysis	   of	   the	  individual	   tumors	   by	   flow	   cytometry	   revealed	   the	   presence	   of	   CD151+	   cells	   in	   these	  tumors	   (data	   not	   shown).	   This	   observation	   was	   also	   confirmed	   by	  immunohistochemistry	  (Figure	  31,	  OC15	  CD151-­‐#3).	  	  	  
	  
Figure	  31	  –	  Immunohistochemical	  analyses	  of	  CD151	  expression	  in	  tumors	  and	  lungs	  dissected	  from	  mice	  injected	  with	  either	  parental	  OC14	  /OC15	  cell	  lines	  or	  their	  purified	  subpopulations.	  CD151	  staining	  is	  predominantly	  membraneous.	  The	  staining	  intensity	  is	  slightly	  increasing	  from	  parental	  to	  purified	  CD151+	  cells.	  Note,	  OC15	  CD151-­‐	  #3	  showed	  expression	  of	  CD151+	  cells,	  probably	  due	  to	  contamination	  with	  CD151+	  cells	  during	  FACS	  sorting.	  Mice	  injected	  with	  CD151+	  cells	  (OC14)	  developed	  lung	  metastasis	  that	  stain	  positive	  for	  CD151	  and	  Ki67	  (scale	  bar	  100	  μm).	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Given	   the	   mostly	   unidirectional	   repopulation	   dynamics	   we	   showed	   in	   vitro,	   this	  retrospective	  observation	  strongly	   suggests	  an	   initial	   contamination	  of	   the	  CD151-­‐	  cell	  input	  with	  CD151+	  cells	  during	  enrichment	  by	  flow	  cytometry.	  	  To	   further	   investigate	   the	   possible	   mechanisms	   behind	   the	   obtained	   results,	   we	  examined	   the	   expression	   of	   CD151	   in	   association	   with	   described	   markers	   for	   tumor	  initiating	   cells	   in	   ovarian	   carcinoma.	   Therefore,	   we	   analysed	   if	   CD151	   is	   coexpressed	  with	  CD24	  and/or	  CD44	  on	   the	   surface	  of	   our	   cell	   lines.	   The	   enrichment	   of	   described	  cancer	  stem	  cell	  markers	  in	  the	  CD151+	  subpopulation	  might	  be	  a	  possible	  explanation	  for	  the	  enhanced	  tumorigenic	  potential	  of	  these	  cells.	  Interestingly,	  only	  in	  one	  cell	  line	  we	   found	   a	   significant	   upregulation	   of	   a	   putative	   TIC	   marker	   in	   the	   CD151+	  subpopulation	  (OC15)	  (Figure	  32).	  In	  none	  of	  the	  other	  cell	  lines	  we	  found	  a	  correlation	  of	  the	  expression	  of	  CD151	  with	  CD24	  or	  CD44.	  Hence,	  we	  concluded	  that	  other	  factors	  might	  contribute	  to	  the	  differences	  observed	  in	  the	  subpopulations	  of	  CD151.	  	  
	  
Figure	  32	  –	  FACS	  Analysis	  of	  described	  TIC	  markers	  in	  ovarian	  cancer	  in	  correlation	  to	  the	  expression	  of	  CD151	  in	  the	  surface	  of	  primary	  SOC	  cell	  lines.	  Note,	  only	  for	  the	  cell	  line	  OC15	  an	  enrichment	  of	  a	  TIC	  marker	  (CD24)	  in	  the	  CD151+	  subpopulation	  was	  observed.	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Taken	  together,	   these	  data	   indicate	   that	   the	  CD151+	  cells	  of	  our	  primary	  SOC	  cell	   lines	  have	  an	   increased	   tumorigenic	  capacity	  compared	   to	   their	  CD151-­‐	  counterparts.	   In	   the	  tested	  cell	  lines	  OC12	  and	  OC14,	  the	  CD151+	  fraction	  was	  capable	  of	  generating	  tumors	  following	  injection	  of	  1x104	  cells	  whereas	  CD151-­‐	  cells	  generated	  only	  one	  tumor	  in	  the	  same	   time	  period.	   Importantly,	   this	   tumor	  displayed	  a	  high	  expression	  of	  CD151+	  cells	  indicating	  a	  contamination	  and	  subsequent	  outgrowth	  of	  CD151+	  cells.	  Additionally,	  we	  observed	  the	  metastatic	  colonization	  of	  the	  lungs	  in	  mice	  injected	  with	  the	  CD151+	  cell	  fraction	  (Table	  8).	  These	  metastatic	  cells	  expressed	  CD151	  and	  stained	  positive	  for	  the	  proliferation	  marker	   Ki67.	   In	   further	   investigations,	   we	   have	   been	   able	   to	   show	   that	  CD151	  is	  not	  enriching	  for	  already	  described	  TIC	  markers	  in	  ovarian	  cancer,	  indicating	  that	  CD151	  is	  functionally	  independent	  of	  these	  markers.	  These	  results	  strongly	  suggest	  that	  the	  CD151+	  cell	  fraction	  of	  serous	  ovarian	  tumor	  cells	  is	  enriched	  for	  TICs.	  	  
Table	  8–	  Tumorigenic	  capacity	  as	  well	  as	  induction	  of	  lung	  metastases	  of	  CD151+	  and	  CD151-­‐	  subpopulations	  
Cell	  line	  
	  
Subpopulation	   Tumor	  formation	   Lung	  metastasis	  
OC12	  
CD151+	   6/6	   2/6	  CD151-­‐	   1/7	   0/7	  
OC14	  
CD151+	   6/6	   3/6	  CD151-­‐	   0/6	   0/6	  
OC15	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Analysis	  of	  CD151	  mediated	  signaling	  	  
Gene	  expression	  analysis	  on	  CD151	  predicts	  differences	  in	  pathway	  
activity	  	  Given	  the	  observed	  differences	  in	  growth	  and	  tumorigenicity	  between	  purified	  CD151+	  and	   CD151-­‐	   cells,	   we	   hypothesized	   that	   more	   complex	   molecular	   differences	   might	  underlie	   these	   discrepancies.	   To	   uncover	   these	   mechanisms,	   we	   generated	   gene	  expression	  profiles	   of	   purified	  CD151	  positive	   and	  –negative	   subpopulations	   from	   the	  cell	   lines	   OC12,	   OC14,	   OC15	   and	   OC18	   using	   the	   Illumina	   BeadChip	   Technology	  (HumanHT-­‐12v4)	   (Figure	  33A).	  These	  gene	  expression	  profiles	  were	  applied	  for	  gene	  set	   enrichment	   analysis	   (GSEA)	   and	   correlated	   to	  described	   gene	   expression	  datasets.	  This	  analysis	  revealed	  a	  strong	  positive	  enrichment	  of	  distinct	  proliferation	  associated	  signatures	  such	  as	  the	  JNK/MAPK	  signaling	  pathway-­‐	  or	  the	  EGFR	  signaling	  signature	  in	  the	  CD151+	  cells	  (Figure	  33B).	  One	  of	  the	  main	  activators	  of	  the	  JNK/MAPK	  pathway	  are	  integrins	  that	  signal	  through	  the	  recruitment	  and	  activation	  of	  Src	  family	  kinases	  (SFKs).	  These	  kinases	  activate	  Rac,	  which	  is	  upstream	  of	  PAK,	  NF-­‐κB	  and	  the	  Jun	  amino-­‐terminal	  kinase,	  JNK.	  A	  major	  JNK	  target	  is	  the	  transcription	  factor	  AP1,	  which	  is	  composed	  of	  Fos	  and	  Jun.	  The	  JNK/JUN	  pathway	  regulates	  a	  plethora	  of	  target	  genes,	  which	  are	  involved	  in	  cell	  cycle	  as	  well	  as	  survival	  and	  apoptosis	  198.	  Intriguingly,	  CD151	  has	  been	  shown	  to	  directly	  interact	  with	  integrins	  and	  thereby	  regulating	  their	  signaling	  191,192.	  In	  parallel,	  CD151	  has	  been	  proposed	  to	  be	  a	  molecular	  linker	  between	  integrins	  and	  growth	  factor	  receptors	   such	   as	   epidermal	   growth	   factor	   receptor	   (EGFR)	   199.	   Upon	   activation,	   EGF	  receptors	  recruit	  signaling	  proteins,	  such	  as	  Shc,	  Grb7,	  Grb2,	  Crk,	  Nck,	  the	  phospholipase	  Cγ	   (PLCγ),	   the	   intracellular	   kinases	   Src	   and	   PI3K,	   the	   protein	   tyrosine	   phosphatases	  SHP1	  and	  SHP2	  and	  the	  Cbl	  E3	  ubiquitin	  ligase.	  This	  leads	  to	  the	  subsequent	  activation	  of	   the	   RAF/MAPK	   pathway,	   the	   phosphoinositide 3-kinase (PI3K) and the STAT 
signaling pathway, which induce cell proliferation, angiogenesis, migration, survival, 
and adhesion 200.	  A	  distinct	  activation	  of	   these	  pathways	   in	   the	  CD151+	  subpopulation	  might	   explain	   the	   previous	   observations	   of	   a	   higher	   proliferation	   and	   an	   increased	  tumorigenic	   capacity	   of	   these	   cells.	   Importantly,	   the	   identified	   gene	   sets	   were	  exclusively	  enriched	  in	  the	  CD151+	  subpopulation.	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We	  also	  found	  signatures	  that	  point	  to	  an	  activation	  of	  the	  Wnt	  pathway	  in	  the	  CD151+	  subpopulation.	  An	   important	  pathway	   for	  non-­‐canonical	  Wnt	   signal	   transduction	   is	   in	  turn	  the	  activation	  of	  JNK	  201.	  	  
	  
Figure	  33	  –	  Gene	  expression	  analysis	  on	  purified	  CD151+	  and	  CD151-­‐	  cells	  from	  the	  cell	  lines	  OC12,	  OC14,	  OC15	  and	  OC18.	  (A)	  Heatmap	  generated	  by	  GSEA	  depicting	  strongest	  upregulated	  genes	  in	  CD151+	  subpopulation	  compared	  to	  CD151-­‐	  cells.	  (B)	  Overview	  of	  differentially	  enriched	  pathway	  signatures	  in	  CD151+	  cells	  (statistics	  calculated	  by	  GSEA).	  	  We	   next	   wanted	   to	   investigate	   whether	   the	   predicted	   activation	   of	   pathways	   in	   the	  specific	   subpopulation	   was	   also	   displayed	   on	   protein	   level.	   Therefore,	   we	   prepared	  protein	   lysates	   of	   the	  parental	  OC12	   cell	   line	   as	  well	   as	   purified	  CD151+	  -­‐	   and	  CD151-­‐	  cells	  and	   tested	   the	   total	  expression	   level	  as	  well	  as	   the	  phosphorylation	  status	  of	  key	  proteins	   of	   respective	   pathway	   by	  Western	   blotting.	   As	   gene	   set	   enrichment	   analysis	  predicted	   a	   positive	   correlation	   of	   the	   purified	   CD151+	  cells	   and	   an	   activation	   of	   the	  JNK/MAPK	   signaling	   pathway,	   we	   wanted	   to	   further	   investigate	   this	   pathway.	   The	  JNK/MAPK	  pathway	  comprises	  of	  a	  core	  signaling	  unit	  that	  is	  composed	  of	  a	  MAPKKK,	  typically	  MEKK1-­‐MEKK4,	  which	   phosphorylate	  MKK4/7.	   These	  MKKs	   in	   turn	   activate	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JNK	  202.	  Small	  GTPases	  of	   the	  Rho	  family	  (Rac,	  Rho,	  Cdc42)	  are	  the	  major	  activators	  of	  this	  pathway.	  Upon	  activation	  JNK	  dimerises	  and	  translocates	  to	  the	  nucleus	  to	  where	  it	  mediates	  the	  stimulation	  of	  the	  transcription	  factor	  AP-­‐1	  203.	  	  Moreover,	   to	   prove	   the	   direct	   connection	   between	   integrin	   signaling	   and	   CD151	   as	   a	  modulator	  and	  activator	  of	   these,	  we	   included	   the	  determination	  of	   the	  activity	  of	   the	  Src	   family	  kinases	  (SFKs).	  As	  stated	  above,	   integrins	  signal	  predominantly	  through	  the	  recruitment	  and	  activation	  of	  SFKs	   198.	  Furthermore,	  SFKs	  can	  be	  stimulated	  by	  EGFR.	  The	  SFK	  members	  are	  activated	  by	  the	  phosphorylation	  of	  a	  tyrosine	  at	  (Tyr416)	  that	  can	  be	  detected	  by	  Western	  blotting.	  	  
	  
Figure	  34	  –Western	  blot	  analysis	  of	  pathway	  activation	  as	  predicted	  by	  gene	  set	  enrichment	  analysis.	  Protein	  lysates	  of	  two	  independent	  FACS	  sorting	  experiments	  were	  analysed	  for	  the	  expression	  and	  phosphorylation	  status	  of	  members	  of	  the	  oncogenic	  Src	  family	  kinases	  (top)	  as	  well	  as	  the	  JNK/MAPK	  pathway	  (bottom).	  Vinculin	  was	  used	  as	  a	  loading	  control.	  	  Western	   blot	   analysis	   revealed	   a	   significantly	   increased	   phosphorylation	   at	   Tyr416	   for	  the	  purified	  CD151+	  cells	  compared	  to	  the	  parental	  cell	  line	  or	  the	  CD151-­‐	  cells	  (Figure	  
34).	   Additionally,	  we	  observed	   an	   increased	   expression	  of	   the	   total	   Src	  protein	   in	   the	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CD151	   positive	   fraction.	   MKK4,	   a	   member	   of	   JNK/MAPK	   pathway,	   showed	   a	   similar	  phosphorylation	  as	  Src.	  The	  activation	  of	   this	  protein	  was	  significantly	  stronger	   in	   the	  CD151+	  cells	   than	   in	   the	  CD151-­‐	  cells,	   but	   only	   slightly	   compared	   to	   the	  parental	   cells.	  Also	  the	  two	  isoforms	  of	  JNK	  itself	  displayed	  a	  stronger	  phosphorylation	  in	  the	  CD151+	  subpopulation	  than	  in	  the	  CD151-­‐	  cells	  (Figure	  34).	  Altogether,	  these	  results	  confirmed	  our	   assumption	   that	   the	   CD151+	   subpopulation	   shows	   an	   increased	   activity	   of	   the	  JNK/MAPK	   pathway.	  We	   found	   an	   exclusive	   activating	   phosphorylation	   of	   MKK4	   and	  JNK	   itself	   in	   the	   CD151+	   cells.	   Furthermore,	   we	   observed	   a	   significantly	   stronger	  phosphorylation	  of	  SFKs,	  an	  important	  signaling	  node	  between	  integrins,	  growth	  factor	  receptors	  and	  downstream	  pathways	  such	  as	   JNK/MAPK,	  RAF/MAPK	  and	  PI3K,	  which	  promote	  survival,	  angiogenesis,	  proliferation	  and	  invasion.	  	  
CD151	  ablation	  directly	  affects	  cell	  signaling	  The	  results	  shown	  above	  suggested	  CD151	  to	  play	  an	  important	  role	  in	  the	  modulation	  and	  activation	  of	  integrin	  and	  EGFR	  signaling	  leading	  to	  an	  increased	  proliferation	  and	  tumorgenicity	   in	  vivo.	  To	   further	  prove	   that	  CD151	  directly	  affects	   signaling	  pathways	  and	  thus	  influences	  the	  proliferation	  of	  tumor	  cells,	  we	  performed	  a	  stable	  silencing	  of	  CD151	  by	  the	  lentiviral-­‐mediated	  expression	  of	  shRNA	  specifically	  targeting	  the	  CD151	  transcript	  in	  the	  cell	  lines	  OC12,	  OC14	  and	  OC15.	  A	  scrambled	  shRNA	  (con)	  was	  used	  as	  a	  control	  and	  also	  introduced	  in	  the	  different	  cell	  lines.	  The	  constructs	  contained	  a	  GFP	  reporter	  cassette,	  which	  allowed	  the	  purification	  of	  transduced	  cells	  by	  flow	  cytometry.	  For	   further	   experiments,	   we	   went	   on	   with	   two	   different	   shRNA´s	   targeting	   CD151	  (sh_RNA1/sh_RNA2),	  which	  have	  been	   selected	  by	   their	   efficiency	   in	   silencing	  CD151.	  The	  knockdown	  of	  CD151	  was	  demonstrated	  by	  the	  flow	  cytometric	  measurement	  of	  the	  surface	   protein.	   For	   the	   cell	   line	   OC12,	   we	   reached	   a	   silencing	   of	   >95%,	  whereas	   for	  OC14	  and	  OC15	  the	  knockdown	  amounted	  between	  60	  and	  70%	  (Figure	  35A).	  	  	  Previous	   results	   indicated	   differences	   in	   growth	   behaviour	   between	   purified	   CD151+	  and	  CD151-­‐	  cells.	  Therefore,	  we	  performed	  an	  analysis	  of	  the	  in	  vitro	  growth	  comparing	  control	  cells	  of	  the	  respective	  cell	  line	  with	  the	  corresponding	  CD151	  silenced	  cells.	  We	  observed	   minor	   discrepancies	   in	   the	   growth	   behaviour	   between	   konockdown-­‐	   and	  control	  shRNA	  transduced	  cell	  lines,	  that	  where	  more	  distinct	  in	  the	  cell	  lines	  OC14	  and	  OC15	  (Figure	  35B).	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Figure	  35	  –	  (A)	  Lentiviral	  mediated	  shRNA	  knockdown	  of	  CD151	  in	  the	  cell	  lines	  OC12,	  OC14	  and	  OC15.	  Depicted	  are	  expression	  levels	  of	  CD151	  as	  determined	  by	  flow	  cytometry	  on	  cells	  transduced	  with	  either	  scrambled	  control	  shRNA	  or	  two	  different	  shRNAs	  against	  CD151.	  (B)	  In	  
vitro	  growth	  of	  SOC	  cell	  lines	  transduced	  with	  a	  scrambled	  shRNA	  con)	  or	  CD151	  targeting	  shRNAs	  (shRNA1/2).	  	  As	  previously	  shown,	  CD151	  affects	   the	  activation	  of	  Src	  and	  seems	  to	  play	  role	   in	  the	  upregulation	  of	  integrin	  signaling	  to	  Src	  (Figure	  34).	  We	  next	  examined	  whether	  CD151	  directly	  participates	  in	  pathway	  signaling	  or	  if	  CD151	  as	  a	  marker	  indirectly	  enriches	  for	  a	  subpopulation	  with	  a	  certain	  pathway	  activation.	  To	  clarify	  this	  question,	  we	  analysed	  global	   changes	   in	   gene	   expression	   induced	   by	   silencing	   of	   CD151	   by	   gene	   expression	  profiling	  comparing	  CD151	  knockdown	  cells	  with	  scrambled	  control	  shRNA	  transduced	  cells.	   In	   the	   subsequent	   analysis	   by	   GSEA,	   we	   exclusively	   focused	   on	   gene	   sets	   that	  predict	   pathways	   that	   are	   deregulated	   in	   CD151	   silenced	   cells.	   Under	   the	   top	  deregulated	   pathways,	   we	   found	   multiple	   gene	   signatures	   associated	   with	   the	   EGFR	  signaling	  pathway,	  the	  oncogenic	  Src	  pathway	  and	  targets	  of	  Myc	  (data	  not	  shown).	  These	  data	  also	  supported	  our	  previous	  findings	  that	  CD151	  affects	  the	  activation	  of	  Src	  and	  seems	  to	  play	  role	  in	  the	  upregulation	  of	  integrin	  signaling	  to	  Src	  (Figure	  34).	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  We	   next	   wanted	   to	   investigate	   if	   the	   predicted	   activation	   of	   pathways	   could	   also	   be	  detected	  on	  protein	  level.	  Therefore,	  we	  prepared	  protein	  lysates	  of	  the	  parental	  OC12	  cell	   line,	   the	   scramled	   control	   (con)	   and	   the	   two	   CD151	   silenced	   cell	   lines	  (shRNA1/shRNA2).	  	  Western	   blot	   analysis	   revealed	   that	   CD151	   ablation	   almost	   completely	   abrogated	   the	  activating	  phosphorylation	  of	  Src	  at	  Tyr416	   in	   the	  CD151	  knockdown	  cell	   lines	  (Figure	  
36).	   In	   parallel,	   cells	   transduced	   with	   the	   scrambled	   shRNA	   showed	   similar	  phosphorylation	   levels	   at	   Tyr416	   as	   parental	   tumor	   cells.	   We	   therefore	   excluded	   an	  indirect	  effect	  of	  the	  virus	  transduction.	  	  	  	  	  
Figure	  36	  –	  Lysates	  of	  the	  parental	  OC12	  cell	  line,	  scrambled	  shRNA	  transduced	  cells	  and	  CD151	  silenced	  cells	  were	  analysed	  by	  immunoblot	  for	  the	  expression	  and	  phosphorylation	  status	  of	  members	  of	  the	  oncogenic	  Src	  family	  kinases.	  	  In	   summary,	  we	   have	   been	   able	   to	   prove	   that	   the	   predictions	   of	   our	   gene	   expression	  approach	   can	   be	   used	   for	   the	   identification	   of	   differentially	   activated	   signaling	  pathways.	   We	   were	   able	   to	   link	   the	   increased	   tumorigenic	   capacity,	   observed	   in	   the	  CD151+	   subpopulation	   of	   various	   cell	   lines,	   to	   the	   activation	   of	   distinct	   signaling	  pathways.	   With	   the	   help	   of	   pathway	   predictions	   based	   on	   gene	   expression	   data,	   we	  identified	  several	  proliferative	  pathways	  such	  as	  the	  JNK/MAPK	  signaling	  pathway,	  the	  EGFR	  signaling	  pathway	  as	  well	  as	  the	  oncogenic	  Src	  pathway	  to	  be	  activated	  in	  CD151+	  cells.	   Furthermore,	  we	  were	   able	   to	   show	   CD151	   ablation	   directly	   impacts	   Src	   family	  kinase	  activation.	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Correlation	  of	  CD151	  expression	  with	  clinical	  outcome	  in	  
serous	  ovarian	  carcinoma	  Our	  previous	  results	  strongly	  suggested	  that	  the	  CD151+	  subpopulation	  is	  enriched	  for	  a	  tumor	   initiating	   subpopulation	   in	   serous	   ovarian	   carcinoma.	   In	   our	   xenograft	   studies,	  we	   have	   been	   able	   to	   show	   that	   purified	   CD151+	   cells	   have	   a	   significant	   increased	  tumorigenic	   capacity	   compared	   to	   their	   CD151-­‐	  counterparts.	   However,	  we	  wanted	   to	  translate	  these	  findings	  to	  a	   larger	  cohort	  of	  patients	  and	  validate	  our	  previous	  gained	  results.	   We	   investigated	   whether	   differences	   in	   CD151	   expression	   levels	   in	   primary	  tumors	  were	  associated	  with	  progression-­‐free	  and	  overall	  survival	  in	  SOC.	  To	  this	  end,	  we	   analysed	   a	   representative	   pooled	   cohort	   of	   489	   patients	   for	  which	   transcriptomic	  profiles	  and	  clinical	  follow	  up	  were	  publicly	  available	  66.	  	  	  
	  
Figure	  37	  –	  Kaplan-­‐Meier	  plots	  displaying	  overall	  survival	  (A)	  and	  progression-­‐free	  survival	  (B)	  for	  four	  groups	  defined	  according	  to	  CD151	  expression.	  (C)	  CD151	  expression	  increases	  with	  tumor	  grade.	  (D)	  Overall	  survival	  is	  significant	  decreased	  for	  patients	  with	  a	  high	  expression	  of	  CD151	  compared	  to	  patients	  with	  a	  low	  expression	  of	  CD151	  in	  grade	  2	  tumors.	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According	  to	  their	  expression	  of	  CD151,	  the	  patient	  cohort	  was	  divided	  into	  four	  groups	  (group	  1:0-­‐25%,	  group	  2:	  25-­‐50%,	  group	  3:	  50-­‐75%,	  group	  4:	   	  75-­‐100%	  expression	  of	  CD151).	   Based	   on	   these	   groups,	  we	   investigated	   the	   correlation	   of	   CD151	   expression	  with	   progression-­‐free	   and	   overall	   survival.	   This	   comparison	   did	   not	   reach	   statistical	  significance	  neither	   for	  progression-­‐free	   survival	  nor	   for	  overall	   survival	   SOC	  patients	  
(Figure	  37A/B).	  We	  next	  wondered	  if	  this	  might	  be	  attributed	  to	  the	  characteristics	  of	  our	  patient	   cohort	  and	   included	   further	  parameters	   in	  our	  analysis.	  We	  observed	   that	  the	   expression	   of	   CD151	   significantly	   correlated	   with	   grading	   of	   the	   tumor,	   meaning	  patients	  with	  an	  advanced	  disease	  exhibit	  elevated	  expression	  levels	  of	  CD151	  (Figure	  
37C).	   We	   analysed	   the	   two	   grading’s	   provided	   in	   out	   patient	   cohort	   separately.	  Interestingly,	  patients	  with	  a	  low-­‐grade	  tumor	  (G2)	  showing	  a	  high	  expression	  of	  CD151	  had	  a	  significant	  shorter	  overall	  survival	  compared	  to	  patients	  with	  a	  low	  expression	  of	  CD151	  and	  a	  tumor	  of	  this	  grading	  (Figure	  37D).	  These	  observations	  would	  suggest	  a	  selection	  for	  CD151+	  cells	  during	  tumor	  development.	  Furthermore,	  patients	  showing	  a	  high	  expression	  of	  CD151	  have	  a	  significant	  poorer	  prognosis	  than	  patients	  with	  a	  low	  expression	  of	  CD151	  in	  low-­‐grade	  tumors.	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6	   Discussion	  	  Ovarian	  cancer	  represents	  the	  fifth-­‐leading	  cause	  of	  cancer	  related	  death	  among	  women	  in	   the	  United	  States	  and	  Europe	   204.	  Among	  ovarian	  cancer,	  high	  grade	  serous	  ovarian	  carcinoma	  (SOC)	  represents	  the	  most	  aggressive	  subtype	  accounting	  for	  approximately	  70%	  of	  all	  deaths	  66.	  The	  overall	   five-­‐year	  survival	  probability	   is	  only	  30%	  205.	  Despite	  improvements	  in	  diagnosis	  and	  therapy,	  the	  survival	  rate	  did	  not	  virtually	  change	  in	  the	  last	  three	  decades.	  A	  major	  obstacle	   in	  SOC	  is	  disease	  recurrence	  after	  therapy,	   	  which	  prohibits	  the	  cure	  of	  this	  cancer	  206.	  	  Disease	  recurrence	  is	  believed	  to	  b	  by	  small	  numbers	  of	  persisting	  cells	  that	  have	  been	  able	  to	  escape	  standard	  treatment	  by	  platinum-­‐taxane	  based	  chemotherapy,	  raising	  the	  possibility	   that	   intrinsically	   resistant	   cancer	   cells	   account	   for	   re-­‐growth	   of	   the	   tumor,	  treatment	  failure	  and	  relapse.	  In	  the	  CSC	  model,	  treatment	  failure	  is	  reflected	  by	  the	  fact	  that	  conventional	  chemotherapies	  are	  rather	  unspecific	  and	  mainly	  eradicate	  the	  tumor	  bulk	  sparing	  the	  cancer	  stem	  cell	  compartment.	  Therefore,	  it	  is	  of	  highest	  importance	  to	  identify	  targets,	  which	  would	  enable	  the	  treatment	  of	  these	  cells.	  In	  order	  to	  do	  so,	  these	  cells	  need	  to	  be	  purified	  and	  characterized,	  which	  requires	  CSC	  specific	  markers.	  	  In	  this	  study,	  we	  present	  the	  establishment	  and	  first	  characterization	  of	  a	  novel	  model	  for	  serous	  ovarian	  carcinoma,	  which	  fully	  recapitulates	  the	  human	  disease.	  Importantly,	  we	  showed	  that	  xenograft	   tumors	   formed	  upon	   injection	  of	  our	  primary	  SOC	  cell	   lines	  display	   histopathological	   features	   of	   the	   patient	   tumor	   and	   express	   the	   two	   clinically	  used	  SOC	  specific	  markers	  CA125	  and	  WT1.	  By	  the	  help	  of	  this	  model	  we	  were	  able	  to	  demonstrate	   that	   the	   four	  SOC	  subtypes,	   recently	  described	  by	   the	   researchers	  of	  The	  Cancer	   Genome	   Atlas	   (TCGA),	   are	   also	   present	   in	   in	   vitro	   cultivated	   cells	   and	   that	  respective	  subtype	  is	  maintained	  in	  their	  corresponding	  xenograft	  tumors.	  	  Furthermore,	   we	   describe	   a	   novel	   surface	   marker	   (CD151)	   identifying	   a	   functionally	  different	  subpopulation	  within	  the	  tumor,	  which	  displays	  properties	  of	  tumor	  initiating	  cells.	   Cells	   that	   have	   been	   purified	   for	   the	   expression	   of	   CD151	   exhibits	   an	   increased	  tumorigenic	  potential	  compared	  to	  their	  CD151-­‐	  counterparts	  in	  xenoraft	  mouse	  models.	  Moreover,	  these	  cells	  show	  a	  distinct	  activation	  of	  pathways	  implicated	  in	  proliferation,	  migration	   and	   invasion.	   We	   proved	   that	   the	   expression	   of	   CD151	   correlates	   with	   an	  advanced	  disease	  stage	  and	  defines	  patients	  with	  a	  significant	  decreased	  overall	  survival	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in	  low-­‐grade	  tumors	  of	  serous	  ovarian	  carcinoma.	  Taken	  together,	  our	  model	  is	  perfectly	  suited	  for	  the	  evaluation	  of	  molecular	  subtypes	  within	  SOC,	  drug	  screens	  and	  the	  study	  of	  tumor	  initiating	  cells	  in	  SOC.	  	  
Establishment	  and	  characterization	  of	  a	  novel	  patient	  
matched	  model	  system	  for	  serous	  ovarian	  carcinoma	  In	  order	  to	  study	  serous	  ovarian	  carcinoma	  more	  precisely	  we	  established	  a	  novel	  model	  system,	   which	   combines	   serum-­‐free	   cultivation	   of	   primary	   cell	   lines	   with	  xenotransplantation.	   This	   advanced	   model	   faithfully	   recapitulates	   histolopathological	  features	   of	   the	   patient	   tumor	   and	   reflects	   recently	   described	   molecular	   subtypes	   of	  serous	   ovarian	   carcinoma.	   Additionally,	   we	   showed	   that	   our	   model	   preserves	   the	  heterogeneous	  nature	  of	  each	   individual	  patient	   tumor.	  After	   the	  enrichment	  of	   tumor	  cell	  content	  using	  a	  xenograft	  mouse	  model,	  we	  were	  able	  to	  directly	  establish	  primary	  cell	   lines	   out	   of	   the	   patient	   specimen.	   Previous	   studies	   proved	   that	   primary	   and	   low	  passage	  xenografts	  recapitulate	  the	  histology	  of	  the	  primary	  tumor	  in	  ovarian	  cancer	  141-­‐143,	   but	   they	   also	   showed	   that	   after	   a	   certain	   passage	   in	   the	   xenograft	   nuclear	   and	  morphological	   changes	   were	   apparent,	   highlighting	   the	   importance	   of	   a	   careful	  histological	   evaluation	   142.	   A	   comparison	   of	   the	   original	   patient	   tumors	   and	   their	  corresponding	   primary	   xenograft	   tumors	   revealed	   that	   all	   histological	   features	   of	   the	  primary	   tumor	   are	  well	   preserved	   in	   our	  model.	   These	   observations	   are	   in	   line	   with	  other	  studies	  141-­‐143.	  In	  addition,	  our	  established	  primary	  xenograft	  tumors	  express	  the	  two	  clinically	  used	  serous	  ovarian	  carcinoma	  specific	  markers	  CA125	  and	  WT1.	  	  Xenograft	  mouse	  models	  are	  well	  accepted	  tools	  for	  the	  identification	  of	  tumor	  initiating	  cells	   141-­‐143	   and	   drug	   screenings	   in	   ovarian	   cancer	   207.	   Usually,	   highly	  immunocompromised	   mice	   are	   used	   in	   these	   studies,	   which	   have	   been	   genetically	  modified	  and	  therefore	  harbour	  defects	  in	  important	  parts	  of	  the	  immune	  system.	  This	  immunodeficiency	  inhibits	  the	  rejection	  of	  the	  graft	  by	  the	  host	  immune	  system	  and	  the	  extent	   influences	   the	   success	   rate	   of	   transplantations	   208.	   However,	   these	  xenotransplantation	   assays	   have	   certain	   limitations.	   Major	   problems	   are	   nuclear	   and	  morphological	   changes	   in	   the	   xenograft	   tumors,	   which	   occur	   already	   after	   a	   few	  passages.	   Furthermore,	   hamper	   the	   strong	   differences	   between	   individual	   tumor	  specimen,	  e.g.	  variable	  tumor	  cell	  contents,	  the	  reproducibility	  of	  such	  assays.	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Additionally,	   because	   of	   the	   high	   degree	   of	   immunodeficiency,	   the	   influence	   of	   the	  immune	   system	   on	   tumor	   development	   cannot	   be	   considered.	   This	   is	   especially	  problematic	   for	   immunotherapeutic	   approaches,	   which	   aim	   to	   engage	   the	   immune	  system	  against	  tumor	  cells.	  To	   circumvent	   these	   problems	   genetic	   engineered	   mouse	   models	   for	   ovarian	   cancer	  have	   been	   developed,	   which	   should	   mimic	   the	   human	   disease	   more	   faithfully.	   These	  models	   possess	   a	   complete	   functional	   immune	   system	   and	   thus	   allow	   the	   study	   of	  interactions	  between	   tumor	   cells	   and	   the	  host	   immune	  system.	  Furthermore,	   they	  are	  indispensable	   for	   the	   realistic	   investigation	   of	   the	   role	   of	   the	   microenvironment	   in	  tumor	  progression.	  However,	  the	  development	  of	  genetically	  engineered	  mouse	  models	  for	  ovarian	  cancer	  has	  been	  hindered	  due	   to	   the	   lack	  of	  ovary	  specific	  promoters	   that	  drive	   transgene	   expression	   exclusively	   in	   the	   ovarian	   surface	   epithelium.	   Nowadays,	  several	   GEMs	   for	   ovarian	   cancer	   exist,	   which	   differ	   in	   the	   histological	   tumor	   subtype	  that	   is	   induced	   (Table	   2).	   These	  models	   improved	  our	  understanding	   regarding	   gene	  dysfunction	   necessary	   for	   tumorigenesis	   such	   as	   the	   deletion	   of	   p53	   and	   Rb	   or	   the	  overexpression	   of	   the	   known	   oncogenes	   c-­‐myc,	  Kras	   and	  Akt	   .	   In	   order	   to	   completely	  understand	  the	  complexity	  of	  ovarian	  cancer	  and	  to	  use	  them	  as	  pre-­‐clinical	  models	  for	  drug	  screening	  approaches,	  mouse	  models	  representing	  each	  subtype	  of	  ovarian	  cancer	  are	  needed.	  	  Despite	   the	  mentioned	  advantages	  of	   these	  models,	   they	  also	  have	   certain	   limitations.	  Induction	   of	   ovarian	   tumors	   by	   the	   inactivation	   of	   the	   two	   major	   tumor	   suppressor	  genes	   p53	   and	   Rb	   using	   the	   Cre-­‐loxP	   system	   is	   fairly	   costly	   and	   labor-­‐intesive	   and	  therefore	  inappropriate	  for	  high-­‐throughput	  compound	  screens.	  In	  this	  regard,	  the	  lack	  of	   an	   ovarian	   epithelium	   specific	   promoter	   remains	   a	   major	   problem	   for	   the	  development	   of	  GEM	  models	   for	   ovarian	   cancer.	   Furthermore,	   several	   studies	   already	  showed	  that	  findings	  acquired	  by	  the	  use	  of	  these	  mouse	  models	  have	  to	  be	  considered	  carefully	   and	   cannot	   be	   translated	   per	   se	   to	   the	   human	   situation.	   There	   is	   no	   direct	  correlation	   between	   drug	   responses	   observed	   in	   mouse	  models	   and	   the	   success	   of	   a	  therapy	  in	  the	  clinic	  181.	  Even	   though	   xenograft-­‐	   as	   well	   as	   genetically	   engineered	   mouse	   models	   represent	  useful	   tools	   for	   the	   study	   of	   ovarian	   cancer,	   in	   vitro	   cell	   culture	   systems	   are	  indispensible	   for	   the	   investigation	  of	   cellular	  processes	   in	  a	  defined	  environment.	  Cell	  culture	   systems	   allow	   various	   manipulations	   of	   the	   cells	   and	   enable	   testing	   of	  hypotheses	   in	  a	   less	  complex	  system	  compared	  to	   the	   in	  vivo	   setting.	  By	   the	  help	  of	   in	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vitro	  culture	  systems	  major	  insights	  has	  been	  gained	  into	  the	  biology	  of	  several	  cancers.	  In	  this	  respect,	  it	  has	  been	  shown	  that	  the	  culture	  conditions	  have	  a	  great	  impact	  on	  the	  genetic	   stability	   of	   the	   cells.	   Since	   development	   of	   the	   first	   in	   vitro	   cultures	   fetal	   calf	  serum	  (FCS)	  was	  usually	  added	  to	  the	  media	  as	  a	  source	  of	  nutrients	  and	  growth	  factors	  209.	   However,	   FCS-­‐cultured	   cell	   lines	   often	   fail	   to	   recapitulate	   the	   morphological	   and	  histopathological	  characteristics	  of	  the	  original	  patient	  tumor	  upon	  xenotransplantation	  167.	  The	  loss	  of	  the	  stromal	  compartments	  within	  the	  xenograft	  tumor	  is	  one	  example	  for	  changes	   that	  were	   observed	   for	   FCS-­‐cultured	   cells.	   Indeed,	  when	  we	   investigated	   the	  morphology	  of	  xenograft	  tumors	  induced	  by	  two	  of	  the	  most	  prominent	  ovarian	  cancer	  cell	   lines,	   SKOV-­‐3	   and	   OVCAR-­‐3,	   it	   became	   clearly	   evident	   that	   SKOV-­‐3	   tumors	  completely	  lacked	  stromal	  parts	  and	  OVCAR-­‐3	  tumors	  showed	  only	  a	  minor	  presence	  of	  them	  (Figure	  17B).	  Furthermore,	  Lee	  and	  colleagues	  show	  that	  cells	  serially	  passaged	  in	  medium	  containing	  FCS	  acquire	  secondary	  mutations	  over	  time,	  which	  are	  not	  found	  in	   the	   original	   primary	   tumor.	   Additionally,	   cultivation	   with	   FCS	   promotes	   the	  outgrowth	  of	  subclones	  and	  the	  original	  heterogeneity	  of	  the	  patient	  tumor	  is	  lost	  over	  time	  210.	  	  In	  order	  to	  improve	  currently	  used	  culture	  systems	  for	  ovarian	  cancer	  cells,	  we	  applied	  serum-­‐free	  cultivation	  techniques	  for	  the	  establishment	  of	  primary	  SOC	  cell	  lines.	  These	  serum-­‐free	  cultures	  have	  been	  shown	  to	  preserve	  the	  genotypic	  and	  phenotypic	  features	  of	  several	  tumor	  entities	  137,167,180.	  For	  the	  establishment	  of	  the	  adherent	  in	  vitro	  culture	  system,	   we	   used	   primary	   xenograft	   tumors.	   Xenograft	   derived	   SOC	   cell	   lines	   were	  further	  investigated	  for	  their	  ability	  to	  form	  tumors	  in	  secondary	  recipient	  mice	  and	  the	  resulting	   tumors	   were	   evaluated	   for	   their	   histopathology.	   According	   to	   histological	  characteristics	  ovarian	  cancer	   is	  clinically	  classified	   into	   five	  distinct	  histotypes,	  which	  have	   significant	   different	   prognoses	   as	   well	   as	   sensitivities	   to	   platinum-­‐	   and	   taxane	  based	  chemotherapies	  12.	  Therefore,	  the	  histopathological	  classification	  and	  verification	  of	   xenograft	   tumors	   is	   of	   highest	   importance.	   For	   instance,	   several	   commonly	   used	  ovarian	  cancer	  cell	  lines	  have	  been	  reported	  to	  not	  resemble	  the	  tumor	  subtype	  they	  are	  originated	  from	  211.	  To	  ensure	  that	  all	  primary	  cell	  lines,	  which	  have	  been	  established	  in	  this	  study,	  still	  recapitulate	  the	  histopathological	  features	  of	  their	  corresponding	  patient	  tumor,	   they	   were	   pathologically	   classified	   at	   the	   Department	   of	   Pathology	   of	   the	  University	  of	  Heidelberg.	  The	  direct	  comparison	  of	  patient	  tumor	  and	  corresponding	  cell	  line	   derived	   tumor	   revealed	   that	  morphological	   characteristics	   and	   the	   expression	   of	  histotype	  specific	  markers	  was	  very	  well	  retained	  in	  our	  model	  (Figure	  17A).	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A	  total	  of	  15	  human	  SOC	  xenografts	  were	  established	  following	  intraperitoneal	  injection	  of	  1x105	  –	  1x106	  CD45	  depleted	  ovarian	  tumor	  cells	  with	  an	  engraftment	  success	  rate	  of	  65%.	   	  The	   tumor	   formation	   rate	  of	   the	   initial	   xenograft	  was	  mainly	  depending	  on	   the	  FIGO	   stage	   of	   the	   tumor	   and	   overall	   quality	   of	   the	   tumor	   sample.	   Whereas	   primary	  tumors	  with	  FIGO	  stages	  III	  and	  IV	  grafted	  with	  a	  success	  rate	  of	  68%,	  we	  were	  not	  able	  to	  expand	  any	  tumor	  with	  the	  FIGO	  stage	  I.	  	  A	  further	  parameter,	  which	  was	  identified	  to	  influence	  the	  engraftment	  success	  rate	  was	  the	   general	   quality	   of	   the	   primary	   specimen,	   particularly	   the	   quantity	   of	   cancer	   cells	  within	   the	   received	   tumor	   piece.	   Before	   preparation	   of	   primary	   tumor	   material	   for	  intraperitoneal	   injection,	   a	   part	   of	   the	   tumor	   was	   used	   for	   immunohistochemical	  analysis.	   Based	   on	   the	   results	   of	   immunohistochemistry	   we	   assessed	   the	   quantity	   of	  tumor	   cells	   within	   the	   received	   tumor	   piece	   and	   retrospectively	   link	   to	   engraftment	  success.	   However,	   we	   cannot	   exclude	   further	   factors,	   which	   might	   have	   influenced	  tumor	   growth.	   As	   described	   before,	   many	   tumors	   contain	   phenotypically	   and	  functionally	  heterogeneous	  cell	  populations	  124,	  which	  might	  exhibit	  different	  abilities	  to	  grow	   in	   the	   xenograft	   model.	   Furthermore,	   the	   normal	   ovary	   is	   a	   complex	   tissue	  containing	   several	   distinct	   cell	   types	   and	   the	   cell	   of	   origin	   for	   SOC	   has	   not	   been	   fully	  defined	  yet	  26.	  For	  that	  reasons,	  we	  cannot	  ensure	  that	  the	  heterogeneous	  nature	  of	  the	  original	  patient	  tumor	  is	  completely	  reflected	  by	  the	  corresponding	  xenograft.	  	  	  For	  the	  establishment	  of	  a	  primary	  serum-­‐free	  culture	  system	  for	  SOC,	  we	  tested	  several	  substrates	   and	  growth	   factors	   to	  define	   the	  optimal	   conditions	   for	   the	   cultivation	  and	  expansion	   of	   primary	   human	   ovarian	   cancer	   cells.	   First,	   we	   determined	   a	   substrate,	  which	   yielded	   a	   maximal	   outgrowth	   of	   primary	   epithelial	   ovarian	   cancer	   cells.	  Therefore,	  we	  compared	  the	  growth	  of	  tumor	  cells	  on	  Primaria	  flasks	  to	  the	  expansion	  on	   flasks	   with	   different	   coatings	   (3%	   FCS	   and	   Collagen)	   as	   well	   as	   the	   cultivation	   in	  suspension.	  We	  detected	   the	  proliferation	  of	   adherent	   cells	   on	   every	   tested	   substrate.	  However,	  we	  observed	  no	  significant	  growth	  advantage	  of	  any	  kind	  of	  coating	  (Figure	  
11A).	   Spheroid	   cultures	   have	   been	   described	   for	   the	   cultivation	   of	   several	   primary	  tumor	  cells	  180,	   including	  ovarian	  cancer	  cells	  143.	   In	  serous	  effusions	  of	  ovarian	  cancer	  patients,	  similar	  structures	  have	  been	  observed	  212.	  We	  confirmed	  these	  results	  by	  our	  observations	  on	  ascites	  originating	  from	  patients	  as	  well	  as	  our	  xenograft	  models.	  	  However,	  when	  we	   compared	   the	   adherent	   cultivation	   of	   our	   primary	   tumor	   cells	   on	  Primaria	  flasks	  with	  the	  spheroid	  culture	  on	  ultra-­‐low	  attachment	  flasks	  (Figure	  11A),	  we	  noticed	  significant	  faster	  outgrowth	  in	  the	  adherent	  culture.	  Moreover,	  we	  detected	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also	  a	  lower	  amount	  of	  dead	  cells	  using	  Primaria	  flasks	  instead	  of	  ultra-­‐low	  attachment	  flasks.	  We	   explained	   these	   results	  with	   the	   fact	   that	   the	   adherent	   culture	  provides	   an	  optimal	   supply	   of	   nutrients	   and	   growth	   factors	   for	   nearly	   all	   cells.	   In	   contrast,	   we	  detected	  especially	   in	   larger	   spheroids	   the	  appearance	  of	  dead	  cells	   in	   the	   core	  of	   the	  spheroid,	   which	   might	   be	   due	   to	   a	   worse	   supply	   with	   nutrients	   for	   these	   cells.	  Additionally,	  several	  studies	  reported	  that	  the	  insufficient	  access	  to	  growth	  factors	  leads	  to	  differentiation	  of	  the	  cells	  167,176.	  	  According	  to	  previous	  reports,	  we	  selected	  a	  panel	  of	  growth	  factors	  and	  hormones	  for	  further	   experiments	   on	   the	   optimal	   cultivation	   of	   primary	   ovarian	   cancer	   cells	   183-­‐185.	  Female	   sex	   hormones	   such	   as	   human	   menopausal	   gonadotropin,	   human	   chorionic	  gonadotropin	   and	   estrogen	   have	   been	   described	   to	   stimulate	   the	   growth	   of	   primary	  ovarian	   tumor	   cells.	   Therefore,	   we	   included	   these	   substances	   in	   our	   cultivation	  experiments.	   However	   in	   our	   hands,	   only	   the	   combination	   of	   our	   basic	   SCM	   with	  estradiol	   led	   to	   significant	   increase	   in	   the	  number	  of	   outgrowing	   cells.	   In	   the	   cultures	  supplemented	   with	   hMG	   and/or	   hCG,	   we	   could	   only	   detect	   a	   higher	   number	   of	  differentiated	  cells	  (Figure	  11B).	  Furthermore,	  we	  tested	  the	  supplement	  of	  the	  growth	  factor	   heregulin	   to	   our	   basic	   media.	   As	   we	   observed	   a	   significant	   enhancement	   in	  growth	   of	   primary	   ovarian	   cancer	   cells	   only	   estradiol,	   we	   decided	   to	   use	   hormone	  together	  with	  our	  basic	  SCM	  and	  Primaria	  flasks	  for	  all	  further	  experiments	  (Table	  3).	  Even	   though,	  we	  cannot	  exclude	   that	   tumor	  cells,	  which	  were	  not	   tested	   in	   this	   initial	  experiment,	  would	  need	  these	  hormones/growth	  factors	  to	  proliferate	  in	  vitro.	  We	   were	   able	   to	   establish	   8	   stable	   primary	   SOC	   cell	   lines,	   which	   show	   a	   broad	  heterogeneity	   in	  morphology,	   in	  vitro	  growth,	  clongenicity	  as	  well	  as	  the	  expression	  of	  markers	   for	   putative	   tumor	   initiating	   cells.	   Out	   of	   four	   described	   TIC	   markers	   for	  ovarian	  cancer,	  we	  found	  three	  of	  these	  markers,	  CD24,	  CD44	  and	  CD117,	  expressed	  at	  different	  levels	  on	  our	  SOC	  models.	  CD117	  was	  not	  expressed	  on	  every	  cell	  line,	  which	  is	  in	   line	   with	   previous	   reports	   142.	   However,	   none	   of	   the	   tested	   cell	   lines	   showed	   the	  expression	  of	  CD133	  (Table	  4).	  Stewart	  et	  al.	  reported	  that	  the	  expression	  of	  CD133	  on	  tumorigenic	   cells	   changed	   during	   passaging,	   suggesting	   that	   CD133	   is	   not	   stably	  expressed	  on	  ovarian	  cancer	  cells.	  Taken	   together,	  we	   cannot	  exclude	   the	   introduction	  of	   a	   certain	   selection	  pressure	  by	  our	  in	  vitro	  culture,	  and	  the	  subsequent	  outgrowth	  of	  distinct	  clones.	  On	  the	  other	  hand,	  tumors	  that	  were	  derived	  from	  our	  primary	  SOC	  cell	  lines	  represent	  several	  hallmarks	  of	  human	  serous	  ovarian	  carcinoma,	  including	  the	  stable	  expression	  of	  SOC	  specific	  clinical	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markers	   (CA125	   and	   WT1).	   Additionally,	   we	   observed	   a	   broad	   heterogeneity	   in	   the	  morphology	   of	   the	   cell	   lines	   as	   well	   as	   in	   their	   expression	   of	   putative	   TIC	   markers,	  indicating	  the	  presence	  of	  a	  certain	  repertoire	  of	  different	  cells.	  The	   combination	   of	   serum-­‐free	   cultures	  with	   advanced	   xenograft	  models	   enables	   the	  dissection	  of	  the	  biology	  of	  SOC	  at	  a	  molecular	  level	  as	  well	  as	  the	  functional	  validation	  in	   xenograft	   tumors.	   Therefore,	   our	   system	   has	   the	   potential	   to	   significantly	   improve	  existing	  models.	  
	  
Gene	  expression	  profiling	  on	  the	  SOC	  model	  reveals	  signaling	  
pathways	  activated	  in	  ovarian	  cancer	  and	  the	  presence	  of	  all	  
four	  SOC	  subtypes	  To	  identify	  molecular	  pathways	  that	  contribute	  to	  SOC	  and	  subsequent	  new	  therapeutic	  approaches,	  we	  analysed	  the	  gene	  expression	  profiles	  of	  our	  primary	  SOC	  cell	  lines	  and	  their	   corresponding	   derived	   tumors.	   The	   analysis	   of	   differential	   gene	   expression	  between	   our	   SOC	   models	   and	   normal	   human	   ovarian	   surface	   epithelium	   revealed	  pathways	  specifically	  altered	  in	  ovarian	  cancer.	  	  Interestingly,	  we	   found	   that	   the	   vast	  majority	   of	   upregulated	   genes	   in	   the	   SOC	  model	  compared	   to	   human	   ovarian	   surface	   epithelium	   are	   associated	  with	   the	   regulation	   of	  mitosis,	  cell	  division,	  cell	  cycle	  processes	  and	  proliferation.	   In	  particular,	  we	   identified	  several	  members	  of	  the	  FOXM1	  transcription	  network	  such	  as	  AURA,	  CCNB1,	  BIRC5	  and	  
CDC25	  (Figure	  20A).	  In	  non-­‐neoplastic	  cells,	  FOXM1	  is	  regulated	  by	  TP53	  and	  repressed	  upon	  DNA	  damage	  213.	  The	  overexpression	  of	  FOXM1	  and	  its	  proliferation-­‐related	  target	  genes	   suggests	   a	   high	   frequency	   of	  TP53	   mutations	   in	   the	   SOC	  models.	   Several	   other	  studies	   also	   described	   a	   significant	   activation	   of	   this	   network	   when	   they	   compared	  tumors	  with	  normal	  epithelial	  tissue	  in	  SOC	  66.	  	  	  Furthermore,	   using	   gene	   set	   enrichment	   analysis	   (GSEA)	   we	   found	   multiple	   gene	  signatures	  related	  to	  alterations	  in	  DNA	  repair	  pathways	  positively	  enriched	  in	  the	  SOC	  specific	  gene	  expression	  datasets	  (Figure	  21B,C).	  Defects	   in	  DNA	  repair	  pathways	  are	  very	   common	   in	   SOC,	   especially	   mutations	   in	   BRCA1	   and	   BRCA2.	   These	   proteins	   are	  required	   for	   DNA	   double	   strand	   break	   repair	   by	   homologous	   recombination.	   Cells	  without	   functional	   BRCA1	   or	   BRCA2	   perform	   DNA	   repair	   by	   non-­‐homologous	   end	  joining	  which	   leads	   to	   chromosomal	   rearrangements	  and	  genomic	   instability	   26.	   It	  has	  been	  shown	  that	  cells	  with	  a	  mutated	  or	  methylated	  BRCA1	  or	  mutated	  BRCA2	  are	  highly	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responsive	  to	  PARP	  inhibitors	  66,	  indicating	  the	  use	  of	  our	  model	  system	  for	  preclinical	  trials.	  	  In	   line	   with	   other	   studies	   26,	   also	   signatures	   that	   point	   to	   an	   activation	   of	   the	   IL-­‐6	  pathway	  were	  positive	  correlated	  with	   the	  gene	  expression	  datasets	  of	   the	  SOC	  model	  
(Figure	   21B,C).	   The	   vast	  majority	   of	   ovarian	   cancers	   show	  an	  overexpression	  of	   IL-­‐6	  leading	   to	   an	   autocrine	   stimulation	   of	   the	   IL-­‐6	   receptor.	   This	   in	   turn	   facilitates	   the	  nuclear	   translocation	   of	   STAT3	   and	   upregulation	   of	   target	   genes,	   which	   drive	  proliferation,	  inhibit	  apoptosis	  and	  induce	  angiogenesis.	  The	  analysis	  of	  the	  gene	  expression	  profiles	  in	  our	  model	  system	  revealed	  the	  activation	  of	   several	   described	   key	   pathways	   of	   SOC.	   We	   confirmed	   that	   in	   addition	   to	  morphological-­‐	   and	   histopathological	   features,	   our	   primary	   SOC	   cell	   lines	   also	   reflect	  genetic	   hallmarks	  of	   ovarian	   cancer.	   Furthermore,	   our	  model	  might	   serve	   as	  basis	   for	  molecular	  studies	  on	  the	  identified	  pathways	  and	  provide	  the	  opportunity	  for	  preclinical	  drug	  screening.	  
	  Combined	   efforts	   by	   the	   researchers	   of	   The	   Cancer	   Genome	   Atlas	   Research	   Network	  (TCGA)	  led	  to	  the	  identification	  of	  at	  least	  four	  distinct	  transcriptional	  subtypes	  of	  SOC.	  These	  subtypes	  were	  based	  on	  gene	  expression	  analyses	  on	  a	  set	  of	  489	  human	  serous	  ovarian	   tumors.	   The	   subtypes	   were	   termed	   ‘differentiated’,	   ‘immunoreactive’,	  ‘mesenchymal’	   and	   ‘proliferative’	   on	   the	   basis	   of	   gene	   content	   in	   the	   clusters	   66.	   The	  study	   by	   the	  TCGA	  did	   not	   include	   any	   xenograft	   or	   in	  vitro	   cell	   line	  models,	   thus	  we	  were	  interested	  if	  the	  described	  subtypes	  are	  also	  present	  in	  our	  SOC	  model.	  Indeed,	  we	  were	  able	  to	  clearly	  assign	  every	  SOC	  cell	  line	  as	  well	  as	  their	  corresponding	  xenograft	  tumor	  to	  one	  of	  the	  described	  subtypes	  (Table	  7).	  As	  we	  were	  able	  to	  establish	  in	  vitro	  cultures	  for	  every	  of	  the	  four	  subtypes,	  we	  concluded	  that	  none	  of	  the	  subtypes	  has	  significant	  lower	  potential	  to	  grow	  in	  vitro	  or	  in	  the	  xenograft	  model	  under	  the	  given	  conditions.	  However,	  at	  the	  moment	  our	  data	  are	  based	  on	  quite	  a	  low	  number	  of	  cell	  lines	  per	  subtype.	  Further	  investigations	  are	  necessary	  to	  enable	  significant	  conclusions	  on	  the	  molecular	  features	  of	  these	  subtypes.	  Anyhow,	  as	  the	  TCGA	  study	  did	  not	  include	  any	  subtype	  specific	  pathway	  analysis	  or	  researches	  on	  drug	  sensitivities	  of	  the	  different	  subtypes	  in	  e.g.	  available	  human	  ovarian	  cancer	  cell	  lines,	  our	  model	  might	  serve	  as	  basis	  for	  first	  pathway	  analysis	  and	  subsequent	  subtype-­‐specific	  therapies.	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CD151	  enriches	  for	  tumor	  initiating	  cells	  in	  serous	  ovarian	  
carcinoma	  So	  far,	  several	  groups	  have	  claimed	  to	  identify	  tumor	  initiating	  cells	  in	  ovarian	  cancer.	  	  Described	  markers	  for	  the	  enrichment	  of	  tumorigenic	  cells	   in	  ovarian	  cancer	  are	  CD24	  144,	   CD44	   140,	   CD117/CD44	   143,	   and	  CD133	   141.	  However,	   the	  distinct	  phenotype	  of	   the	  TIC	   population	   in	   ovarian	   cancer	   has	   not	   been	   defined	   satisfying.	   Stewart	   et	   al.	  investigated	   a	   cohort	   of	   138	   SOC	   patient	   samples	   and	   tried	   to	   confirm	   the	   previous	  mentioned	  TIC	  markers.	  They	  reported	  that	  most	  of	  the	  ovarian	  cancers	   in	  their	  study	  showed	  no	  expression	  of	  a	  CD44+CD117+	  subpopulation.	  We	  gained	  similar	  results	   for	  our	   primary	   SOC	   cell	   lines.	   Whereas	   CD44	   was	   expressed	   at	   medium	   or	   high	   levels,	  CD117	   showed	   only	   a	   very	   low	   or	   no	   expression	   (Table	   4).	   Furthermore,	   this	   study	  could	  not	  confirm	  an	  increased	  tumorigenic	  potential	  in	  the	  described	  subpopulation	  142.	  	  In	  order	  to	  identify	  novel	  differentially	  expressed	  surface	  markers	  on	  our	  primary	  SOC	  cell	   lines,	   which	   might	   lead	   to	   the	   identification	   of	   functional	   subpopulations,	   we	  performed	  a	  large	  scale	  surface	  marker	  screen.	  In	  addition	  to	  previous	  identified	  surface	  molecules	   such	   as	   CD24	   and	   CD44,	   the	   screen	   revealed	   multiple	   heterogeneous	  expressed	   markers	   (Figure	   23).	   As	   our	   aim	   was	   to	   discover	   and	   characterize	   novel	  surface	  markers	  that	  define	  TIC	  populations	  in	  ovarian	  cancer,	  we	  focused	  on	  molecules	  that	  have	  not	  been	   implicated	   in	   tumor	   initiation	   in	  ovarian	  cancer	  before.	  One	  of	   the	  molecules,	  which	  attracted	  our	  attention,	  was	  CD151	  (Figure	  23,	  Plate2).	  Interestingly,	  CD151	  was	  highly	  differential	  expressed	  among	  all	  our	  primary	  SOC	  cell	   lines	  (Figure	  
24A).	  This	  marker	  was	  not	  yet	  described	   to	  enrich	   for	  TICs	   in	  ovarian	  cancer	  but	  has	  been	  proposed	  for	  prostate	  cancer	  197.	  Furthermore,	  the	  expression	  of	  CD151	  has	  been	  shown	   to	   correlate	   with	   a	   poor	   prognosis,	   advanced	   disease	   stage	   and	   metastasis	   in	  several	   types	   of	   cancer	   193-­‐196.	   Indeed,	   we	   gained	   similar	   results	   by	   comparing	   the	  expression	   level	   of	   CD151	   to	   the	   origin	   of	   the	   tumor	   cells.	   Cell	   lines	   that	   were	  established	   from	   serous	   effusions	   such	   as	   ascites	   or	   pleural	   effusion	   expressed	  significant	  higher	   levels	  of	  CD151	  than	  cell	   lines	  derived	  directly	   from	  tumor	  material.	  For	  instance,	  the	  cell	  lines	  OC12	  and	  OC21	  that	  were	  directly	  derived	  from	  tumor	  show	  a	  significant	   lower	   expression	   of	   CD151	   compared	   to	   cell	   lines	   originating	   from	   ascites	  (OC15)	  or	  pleural	  effusion	  (OC20)	  (Figure	  24B).	  Next	   we	   were	   interested	   if	   the	   expression	   levels	   of	   CD151	   are	   retained	   in	   xenograft	  tumors	   derived	   from	   the	   corresponding	   SOC	   cell	   line.	   The	   analysis	   of	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immunhistochemical	   stainings	   of	   different	   SOC	   cell	   line	   derived	   xenograft	   tumors	  confirmed	   that	   the	   CD151	   is	   expressed	   in	   the	   corresponding	   tumors	   and	   that	   the	  expression	   level	   is	   reflected	   by	   the	   corresponding	   tumor	   (Figure	   25).	   Moreover,	   we	  observed	  a	  specific	  membrane	  associated	  expression	  pattern	  of	  CD151	  in	  the	  xenograft	  tumors,	  which	  is	  line	  with	  previous	  reports	  describing	  CD151	  to	  be	  mainly	  expressed	  on	  the	  cell	  membrane	  and	  to	  interact	  directly	  with	  several	  integrins	  191.	  Particularly,	  CD151	  is	  a	  member	  of	  the	  transmembrane	  4	  superfamily	  whose	  members	  play	  a	  role	  in	  various	  cellular	  functions	  such	  as	  proliferation,	  differentiation	  as	  well	  as	  cancer	  cell	  invasion	  and	  metastasis	  189,190.	  	  Having	   confirmed	   that	   the	   heterogeneous	   phenotype	   of	   CD151	   is	   stable	   between	  primary	  SOC	  cell	   lines	  and	  corresponding	  xenograft	   tumor,	  we	  wondered	  whether	   the	  CD151+	   subpopulation	   has	   different	   capacities	   concerning	   self-­‐renewal	   and	  differentiation	   compared	   to	   the	   CD151-­‐	   subpopulation.	   Keeping	   in	   mind	   that	   the	  expression	  of	   the	  molecule	  correlates	  with	  a	  poor	  prognosis	  as	  well	  as	  metastasis	  and	  CD151	  was	  shown	  to	  be	  involved	  in	  the	  adhesion	  dependent	  activation	  of	  RAS,	  RAC1	  and	  CDC42	  192.	  	  	  To	   investigate	   if	   the	   two	   populations	   show	   different	   characteristics,	   we	   purified	  Venus+/CD151+	  and	  Venus-­‐/CD151-­‐	  cells	   from	   the	  SOC	   cell	   line	  OC12.	  To	  note,	   this	   cell	  line	   has	   been	   transduced	   before	   with	   a	   lentiviral	   reporter	   containing	   the	   Venus	  fluorochrome.	   The	   purified	   populations	   were	   mixed	   together	   in	   the	   same	   ratio	   and	  analysed	   in	   regular	   intervals.	   By	   the	   help	   of	   this	   experiment,	   we	   clearly	   showed	   that	  CD151+	  cells	  give	  rise	  to	  CD151+	  and	  CD151-­‐	  cells,	  whereas	  CD151-­‐	  cells	  were	  not	  able	  to	  repopulate	  the	  CD151+	  cell	   fraction	  (Figure	  26A/B).	  Furthermore,	  we	  noticed	  that	  the	  total	  amount	  of	  cells	  originating	   from	  the	  Venus-­‐/CD151-­‐	  cell	  population	  declined	  over	  time	  in	  our	  culture	  (Figure	  26D).	  These	  results	  led	  to	  the	  assumption	  that	  CD151+	  cells	  might	   have	   an	   increased	   proliferative	   ability	   and	   that	   CD151-­‐	  cells	   represent	   a	   more	  differentiated	  state	  exhibiting	  a	   lower	  potential	   to	  differentiate.	   Interestingly,	  Ang	  and	  colleagues	   described	   in	   a	   study	   on	   prostate	   cancer	   that	   the	   expression	   of	   CD151	  inversely	   correlates	   with	   the	   differentiation	   status	   of	   the	   tumor,	   meaning	   well-­‐differentiated	  tumors	  show	  no	  or	  only	  a	  weak	  expression	  of	  CD151.	  Given	   the	   observed	   discrepancies	   in	   self-­‐renewal	   and	   differentiation	   between	   the	  CD151+	  subpopulation	  and	  the	  CD151-­‐	  counterpart,	  we	  wondered	  whether	  this	  might	  be	  explained	  by	  a	  differential	  proliferative	  capacity.	  The	  analysis	  of	  the	  proliferation	  of	  both	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subpopulations	  revealed	  a	  higher	  proliferation	  of	  the	  CD151+	  cell	  population	  in	  general.	  However,	   these	   differences	   did	   not	   reach	   statistical	   significance	   in	   all	   tested	   cell	   lines	  
(Figure	  27).	  At	  this	  point	  it	  has	  to	  be	  admitted	  that	  the	  short	  term	  application	  of	  EdU,	  used	  in	  this	  assay,	  could	  lead	  to	  the	  incorporation	  into	  cells,	  which	  will	  arrest	  posterior	  to	   the	   EdU	   pulse	   214.	   Thus,	   a	   significant	   difference	   for	   all	   cell	   lines	   between	   the	  subpopulations	  might	  be	  masked	  due	  to	  the	  selection	  of	  an	  inadequate	  pulse	  period.	  	  In	  order	  to	  further	  investigate	  functional	  differences	  between	  CD151+	  and	  CD151-­‐	  cells,	  we	   performed	   a	   xenotransplantation	   assay	   comparing	   the	   two	   purified	   CD151	  subpopulations.	  We	  assessed	  the	  ability	  of	  both	  purified	  populations	  to	  form	  tumors	  in	  immunocompromised	  mice	   for	   three	   different	   SOC	   cell	   lines.	   In	   all	   three	   experiments	  CD151+	  cells	  were	  able	  to	  induce	  growth	  of	  tumors,	  whereas	  CD151-­‐	  could	  not	  (Table	  8).	  In	  some	  cases,	  we	  observed	  tumor	  growth	  in	  mice	  injected	  with	  CD151-­‐	  cells,	  but	  have	  been	  able	  to	  	  show	  that	  this	  was	  due	  to	  a	  contamination	  with	  CD151+	  cells.	  CD151+	  cells	  in	   these	   tumors	   were	   detected	   by	   flow	   cytometry	   as	   well	   as	   immunohistochemistry	  
(Figure	  31).	  Mice	  injected	  with	  CD151-­‐	  cells	  were	  further	  monitored	  for	  appearance	  to	  tumor	   growth	   for	   at	   least	   140	   days	   or	   more.	   In	   vivo	   growth	   curves	   determined	   by	  bioluminescence	   imaging	   as	   well	   as	   overall	   survival	   of	   mice	   was	   highly	   significant	  
(Figure	   28/30).	   According	   to	   these	   data,	   we	   assume	   that	   CD151	   defines	   a	   tumor	  initiating	  subpopulation	  in	  SOC.	  Per	  definition,	  TICs	  are	  able	  to	  adjust	  better	  to	  changing	  environmental	   conditions	   and	   thus	   able	   to	   induce	   tumor	   growth	   124.	   Interestingly,	  CD151	   has	   been	   reported	   previously	   to	   enrich	   TICs	   in	   prostate	   cancer	   together	   with	  further	  markers	   confirming	   our	   data	   197.	   Consistent	  with	   the	   CSC	  model,	   CD151+	  TICs	  yield	  tumors	  containing	  both	  CD151+	  and	  CD151-­‐	  cells	  (Figure	  29/31).	  In	  line	  with	  our	  data,	   several	   studies	   described	   that	   the	   ablation	   of	   CD151	   notably	   delays	   tumor	  progression	  in	  various	  mouse	  xenograft	  models	  199.	  Additionally,	   we	   observed	   metastatic	   spread	   to	   the	   lungs	   in	   the	   mice	   injected	   with	  purified	  CD151+	  cells	  for	  two	  of	  the	  three	  cell	  lines	  tested.	  Metastatic	  colonies	  in	  the	  lung	  stained	  positive	  for	  CD151	  as	  well	  as	  Ki67,	  indicating	  that	  are	  also	  proliferative.	  To	  note,	  we	  did	  not	  detect	  occurrence	  of	  lung	  metastasis	  in	  the	  parental	  OC	  12	  cell	  line	  indicating	  an	  enrichment	  of	  for	  more	  metastatic	  cells	  by	  purification	  for	  CD151	  positivity	  (Figure	  
29).	  As	   stated	  above,	  CD151	  has	  been	   implicated	   several	   times	   to	  promote	  metastatic	  growth	  to	  the	  lung	  192,215,216.	  These	  reports	  strongly	  support	  our	  findings.	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To	  investigate	  if	  the	  CD151+	  subpopulation	  enriches	  for	  already	  described	  TIC	  markers,	  we	   analysed	   the	   expression	   of	   CD151	   in	   association	   with	   CD24	   and	   CD44	   in	   several	  primary	  SOC	  lines.	  According	  to	  these	  results,	  we	  excluded	  an	  enrichment	  for	  known	  TIC	  markers	  and	  concluded	  that	  other	  factors	  might	  contribute	  to	  the	  observed	  phenotype.	  In	   summary,	   we	   showed	   that	   our	   primary	   SOC	   cell	   lines	   heterogeneously	   express	  various	   surface	   molecules.	   These	   markers	   can	   lead	   to	   the	   identification	   of	   functional	  subpopulations.	   Our	   data	   strongly	   suggest	   that	   CD151	   enriches	   for	   tumor	   initiating	  subpopulation	   in	   SOC.	   	   Additionally,	   CD151	   has	   been	   shown	   to	   promote	   metastatic	  spread	   to	   the	   lungs	   in	   our	   xenograft	   model.	   Previous	   reports	   support	   these	   results.	  Moreover,	  CD151	  is	  functionally	  independent	  of	  described	  TIC	  markers	  in	  SOC.	  	  
CD151+	  cells	  show	  a	  distinct	  pathway	  activity	  and	  ablation	  of	  
CD151	  directly	  impacts	  signaling	  CD151	  has	  been	   reported	   to	  be	   involved	   in	   the	  adhesion	  dependent	   activation	  of	  Ras,	  Rac1	   and	   Cdc42	   192.	   This	   activation	   is	   mediated	   by	   the	   direct	   interaction	   of	   several	  integrins	  with	  CD151	  191.	  Further	  studies	  described	  CD151	  as	  a	  linker	  between	  integrins	  and	  growth	  factor	  receptors	  such	  as	  EGFR	  and	  c-­‐MET	  199.	  	  However,	   to	   uncover	   possible	   pathways	   regulated	   by	   CD151	   specifically	   in	   SOC,	   we	  performed	  gene	  expression	  profiling	  on	  purified	  CD151+	  cells	  of	   four	  different	  SOC	  cell	  lines	  and	  compared	   them	   to	   the	  profiles	  of	  CD151-­‐	  cells.	  Gene	   set	   enrichment	  analysis	  revealed	   a	   strong	   positive	   correlation	   of	   the	   CD151+	   cells	   with	   distinct	   proliferation	  associated	   signatures	   such	   as	   the	   JNK/MAPK	   signaling	   pathway	   and	   EGFR	   signaling	  
(Figure	  33B).	  Integrins,	  which	  directly	  interact	  with	  CD151,	  have	  been	  described	  to	  be	  main	   activators	   of	   the	   JNK/MAPK	   signaling	   pathway	   198.	   According	   to	   these	   results,	  CD151	  activates	  integrin	  signaling	  via	  the	  JNK/MAPK	  pathway.	  This	  activation	  occurs	  by	  the	  recruitment	  and	  activation	  of	  Src	  family	  kinases	  (SFKs).	  	  When	  we	  analysed	  the	  activation	  of	  SFKs	  and	  members	  of	  the	  JNK	  pathway	  on	  protein	  level,	   we	   indeed	   detected	   a	   specific	   activation	   only	   in	   the	   CD151+	   subpopulation.	   In	  detail,	   Western	   Blot	   analysis	   revealed	   a	   significantly	   increased	   activating	  phosphorylation	  of	  SFKs	  at	  Tyr416.	   	  Furthermore,	  MKK4,	  which	  is	  upstream	  of	  JNK,	  and	  the	   two	   isoforms	   of	   JNK	   itself	   were	   activated	   by	   phosphorylation	   (Figure	   34).	   An	  increased	   kinase	   activity	   of	   JNK	   has	   been	   shown	   to	   control	   tumor	   initiation	   and	  promotion	  by	  affecting	  proliferation	  of	   tumor	  cells	   217,218.	  SFKs	  have	  been	   identified	  to	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be	  overexpressed	  and	  activated	  in	  more	  than	  50%	  of	  ovarian	  cancers	  26.	  These	  kinases	  are	   involved	   in	   a	   variety	   of	   cell	   signalling	   events,	   regulating	   cell	   proliferation	   and	  differentiation	  219.	  Our	  data	  reveal	  an	  increased	  activity	  of	  SFKs	  and	  members	  of	  the	  JNK	  pathway	   in	   the	  CD151+	  cell	   fraction	   compared	   to	  CD151-­‐	  cells	   or	  parental	   cells.	  As	   the	  JNK	  pathway	  regulates	  multiple	   target	  genes,	  which	  are	   involved	   in	  cell	  cycle,	   survival	  and	   apoptosis	   198,	   this	  might	   be	   an	   explanation	   for	   the	   observed	   differences	   between	  CD151+	  and	  CD151-­‐	  cells.	  	  Interestingly,	  JNK	  and	  Jun	  have	  been	  proposed	  to	  be	  essential	  mediators	  of	  oncogenic	  ß-­‐catenin	   signaling	   220,221,	   a	   signature	   that	   was	   also	   enriched	   in	   our	   analysis	   on	   CD151	  
(Figure	  33B).	  Additionally,	  we	  identified	  a	  signature	  predicting	  APC	  targets	  genes	  to	  be	  expressed	   in	   the	   gene	   expression	   profiles	   of	   the	   CD151+	  subpopulation,	   indicating	   an	  activation	  of	  the	  Wnt	  pathway	  in	  CD151+	  cells.	  	  	  To	  directly	  investigate	  the	  effects	  of	  CD151	  on	  growth	  and	  signaling	  in	  our	  SOC	  models,	  we	  stably	  silenced	  CD151	  in	  several	  SOC	  cell	  lines	  by	  the	  lentiviral-­‐mediated	  expression	  of	   shRNAs	   specifically	   targeting	   the	   CD151	   transcript.	   Previous	   results	   suggested	   a	  differential	   growth	   of	   CD151+	   and	   CD151-­‐	   cells.	   Therefore,	   we	   compared	   the	   growth	  behaviour	   SOC	   cell	   lines	   transduced	   with	   a	   scrambled	   shRNA	   to	   cells	   with	   a	   CD151	  knockdown.	  This	  analysis	  yielded	  only	  minor	  discrepancies	   in	   in	  vitro	  growth	  between	  control-­‐	   and	  CD151	   silenced	   cell	   lines	   (Figure	   35B).	   A	   possible	   explanation	  might	   be	  that	   CD151	   is	   in	   vitro	   not	   critical	   for	   the	   growth	   of	   the	   tumor	   cells.	   The	   cells	   are	  supplemented	  with	  various	  growth	  factors	  and	  nutrients	  and	  the	  cell	  culture	  is	  designed	  to	   ensure	   an	   optimal	   growth	   of	   cells.	   In	   contrast,	   the	   situation	   in	   vivo	   is	   completely	  different.	   There,	   cells	   have	   to	   adapt	   to	   a	   certain	   environment,	   growth	   factors	   and	  nutrients	  are	  limited	  and	  cells	  have	  to	  adhere.	  This	  hypothesis	   is	  supported	  by	  several	  reports,	  which	   found	   a	   significant	   the	   ablation	   of	   CD151	   at	   least	   significantly	   delayed	  tumor	  progression	  199.	  	  To	   clarify	   the	  question	   if	   the	  ablation	  of	  CD151	   induces	  global	   in	  gene	  expression,	  we	  compared	   the	   gene	   expression	   data	   of	   SOC	   cell	   lines	   transduced	   with	   the	   scrambled	  control	   shRNA	   to	   CD151	   knockdown	   cells.	   Intriguingly,	   we	   found	   several	   gene	  signatures	   associated	   with	   EGFR	   signaling,	   oncogenic	   Src	   signaling	   and	   targets	   Myc	  significant	   deregulated	   supporting	   our	   previous	   data	   on	   the	   purified	   CD151+	  subpopulation	   (Figure	   34).	   In	   order	   to	   validate	   the	  predicted	  pathway	   activation,	  we	  compared	  the	  phosphorylation	  status	  of	  parental	  cells	   to	  cells	   transduced	  with	  control	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vector	   and	   CD151	   silenced	   cells.	   Indeed,	   Western	   blot	   analysis	   revealed	   an	   almost	  complete	  abrogation	  of	  the	  activating	  phosphorylation	  of	  Src	  at	  Tyr416	  (Figure	  36).	  	  Taken	  together,	  we	  showed	  that	  molecular	  analyses	  on	  our	  advanced	  SOC	  model	  system	  can	  be	  used	   for	   the	   identification	  of	   subpopulation-­‐specific	   pathway	  activities.	  By	   this	  approach,	   we	  were	   able	   associate	   an	   increased	   tumorigenic	   capacity,	   observed	   in	   for	  CD151+	  cells	  of	   various	   cell	   lines,	   by	   the	  activation	  of	  distinct	  pathways.	  We	   identified	  several	  pathways	  driving	  proliferation,	  survival	  and	  metastasis	  such	  as	   the	   JNK/MAPK	  signaling	  pathway,	  the	  EGFR	  signaling	  pathway	  as	  well	  as	  the	  oncogenic	  Src	  pathway	  to	  be	   induced	   by	   the	   interaction	   of	   integrins	   and	   CD151.	   Moreover,	   we	   found	   that	   the	  ablation	  of	  CD151	  directly	  abrogates	  SFK	  activation.	  Interestingly,	   SFK	   inhibitors	   are	   already	   under	   evaluation	   in	   several	   clinical	   trials	   for	  ovarian	  cancer.	  The	  Src	   inhibitor	  Saracatinib	   is	  been	   investigated	   in	   combination	  with	  Paclitaxel	  against	  Platinum-­‐resistant	  ovarian	  cancer	  in	  a	  phase	  II	  study	  (NCT01196741).	  Dasatinib,	  a	  further	  small	  molecule	  kinase	  inhibitor	  targeting	  Src,	  is	  currently	  evaluated	  in	  a	  phase	  I	  clinical	  trial	  in	  combination	  with	  Caboplatin	  and	  Paclitaxel	  (NCT00672295).	  Furthermore,	   several	   studies	   described	   the	   usage	   of	   CD151	   blocking	   antibodies	   in	  different	  animal	  models	  resulting	  in	  an	  inhibition	  of	  metastatic	  spread	  of	  tumor	  cells	  and	  an	   increased	   survival	   of	   treated	   mice	   compared	   to	   non-­‐treated	   mice	   199.	   They	   are	  increasing	  efforts	  in	  the	  development	  of	  antibodies	  targeting	  CD151,	  which	  effect	  tumor	  dissemination	  as	  well	  as	  proliferation.	  Currently,	  these	  antibodies	  are	  under	  evaluation	  199.	  	  	  	  
CD151	  correlates	  with	  an	  advanced	  disease	  stage	  and	  
predicts	  outcome	  in	  low-­‐grade	  serous	  ovarian	  carcinoma	  In	  humans,	  an	  increased	  expression	  of	  CD151	  is	  indicative	  of	  an	  advanced	  disease	  stage	  and	  a	  poor	  prognosis	  in	  multiple	  cancer	  entities	  199.	  However,	  the	  association	  of	  CD151	  with	   clinical	   outcome,	   disease	   stage	   as	   well	   as	   prognostic	   factor	   in	   ovarian	   cancer	   is	  unclear.	  Moreover,	  the	  incidence	  of	  CD151	  expression	  and	  the	  significance	  of	  CD151	  on	  clinical	  outcome	  in	  ovarian	  cancer	  have	  not	  been	  investigated	  so	  far.	  	  Our	   previous	   findings	   revealed	   that	   CD151+	   cells	   have	   a	   significant	   increased	  tumorigenic	   capacity	   compared	   to	   their	   CD151-­‐	  counterparts	   in	   our	   xenograft	   mouse	  model.	  Furthermore,	  we	  showed	  that	  tumor	  cells	  originating	  from	  an	  advanced	  disease	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stage	   express	   significant	   higher	   levels	   of	   CD151	   indicating	   a	   selection	   process	   for	  CD151+	  cells	  during	  tumor	  progression.	  	  In	   order	   to	   prove	   our	   results	   in	   a	   larger	   cohort	   of	   patients,	   we	   investigated	   the	  transcriptomic	  profiles	  as	  well	  as	  clinical	  follow	  up	  data	  of	  a	  representative	  group	  of	  489	  SOC	  patients,	  which	  were	  publicly	  available	  66.	  Indeed,	  our	  analysis	  revealed	  a	  significant	  correlation	   of	   the	   expression	   of	   CD151	   with	   an	   advanced	   disease	   stage.	   Patients	  diagnosed	  with	   a	   lower	   tumor	   grading	   (G2)	   showed	   a	   significant	   lower	   expression	   of	  CD151	  compared	  to	  patients	  with	  an	  advanced	  tumor	  grade	  (G3)	  (Figure	  37	  C).	  Hence,	  we	  were	  able	  to	  confirm	  findings	  made	  for	  lung-­‐,	  colorectal-­‐,	  prostate-­‐,	  pancreatic-­‐	  and	  breast	  cancer	  on	  the	  expression	  of	  CD151	  also	  for	  ovarian	  cancer	  199.	  Next,	  we	  were	  interested	  if	  the	  expression	  of	  CD151	  also	  predicts	  a	  shorter	  progression-­‐free-­‐	   or	   overall	   survival.	   Based	   on	   retrospective	   analysis	   of	   tissue	   microarray	   data	  CD151	  has	  been	  shown	  to	  correlate	  with	  a	  significant	  shorter	  overall	  survival	  in	  various	  cancer	   entities	   222.	   However,	   when	   we	   analysed	   the	   expression	   of	   CD151	   on	  transcriptional	   level	   in	   association	  with	  progression-­‐free-­‐	   and	  overall	   survival,	  we	  did	  not	  detect	  significant	  differences	  in	  the	  two	  parameters	  between	  patients	  with	  a	  high	  or	  a	  low	  expression	  of	  CD151	  (Figure	  37	  A/B).	  A	  possible	  explanation	  for	  the	  gained	  result	  might	  be	  the	  characteristic	  of	  our	  patient	  cohort,	  which	  mostly	  included	  high-­‐grade	  SOC	  patients.	   As	   illustrated	   before,	   the	   expression	   of	   CD151	   increases	   with	   disease	   stage.	  Therefore,	  we	  analysed	  mainly	  patients	  with	  an	  already	  elevated	  expression	  of	  CD151	  distorting	   our	   results.	   A	   further	   reason	   might	   be	   that	   CD151	   is	   typically	   involved	   in	  cancer	   initiation	  and	  progression	   in	  early	  disease	  stages.	  This	  hypothesis	   is	   supported	  by	  findings	  of	  Ang	  and	  colleagues,	  which	  described	  CD151	  as	  a	  prognostic	   indicator	  of	  clinical	   outcome	   in	   low-­‐grade	   prostate	   cancer	   193.	   According	   to	   these	   findings,	   we	  exclusively	   analysed	   patients	   diagnosed	   with	   low-­‐grade	   tumors.	   Intriguingly,	   we	  detected	   a	   significant	  decrease	   in	   overall	   survival	   in	  patients	  wit	   a	   high	   expression	  of	  CD151	  supporting	  the	  previous	  hypothesis.	  	  In	  sum,	  our	  observations	  demonstrate	  a	  significant	  correlation	  between	  an	   increase	   in	  the	   expression	   of	   CD151	   and	   disease	   progression.	   These	   data	   are	   supported	   by	   the	  findings	   of	   several	   groups	   in	  multiple	   cancer	   entities	   199.	   Furthermore,	  we	   have	   been	  able	   to	   demonstrate	   that	   the	   expression	   of	   CD151	   is	   predictive	   a	   decreased	   overall	  survival	  in	  patients	  with	  low-­‐grade	  tumors.	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Concluding	  remarks	  and	  outlook	  In	  this	  study,	  we	  present	  the	  development	  of	  an	  advanced	  model	  system	  combining	  the	  advantages	   of	   the	   serum-­‐free	   culture	   of	   primary	   SOC	   patient	   specimen	   with	  xenotransplantation	   techniques.	   We	   demonstrate	   that	   this	   model	   system	   faithfully	  recapitulates	   all	   hallmarks	   of	   the	   original	   patient	   disease.	   Gene	   expression	   analyses	  based	   on	   established	   primary	   cell	   lines	   as	   well	   as	   corresponding	   xenograft	   tumors	  confirmed	   the	   activation	   of	   SOC-­‐specific	   pathways	   and	   the	   presence	   of	   recently	  described	  subtypes	  of	  SOC.	  Furthermore,	  we	  demonstrate	  the	  successful	  application	  of	  this	  model	   for	  the	   identification	  of	   tumor	   initiating	  cells	   in	  SOC	  and	  identify	  molecular	  mechanisms	  underlying	  tumor	  heterogeneity.	  Further	   analysis	   will	   focus	   on	   the	   molecular	   characterization	   of	   identified	   pathways	  driving	   SOC	   initiation	   and	   progression.	   So	   far,	   existing	   models	   for	   SOC	   have	   been	  incapable	   to	   accurately	   mimic	   the	   human	   disease.	   Drug	   screens	   performed	   using	  conventional	   cell	   lines	   often	   yielded	   targets	   of	   limited	   clinical	   relevance.	   Our	   model	  system	   opens	   up	   completely	   new	   possibilities	   for	   drug	   screening,	   including	   subtype-­‐specific	   treatment.	   This	   could	   finally	   allow	   the	   development	   of	   targeted	   therapies	   for	  SOC.	   Hence,	   our	   model	   system	   could	   provide	   the	   basis	   for	   preclinical	   studies	   on	  inhibitors	   of	   these	   pathways.	   Furthermore,	   we	   confirmed	   the	   FOXM1	   transcription	  network	  as	  well	  as	  several	  DNA	  repair	  pathways	  to	  be	  significantly	  altered	   in	  our	  SOC	  model.	   Several	   of	   therapeutics	   targeting	   these	   pathways	   are	   already	   in	   clinical	   trials	  such	  as	  PARP	  inhibitors.	  	  	  In	  the	  course	  of	  this	  work	  we	  identified	  the	  heterogeneously	  expressed	  surface	  molecule	  CD151	  defining	  a	  TIC	  subpopulation	  in	  our	  primary	  SOC	  model.	  Furthermore,	  we	  were	  able	   to	   assign	   differential	   activated	   pathways	   to	   this	   subpopulation	   that	   explain	   the	  increased	   tumorigenic	   capacity.	   Thus,	   these	   findings	   might	   provide	   the	   basis	   for	   the	  development	   of	   appropriate	   therapeutics	   targeting	   the	   TIC	   population	   in	   SOC.	   As	   we	  identified	   JNK/MAPK-­‐	   and	   EGFR	   signaling	   as	   well	   as	   the	   Src	   kinases	   specifically	  activated	   in	   TICs,	   inhibitors	   targeting	   these	   pathways	   in	   SOC	   in	   combination	  with	   the	  standard	  therapy	  might	   increase	  treatment	  success.	  Even	  though	  some	  of	   the	  pathway	  targets	  that	  were	  found	  in	  this	  study	  are	  already	  under	  evaluation	  in	  clinical	  trials,	  we	  suggest	   novel	   combinatorial	   treatments	   including	   combinatorial	   approaches	   targeting	  the	  described	  pathways.	  Our	  system	  might	  be	   instrumental	  as	  a	  pre-­‐clinical	  model	   for	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ID	   Cell_line	   Age	   Origin	   FIGO	   Nodal	   Metastasis	   Grade	  
Pathological	  
diagnosis	  OT11	   	   76	   Tumor	   Ia	   N0	   M0	   G2	   Adenocarcinoma	  serous	  OT12*	   OC12	   74	   Tumor	   IIIc	   N1	   M1	   G3	   Adenocarcinoma	  serous	  OT13*	   	   59	   Tumor	   IIIc	   N1	   M1	   G3	   Adenocarcinoma	  serous	  Asc1*	   OC14	   61	   Ascites	   IV	   N1	   M1	   G3	   Adenocarcinoma	  serous	  Asc2*	   OC15	   78	   Ascites	   IIIc	   N1	   M1	   G3	   Adenocarcinoma	  serous	  OT15	   	   75	   Tumor	   IIIb	   N1	   M1	   G2	   Adenocarcinoma	  serous	  Asc3*	   	   69	   Ascites	   IIIc	   N1	   M1	   G3	   Adenocarcinoma	  serous	  OT18*	   OC18	   53	   Tumor	   IIIc	   N1	   M1	   G3	   Adenocarcinoma	  serous	  OT19*	   OC19	   57	   Tumor	   IIIc	   N1	   M1	   G3	   Adenocarcinoma	  serous	  PE1*	   OC20	   62	   Pleural	  effusion	   IIIc	   N1	   M1	   G3	   Adenocarcinoma	  serous	  OT21*	   OC21	   60	   Tumor	   IIIc	   N1	   M1	   G3	   Adenocarcinoma	  serous	  OT24	   	   70	   Tumor	   Ic	   N0	   M0	   G2	   Adenocarcinoma	  serous	  OT25*	   OC25	   78	   Tumor	   IIIc	   N1	   M1	   G3	   Adenocarcinoma	  serous	  OT26*	   	   69	   Tumor	   IIIc	   N1	   M1	   G3	   Adenocarcinoma	  serous	  Asc4	   	   66	   Ascites	   IIIc	   N1	   M1	   G3	   Adenocarcinoma	  serous	  OT27*	   	   65	   Tumor	   IIIc	   N1	   M1	   G3	   Adenocarcinoma	  serous	  OT28	   	   63	   Tumor	   IIIc	   Nx	   Mx	   G2	   Adenocarcinoma	  serous	  OT29	   	   60	   Tumor	   Ia	   N0	   M0	   G2	   Adenocarcinoma	  mucinous	  Asc5*	   	   80	   Ascites	   IIIc	   N1	   M1	   G3	   Adenocarcinoma	  serous	  OT30*	   	   72	   Tumor	   IIIc	   N1	   M1	   G3	   Adenocarcinoma	  serous	  Asc6	   	   76	   Ascites	   IV	   N1	   M1	   G3	   Adenocarcinoma	  serous	  Asc7*	   	   69	   Ascites	   IIIc	   N1	   M1	   G3	   Adenocarcinoma	  serous	  OT31	   	   58	   Tumor	   IIIc	   N0	   M0	   G3	   Adenocarcinoma	  serous	  OT32	   	   68	   Tumor	   IIIc	   N1	   M1	   G3	   Adenocarcinoma	  serous	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Vector	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Region 1067 1204 Psi HIV packaging signal 
Region 1688 1928 RRE Rev responsive element 
Region 2422 2599 cPPT central polypurine tract 
Region 2780 3031 EF1a short promotor 
Gene 3060 4712 Luciferase 2 reporter for bioluminescence 
Region 4763 5364 IRES Internal ribosome entry site 
Gene 5365 6084 Venus reporter for fluorescence 
Region 6219 6808 WPRE enhancer 
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ACS	  
	   	   American	  Cancer	  Society	  AIM2	  
	   	   absent	  in	  melanoma	  2	  AJCC	  
	   	   American	  Joint	  Cancer	  Committee	  	  Akt	  
	   	   Proteinkinase	  B	  ANOVA	  	  
	   	   Analysis	  of	  Variance	  APC	   	   	   Adenomatous	  polyposis	  coli	  
ATCC	  
	   	   American	  Type	  Culture	  Collection	  	  BRAF	  	  
	   	   Raf	  murine	  sarcoma	  viral	  oncogene	  homolog	  B1	  BRCA1	   	   	   Breast	  Cancer	  1	  susceptibility	  protein	  
BRCA2	  
	   	   Breast	  Cancer	  2	  susceptibility	  protein	  CA125	  
	   	   carbohydrate	  antigen	  125	  CD133	  	  
	   	   Prominin-­‐1	  CD151	   	   	   Cluster	  of	  Differentiation	  151	  
CD24	  
	   	   Cluster	  of	  Differentiation	  24	  CD44	  
	   	   Cluster	  of	  Differentiation	  44	  CDKN2A	  
	   	   Cyclin-­‐dependent	  kinase	  inhibitor	  2A	  CML	  
	   	   Chronic	  Myloid	  Leukemia	  Cre	  
	   	   Cre	  Recombinase	  CTNNB1	   	   	   ß-­‐Catenin	  
DN	  
	   	   Double	  negative	  DNA	  	  
	   	   Deoxyribonucleic	  acid	  DT	  
	   	   Derived	  Tumor	  EGFR	  
	   	   Epidermal	  growth	  factor	  receptor	  eIF4	  	  
	   	   Eukaryotic	  initiation	  factor	  4	  EMT	  
	   	   Epithelial-­‐to-­‐menenchymal	  transition	  ER	  
	   	   Estrogen	  receptor	  eSC	  
	   	   Embryonic	  Stem	  Cells	  FACS	  
	   	   Flourescent	  activated	  cell	  sorting	  FCS	  
	   	   Fetal	  calf	  serum	  FDA	  
	   	   Food	  and	  Drug	  Administration	  
FIGO	   	   	   International	  Federation	  of	  Gynecology	  and	  Obstetrics	  
G1	  
	   	   Gap	  1	  phase	  G2/M	  	  
	   	   G2-­‐M	  DNA	  damage	  checkpoint	  GEM	  
	   	   Genetically	  engineered	  mouse	  model	  GSEA	  
	   	   Gene	  set	  enrichement	  analysis	  HER2	  
	   	   human	  epidermal	  growth	  factor	  receptor	  type	  2	  	  HER2	   	   	   Human	  Epidermal	  Growth	  Factor	  Receptor	  2	  
IC50	  
	   	   half-­‐maximal	  inhibitory	  concentration	  ICGC	   	   	   International	  Cancer	  Genome	  Consortium	  
IL-­‐6	   	   	   Interleukin	  6	  
iPS	  
	   	   Induced	  pluripotent	  stem	  cells	  JNK	   	   	   c-­‐Jun	  N-­‐terminal	  kinases	  
	  	  
Abbreviations	   	  	   	  
127	  
Ki67	  
	   	   Antigen	  KI-­‐67	  
KRAS2	  	  
	   	   V-­‐Ki-­‐ras2	  Kirsten	  rat	  sarcoma	  viral	  oncogene	  homolog	  LOH	   	   	   Loss	  of	  heterozygosity	  
MKK4	   	   	   Dual	  specificity	  mitogen-­‐activated	  protein	  kinase	  kinase	  4	  
MSig	  	  
	   	   Molecular	  Signatures	  mTOR	  
	   	   Mammalian	  target	  of	  Rapamycin	  NLM	  
	   	   National	  Library	  of	  Medicine	  NOD/SCI
D	  
	   	   Nonobese	  diabetic	  with	  severe	  combined	  immunodeficiency	  	  NSC	  
	   	   Neural	  stem	  cells	  NSG	  
	   	   NOD.Cg-­‐Prkdcscid	  Il2rgtm1Wjl	  	  	  OS	  
	   	   Overall	  survival	  p70S6K	  
	   	   p70S6	  kinase	  PI3K	  
	   	   Phosphoinositide	  3-­‐kinase	  PKB	  
	   	   Proteinkinase	  B	  PR	  
	   	   Progesterone	  receptor	  PR	   	   	   Progesterone	  receptor	  
PRSS1	  	  
	   	   Trypsin-­‐1	  PT	  
	   	   Primary	  Tumor	  PTEN	   	   	   Phosphatase	  and	  tensin	  homolog	  
Rab25	   	   	   Ras-­‐related	  protein	  Rab-­‐25	  
RAF-­‐
MAPK	  
	   	   Raf	  murine	  sarcoma	  viral	  oncogene	  -­‐	  Mitogen-­‐activated	  protein	  (MAP)	  kinases	  	  RalGDS	  	  
	   	   Ral	  guanine	  nucleotide	  dissociation	  stimulator	  Ser	  
	   	   Serine	  SFK	  
	   	   Src	  family	  kinases	  SOC	   	   	   Serous	  Ovarian	  Cancer	  
Src	  
	   	   Tyrosinkinase	  Src	  STAT3	   	   	   Signal	  transducer	  and	  activator	  of	  transcription	  3	  
TCGA	   	   	   The	  Cancer	  Genome	  Atlas	  Network	  
TIC	  
	   	   Tumor	  initiating	  cell	  TIC	   	   	   Tumor	  initiating	  cell	  
TMN	  
	   	   Tumor	  Node	  Metastasis	  TP53	  
	   	   tumor	  protein	  53	  TVS	   	   	   Transvaginal	  ultrasound	  
Tyr	  
	   	   Tyrosine	  VEGF	   	   	   Vascular	  endothelial	  growth	  factor	  
VEGFR2	  
	   	   vascular	  endothelial	  growth	  factor	  receptor	  2	  WT1	   	   	   Wilms	  Tumor	  1	  
µg	   	   	   microgram	  
µM	   	   	   micromolar	  
µm	   	   	   micrometer	  	  
